/raid1/www/Hosts/bankrupt/CAR_Public/201106.mbx
C L A S S A C T I O N R E P O R T E R
Friday, November 6, 2020, Vol. 22, No. 223
Headlines
3052 BRIGHTON: Robertson Claims Rent Overcharge in 421-a Building
8X8 INC: Rivas Employment Class Suit Goes to N.D. California
A-CHECK AMERICA: Banegas Sues Over Illegal Background Check
ALLERGAN PLC: Rosen Law Reminds of Oct. 29 Deadline
ASTRAZENECA PHARMACEUTICALS: Anti-Trust Suit Moved to D. Delaware
ASTRAZENECA PHARMACEUTICALS: IUOE Local 137 Suit Moved to D. Del.
ASTRAZENECA PHARMACEUTICALS: SBA Anti-Trust Suit Moved to D. Del.
ASTRAZENECA PHARMACEUTICALS: UFASBF & RFSBF Suit Moved to D. Del.
AURORA CANNABIS: Rosen Law Reminds of December 1 Deadline
BAIDU INC: Portnoy Law Reminds of Class Action
BAYERISCHE MOTOREN: Rosen Law Probes Firm
BIOMARIN PHARMA: Glancy Prongay Reminds of Nov. 24 Deadline
BIOMARIN PHARMA: Hagens Berman Reminds of Nov. 24 Deadline
BIOMARIN PHARMA: Schall Law Firm Reminds of Nov. 24 Deadline
CABOT OIL: Robbins Geller Files Securities Class Action
CELSION CORPORATION: Faces Spar Class Suit Over Stock Price Drop
CHEMOURS COMPANY: Lifshitz Law Probes Firm
COGNIZANT TECHNOLOGY: Suit Dismissal Bid Denied, Lifshitz Says
COLONY CREDIT: Bronstein Gewirtz Reminds of November 9 Deadline
COUSIN JENNY'S: Chinn et al. Sue Over Unlawful Retention of Tips
CREDIT ACCEPTANCE: Kahn Swick Reminds of December 1 Deadline
CREDIT ACCEPTANCE: Kirby McInerney Reminds of Dec. 1 Deadline
CREDIT ACCEPTANCE: Rosen Law Reminds of Dec. 1 Deadline
ERIC CHURCH: Hayden Sues Over Unpaid Overtime and Retaliation
EVOLUS INC: Glancy Prongay Reminds of Dec. 15 Deadline
FLUIDIGM CORP: Bernstein Liebhard Reminds of November 20 Deadline
GARRETT MOTION: Federman & Sherwood Reminds of Nov. 24 Deadline
GARRETT MOTION: Levi & Korsinsky Reminds of November 24 Deadline
GOHEALTH INC: Wolf Haldenstein Reminds of November 20 Deadline
HALLMARK FINANCIAL: Hagens Berman Files Amended Class Action
HONEYWELL INTERNATIONAL: Suit Dismissal Bid Denied, Lifshitz Says
HUAZHU GROUP: Rosen Law Firm Investigates Securities Claims
INFINITY FASTENERS: Rendon Labor Suit Removed to E.D. California
JOERNS HEALTHCARE: Fails to Pay Proper Overtime, Brooks Claims
LAS VEGAS SANDS: Bronstein Gewirtz Reminds of Dec. 21 Deadline
LAS VEGAS SANDS: Gainey McKenna Reminds of Dec. 21 Deadline
LAS VEGAS SANDS: Rosen Law Reminds of Dec. 21 Deadline
LOOP INDUSTRIES: Howard G. Smith Reminds of Dec. 14 Deadline
LOOP INDUSTRIES: Robbins LLP Reminds of Dec. 14 Deadline
LOOP INDUSTRIES: Rosen Law Reminds of Dec. 14 Deadline
MEI PHARMA: Lifshitz Law Probes Firm
MICROSOFT CORP: Website Inaccessible to Blind Users, Romero Claims
NEXTCURE INC: Bernstein Liebhard Reminds of Nov. 20 Deadline
NIKOLA CORP: Bernstein Liebhard Reminds of November 16 Deadline
NIKOLA CORP: ClaimsFiler Reminds of November 16 Deadline
NIKOLA CORP: Johnson Fistel Reminds of Nov. 16 Deadline
NIKOLA CORP: Kessler Topaz Reminds of November 16 Deadline
NIKOLA CORP: Lifshitz Law Probes Firm
NIKOLA CORPORATION: Rosen Law Reminds of Nov. 16 Deadline
NORTHSTAR LOCATION: Hirsch Sues Over Unlawful Debt Collection
ONESPAN INC: Portnoy Law Reminds of Class Action
PEABODY ENERGY: Frank R. Cruz Reminds of November 27 Deadline
PEABODY ENERGY: Glancy Prongay Reminds of November 27 Deadline
PINTEC TECHNOLOGY: Frank R. Cruz Reminds of November 30 Deadline
PINTEC TECHNOLOGY: Levi & Korsinsky Reminds of Nov. 30 Deadline
PORTLAND GENERAL: Grant & Eisenhofer Reminds of Class Action
QUTOUTIAO INC: Frank R. Cruz Reminds of Class Action
REATA PHARMACEUTICALS: Kehoe Law Announces Securities Class Action
ROYAL CARIBBEAN: Bernstein Liebhard Reminds of Dec. 7 Deadline
ROYAL CARIBBEAN: Glancy Prongay Reminds of Dec. 7 Deadline
ROYAL CARIBBEAN: Howard G. Smith Announces Securities Class Action
ROYAL CARIBBEAN: Rosen Law Reminds of December 7 Deadline
SOCIAL CAPITAL: Chaplin Suit Challenges Merger With Clover Health
TACTILE SYSTEMS: Bernstein Liebhard Reminds of Nov. 30 Deadline
TACTILE SYSTEMS: Frank R. Cruz Reminds of November 30 Deadline
TACTILE SYSTEMS: Hagens Berman Reminds of November 30 Deadline
TACTILE SYSTEMS: Rosen Law Firm Reminds of November 30 Deadline
TEVA PHARMA: Rosen Law Reminds of Nov. 23 Deadline
TURQUOISE HILL: Robbins Geller Reminds of Dec. 14 Deadline
TURQUOISE HILL: Schall Law Announces Securities Class Action
ULTRA PETROLEUM Portnoy Law Reminds of Nov. 9 Deadline
ULTRA PETROLEUM: Wolf Haldenstein Reminds of Class Action
UNITED STATES: NUL, NFHA Balk at Trump's EO on Diversity Trainings
WRAP TECHNOLOGIES: Rosen Law Firm Reminds of November 23 Deadline
YAYYO INC: Lifshitz Law Probes Firm
YAYYO INC: Wolf Haldenstein Reminds of November 9 Deadline
Asbestos Litigation
ASBESTOS UPDATE: AEP Transfers Liabilities for Conesville Plant
ASBESTOS UPDATE: Carlisle Cos. Still Faces Claims at Sept. 30
ASBESTOS UPDATE: Dow Had $1.02BB Noncurrent Liabilities at Sept. 30
ASBESTOS UPDATE: Lennox Int'l. Has $2.4MM Litigation Expense in Q3
ASBESTOS UPDATE: Pentair Units Had 610 Pending Claims at Sept. 30
ASBESTOS UPDATE: PPG Industries Had 600 Open Claims at Sept. 30
ASBESTOS UPDATE: Travelers Had $1.41BB Net Reserves at Sept. 30
ASBESTOS UPDATE: Union Carbide Faces 9,641 Claims at Sept. 30
*********
3052 BRIGHTON: Robertson Claims Rent Overcharge in 421-a Building
-----------------------------------------------------------------
LEONARD ROBERTSON, on behalf of himself and all others similarly
situated, Plaintiff v. 3052 BRIGHTON FIRST LLC, Defendant, Case No.
521058/2020 (N.Y. Sup. Ct., Kings Cty., October 29, 2020) is a
class action against the Defendant for violations of the Rent
Stabilization Law in New York.
The case arises from the Defendant's use of a preferential rent in
its apartment building instead of the initial legal regulated rent.
The Defendant's building participates in the 421-a Program, which
requires landlords to register their units with the Division of
Housing and Community Renewal (DHCR) and to follow the initial
legal regulated rent to be charged for tenants. The Plaintiff
alleges that the Defendant has continued to calculate rent for the
building's units based on a first rent that was higher than the
preferential rent actually charged. The Defendant utilized the
impermissible preferential rent to take rent increases in excess of
those allowed by the Rent Guidelines Board.
3052 Brighton First LLC is an owner of apartment buildings located
at 3052 Brighton First Street in Brooklyn, New York. [BN]
The Plaintiff is represented by:
Lucas A. Ferrara, Esq.
Jarred I. Kassenoff, Esq.
Roger A. Sachar Jr., Esq.
1250 Broadway, 27th Floor
New York, NY 10001
Telephone: (212) 619-5400
E-mail: lferrara@nfllp.com
ikassenoff@nfllp.com
rsachar@nfllp.com
8X8 INC: Rivas Employment Class Suit Goes to N.D. California
------------------------------------------------------------
The case styled DENISE RIVAS, on behalf of herself and others
similarly situated v. 8X8, INC. and DOES 1 through 50, inclusive,
Case No. 20CV370842, was removed from the Superior Court of
California for the County of Santa Clara to the U.S. District Court
for the Northern District of California on October 29, 2020.
The Clerk of Court for the Northern District of California assigned
Case No. 3:20-cv-07607 to the proceeding.
The case arises from the Defendants' alleged violations of the
California Labor Code and the California's Business and Professions
Code including failure to pay minimum wages and overtime pay,
failure to provide meal and rest periods, failure to keep required
payroll records, and failure to make proper disclosure in violation
of the Fair Credit Reporting Act (FCRA).
8X8, Inc. is a provider of voice over internet protocol (IP)
products, with its principle executive offices in Campbell,
California. [BN]
The Defendant is represented by:
Jen Cornell, Esq.
Teresa W. Ghali, Esq.
CDF LABOR LAW LLP
600 Montgomery Street, Suite 440
San Francisco, CA 94111
Telephone: (415) 981-3233
E-mail: jcornell@cdflaborlaw.com
tghali@cdflaborlaw.com
A-CHECK AMERICA: Banegas Sues Over Illegal Background Check
-----------------------------------------------------------
EDWARD BANEGAS, on behalf of himself and all others similarly
situated, Plaintiff v. A-CHEK AMERICA, INC., Defendant, Case No.
5:20-cv-02257 (C.D. Cal., October 28, 2020) is a class action
complaint brought against the Defendant for its alleged failure to
comply with the disclosure and authorization requirements of the
Fair Credit Reporting Act (FCRA).
In connection with his application for employment with Riverside
Medical Clinic, the Plaintiff signed on August 13, 2019 a document
on the Defendant's letterhead, evidently drafted by the Defendant
and provided it to Riverside Medical Clinic for their standard job
application packet. However, the Defendant's "consent" form
violated the FCRA because it included extraneous and unnecessary
disclosures in addition to the disclosed requirements of a
background check.
A-Check America, Inc. provides background checks. [BN]
The Plaintiff is represented by:
Babak Semnar, Esq.
Jared M. Hartman, Esq.
SEMNAR & HARTMAN, LLP
41707 Winchester Road, Suite 201
Temecula, CA 92590
Tel: (951) 293-4187
Fax: (888) 819-8230
- and –
Matthew R. Wilson, Esq.
Michael J. Boyle, Jr., Esq.
MEYER WILSON CO., LPA
305 W Nationwide Blvd.
Columbus, OH 43215
Tel: (614) 224-6000
Fax: (614) 224-6066
E-mail: Mwilson@meyerwilson.com
Mboyle@meyerwilson.com
ALLERGAN PLC: Rosen Law Reminds of Oct. 29 Deadline
---------------------------------------------------
Rosen Law Firm, a global investor rights law firm, reminds
purchasers of the securities of Allergan plc (NYSE: AGN) between
January 30, 2017 and December 19, 2018, inclusive (the "Class
Period"), of the important October 29, 2020 lead plaintiff deadline
in the securities class action. The lawsuit seeks to recover
damages for Allergan investors under the federal securities laws.
To join the Allergan class action, go to
http://www.rosenlegal.com/cases-register-1967.htmlor call Phillip
Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or
cases@rosenlegal.com for information on the class action.
According to the lawsuit, defendants throughout the Class Period
made false and/or misleading statements and/or failed to disclose
that: (1) textured breast implants manufactured by Allergan were
definitively linked to anaplastic large cell lymphoma ("ALCL") as
demonstrated by various medical studies; (2) the defendants knew
of, or recklessly disregarded, the link to ALCL; (3) the foregoing
link to cancer, when revealed, would foreseeably force Allergan to
recall those textured breast implants from certain markets; (4)
while publicly claiming that they were serious about researching
the breast implant-associated ALCL ("BIA-ALCL") link, the Company
shut down its Santa Barbara facility, which was the center of
breast implant research and development; (5) defendants did not
disclose in its FDA-mandated follow-up study the reports of
BIA-ALCL Allergan had received; (6) Allergan failed to report many
adverse events individually and publicly and instead used
inappropriately nonpublic "Alternative Summary Reports" and the
Company submitted at least one case of possible BIA-ALCL through an
alternative summary report; (7) by suppressing the reporting of
adverse event reports Defendants knew or recklessly disregarded the
risk that some BIA-ALCL cases would go undetected by the FDA, which
contradicts their statements of being in compliance with FDA
reporting guidelines; and (8) as detailed in various consumer
complaints, Allergan was not appropriately advising patients of the
risks associated with textured breast implants and the development
of BIA-ALCL. When the true details entered the market, the lawsuit
claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve
as lead plaintiff, you must move the Court no later than October
29, 2020. A lead plaintiff is a representative party acting on
behalf of other class members in directing the litigation. If you
wish to join the litigation, go to
http://www.rosenlegal.com/cases-register-1967.htmlor to discuss
your rights or interests regarding this class action, please
contact Phillip Kim, Esq. of Rosen Law Firm toll free at
866-767-3653 or via e-mail at pkim@rosenlegal.com or
cases@rosenlegal.com.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS
IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN
ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN
ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S
ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT
UPON SERVING AS LEAD PLAINTIFF.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation. Rosen Law Firm was Ranked No. 1
by ISS Securities Class Action Services for number of securities
class action settlements in 2017. The firm has been ranked in the
top 3 each year since 2013. Rosen Law Firm has achieved the largest
ever securities class action settlement against a Chinese Company.
Rosen Law Firm's attorneys are ranked and recognized by numerous
independent and respected sources. Rosen Law Firm has secured
hundreds of millions of dollars for investors. Attorney
Advertising. Prior results do not guarantee a similar outcome [GN]
ASTRAZENECA PHARMACEUTICALS: Anti-Trust Suit Moved to D. Delaware
-----------------------------------------------------------------
The case styled MAYOR AND CITY COUNCIL OF BALTIMORE, on behalf of
itself and all others similarly situated v. ASTRAZENECA
PHARMACEUTICALS LP; ASTRAZENECA LP; ASTRAZENECA UK LIMITED; HANDA
PHARMACEUTICALS, LLC; and PAR PHARMACEUTICAL, INC., Case No.
1:19-cv-08856, was transferred from the U.S. District Court for the
Southern District of New York to the U.S. District Court for the
District of Delaware on October 29, 2020.
The Clerk Court for the District of Delaware assigned Case No.
1:20-cv-01469-UNA to the proceeding.
The case arises from the Defendants' alleged monopolization under
state law, conspiracy to monopolize, combination and conspiracy in
restraint of trade, unfair or deceptive trade practices, and unjust
enrichment. The Plaintiff claims that the Defendants are engaged in
an illegal conduct to delay competition and to artificially inflate
prices for Seroquel XR, a dopamine, serotonin, and adrenergic
antagonist, and its AB-rated generic equivalents.
AstraZeneca Pharmaceuticals LP is a pharmaceutical company, with
its principal place of business located at 1800 Concord Pike,
Wilmington, Delaware.
AstraZeneca LP is a manufacturer and distributor of pharmaceutical
products, with its principal place of business located at 1800
Concord Pike, Wilmington, Delaware.
AstraZeneca UK Limited is a pharmaceutical firm, with its principal
place of business located at 15 Stanhope Gate, London, United
Kingdom.
Handa Pharmaceuticals, LLC is a pharmaceutical company, with its
principal place of business located at 1732 N. 1st Street, Suite
200, San Jose, California.
Par Pharmaceutical, Inc. is a pharmaceutical company, with its
principal place of business located at One Ram Ridge Road, Chestnut
Ridge, New York. [BN]
The Plaintiff is represented by:
Sharon K. Robertson, Esq.
Donna M. Evans, Esq.
COHEN MILSTEIN SELLERS & TOLL PLLC
88 Pine Street, 14th Floor
New York, NY 10005
Telephone: (212) 838-7797
Facsimile: (212) 838-7745
E-mail: srobertson@cohenmilstein.com
devans@cohenmilstein.com
- and –
Archana Tamoshunas, Esq.
TAUS, CEBULASH & LANDAU LLP
80 Maiden Lane, Suite 1204
New York, NY 10038
Telephone: (212) 931-0704
E-mail: atamoshunas@tcllaw.com
- and –
Andre M. Davis, Esq.
Suzanne Sangree, Esq.
CITY OF BALTIMORE DEPARTMENT OF LAW
City Hall, Room 109
100 N. Holiday Street
Baltimore, MD 21202
Telephone: (443) 388-2190
E-mail: Andre.Davis@baltimorecity.gov
Suzanne.Sangree2@baltimorecity.gov
ASTRAZENECA PHARMACEUTICALS: IUOE Local 137 Suit Moved to D. Del.
-----------------------------------------------------------------
The case styled WELFARE PLAN OF THE INTERNATIONAL UNION OF
OPERATING ENGINEERS LOCALS 137, 137A, 137B, 137C and 137R, on
behalf of itself and all others similarly situated v. ASTRAZENECA
PHARMACEUTICALS LP; ASTRAZENECA LP; ASTRAZENECA UK LIMITED; HANDA
PHARMACEUTICALS, LLC; and PAR PHARMACEUTICAL, INC., Case No.
1:19-cv-09036, was transferred from the U.S. District Court for the
Southern District of New York to the U.S. District Court for the
District of Delaware on October 29, 2020.
The Clerk Court for the District of Delaware assigned Case No.
1:20-cv-01470-UNA to the proceeding.
The case arises from the Defendants' alleged monopolization under
state law, conspiracy to monopolize, combination and conspiracy in
restraint of trade, unfair or deceptive trade practices, and unjust
enrichment. The Plaintiff claims that the Defendants are engaged in
an illegal conduct to delay competition and to artificially inflate
prices for Seroquel XR, a dopamine, serotonin, and adrenergic
antagonist, and its AB-rated generic equivalents.
Welfare Plan of The International Union of Operating Engineers
(IUOE) Local 137 is a multi-employer health and welfare fund
located in Briarcliff Manor, New York.
AstraZeneca Pharmaceuticals LP is a pharmaceutical company, with
its principal place of business located at 1800 Concord Pike,
Wilmington, Delaware.
AstraZeneca LP is a manufacturer and distributor of pharmaceutical
products, with its principal place of business located at 1800
Concord Pike, Wilmington, Delaware.
AstraZeneca UK Limited is a pharmaceutical firm, with its principal
place of business located at 15 Stanhope Gate, London, United
Kingdom.
Handa Pharmaceuticals, LLC is a pharmaceutical company, with its
principal place of business located at 1732 N. 1st Street, Suite
200, San Jose, California.
Par Pharmaceutical, Inc. is a pharmaceutical company, with its
principal place of business located at One Ram Ridge Road, Chestnut
Ridge, New York. [BN]
The Plaintiff is represented by:
Frank R. Schirripa, Esq.
David R. Cheverie, Esq.
Daniel B. Rehns, Esq.
HACH ROSE SCHIRRIPA & CHEVERIE LLP
112 Madison Avenue, 10th Floor
New York, NY 10016
Telephone: (212) 213-8311
Facsimile: (212) 779-0028
E-mail: fschirripa@hrsclaw.com
dcheverie@hrsclaw.com
drehns@hrsclaw.com
ASTRAZENECA PHARMACEUTICALS: SBA Anti-Trust Suit Moved to D. Del.
-----------------------------------------------------------------
The case styled SERGEANTS BENEVOLENT ASSOCIATION HEALTH & WELFARE
FUND, on behalf of itself and all others similarly situated v.
ASTRAZENECA PHARMACEUTICALS LP; ASTRAZENECA LP; ASTRAZENECA UK
LIMITED; HANDA PHARMACEUTICALS, LLC; and PAR PHARMACEUTICAL, INC.,
Case No. 1:19-cv-09094, was transferred from the U.S. District
Court for the Southern District of New York to the U.S. District
Court for the District of Delaware on October 29, 2020.
The Clerk Court for the District of Delaware assigned Case No.
1:20-cv-01472-UNA to the proceeding.
The case arises from the Defendants' alleged monopolization under
state law, conspiracy to monopolize, combination and conspiracy in
restraint of trade, unfair or deceptive trade practices, and unjust
enrichment. The Plaintiff claims that the Defendants are engaged in
an illegal conduct to delay competition and to artificially inflate
prices for Seroquel XR, a dopamine, serotonin, and adrenergic
antagonist, and its AB-rated generic equivalents.
Sergeants Benevolent Association Health & Welfare Fund (SBA) is an
organization established for the purpose of providing prescription
drug benefits to active and retired New York City Police Department
Sergeants and their dependents.
AstraZeneca Pharmaceuticals LP is a pharmaceutical company, with
its principal place of business located at 1800 Concord Pike,
Wilmington, Delaware.
AstraZeneca LP is a manufacturer and distributor of pharmaceutical
products, with its principal place of business located at 1800
Concord Pike, Wilmington, Delaware.
AstraZeneca UK Limited is a pharmaceutical firm, with its principal
place of business located at 15 Stanhope Gate, London, United
Kingdom.
Handa Pharmaceuticals, LLC is a pharmaceutical company, with its
principal place of business located at 1732 N. 1st Street, Suite
200, San Jose, California.
Par Pharmaceutical, Inc. is a pharmaceutical company, with its
principal place of business located at One Ram Ridge Road, Chestnut
Ridge, New York. [BN]
The Plaintiff is represented by:
Elizabeth Metcalf, Esq.
Peter Safirstein, Esq.
SAFIRSTEIN METCALF LLP
The Empire State Building
350 Fifth Avenue, Suite 5960
New York, NY 10118
Telephone: (212) 201-2845
E-mail: EMetcalf@SafirsteinMetcalf.com
PSafirstein@SafirsteinMetcalf.com
ASTRAZENECA PHARMACEUTICALS: UFASBF & RFSBF Suit Moved to D. Del.
-----------------------------------------------------------------
The case styled THE UNIFORMED FIREFIGHTERS' ASSOCIATION OF GREATER
NEW YORK SECURITY BENEFIT FUND and THE RETIRED FIREFIGHTERS'
SECURITY BENEFIT FUND OF THE UNIFORMED FIREFIGHTERS' ASSOCIATION,
on behalf of themselves and all others similarly situated v.
ASTRAZENECA PHARMACEUTICALS LP; ASTRAZENECA LP; ASTRAZENECA UK
LIMITED; HANDA PHARMACEUTICALS, LLC; and PAR PHARMACEUTICAL, INC.,
Case No. 1:19-cv-09271, was transferred from the U.S. District
Court for the Southern District of New York to the U.S. District
Court for the District of Delaware on October 29, 2020.
The Clerk Court for the District of Delaware assigned Case No.
1:20-cv-01473-UNA to the proceeding.
The case arises from the Defendants' alleged monopolization under
state law, conspiracy to monopolize, combination and conspiracy in
restraint of trade, unfair or deceptive trade practices, and unjust
enrichment. The Plaintiffs claim that the Defendants are engaged in
an illegal conduct to delay competition and to artificially inflate
prices for Seroquel XR, a dopamine, serotonin, and adrenergic
antagonist, and its AB-rated generic equivalents.
The Uniformed Firefighters Association of Greater New York Security
Benefit Fund (UFASBF) is a health and welfare benefit plan with a
principal place of business in New, York, New York.
The Retired Firefighter Security Benefit Fund of the Uniformed
Firefighters Association (RFSBF) is a health and welfare benefit
plan headquartered in New, York, New York.
AstraZeneca Pharmaceuticals LP is a pharmaceutical company, with
its principal place of business located at 1800 Concord Pike,
Wilmington, Delaware.
AstraZeneca LP is a manufacturer and distributor of pharmaceutical
products, with its principal place of business located at 1800
Concord Pike, Wilmington, Delaware.
AstraZeneca UK Limited is a pharmaceutical firm, with its principal
place of business located at 15 Stanhope Gate, London, United
Kingdom.
Handa Pharmaceuticals, LLC is a pharmaceutical company, with its
principal place of business located at 1732 N. 1st Street, Suite
200, San Jose, California.
Par Pharmaceutical, Inc. is a pharmaceutical company, with its
principal place of business located at One Ram Ridge Road, Chestnut
Ridge, New York. [BN]
The Plaintiffs are represented by:
Brian Murray, Esq.
Lee Albert, Esq.
Brian Brooks, Esq.
GLANCY PRONGAY & MURRAY LLP
230 Park Avenue, Suite 530
New York, NY 10169
Telephone: (212) 682-5340
Facsimile: (212) 884-0988
E-mail: bmurray@glancylaw.com
lalbert@glancylaw.com
bbrooks@glancylaw.com
AURORA CANNABIS: Rosen Law Reminds of December 1 Deadline
---------------------------------------------------------
Rosen Law Firm, a global investor rights law firm, reminds
purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB)
between February 13, 2020 and September 4, 2020 inclusive (the
"Class Period"), of the important December 1, 2020 lead plaintiff
deadline in the securities class action. The lawsuit seeks to
recover damages for Aurora investors under the federal securities
laws.
Rosen Law Firm, P.A. Logo
To join the Aurora class action, go to
http://www.rosenlegal.com/cases-register-1965.htmlor call Phillip
Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or
cases@rosenlegal.com for information on the class action.
According to the lawsuit, defendants throughout the Class Period
made false and/or misleading statements and/or failed to disclose
that: (1) Aurora had significantly overpaid for previous
acquisitions and experienced degradation in certain assets,
including its production facilities and inventory; (2) Aurora's
purported "business transformation plan" and cost reset failed to
mitigate the foregoing issues; (3) accordingly, it was foreseeable
that Aurora would record significant goodwill and asset impairment
charges; and (4) as a result, defendants' public statements were
materially false and misleading at all relevant times. When the
true details entered the market, the lawsuit claims that investors
suffered damages.
A class action lawsuit has already been filed. If you wish to serve
as lead plaintiff, you must move the Court no later than December
1, 2020 . A lead plaintiff is a representative party acting on
behalf of other class members in directing the litigation. If you
wish to join the litigation, go to
http://www.rosenlegal.com/cases-register-1965.htmlor to discuss
your rights or interests regarding this class action, please
contact Phillip Kim, Esq. of Rosen Law Firm toll free at
866-767-3653 or via e-mail at pkim@rosenlegal.com or
cases@rosenlegal.com .
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS
IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN
ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN
ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S
ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT
UPON SERVING AS LEAD PLAINTIFF.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation. Rosen Law Firm was Ranked No. 1
by ISS Securities Class Action Services for number of securities
class action settlements in 2017. The firm has been ranked in the
top 3 each year since 2013. Rosen Law Firm has achieved the largest
ever securities class action settlement against a Chinese Company.
Rosen Law Firm's attorneys are ranked and recognized by numerous
independent and respected sources. Rosen Law Firm has secured
hundreds of millions of dollars for investors. Attorney
Advertising. Prior results do not guarantee a similar outcome. [GN]
BAIDU INC: Portnoy Law Reminds of Class Action
----------------------------------------------
The Portnoy Law Firm advises investors that a class action lawsuit
has been filed on behalf of Baidu, Inc. (NASDAQ: BIDU) investors
that acquired shares between April 8, 2016 and August 13, 2020.
Investors had until October 19, 2020 to seek an active role in this
litigation.
Investors are encouraged to contact attorney Lesley F. Portnoy, to
determine eligibility to participate in this action, by phone
310-692-8883 or email, or click here to join the case.
Baidu founded iQIYI in 2010. Baidu currently owns an approximately
56% controlling interest in iQIYI.
After the market closed on August 13, 2020, iQIYI announced that
the U.S. Securities & Exchange Commission sought "the production of
certain financial and operating records dating from January 1,
2018, as well as documents related to certain acquisitions and
investments that were identified in a report issued by short-seller
firm Wolfpack Research in April 2020."
Baidu's American depositary share ("ADS") price fell $7.83 per ADS,
or 6%, on this news, to close at $116.74 per ADS on August 14,
2020, damaging investors.
A class action lawsuit has already been filed. If you wish to serve
as lead plaintiff, you must move the Court no later than October
19, 2020.
Please visit our website to review more information and submit your
transaction information.
The Portnoy Law Firm represents investors in pursuing claims
arising from corporate wrongdoing. The Firm's founding partner has
recovered over $5.5 billion for aggrieved investors. Attorney
advertising. Prior results do not guarantee similar outcomes. [GN]
BAYERISCHE MOTOREN: Rosen Law Probes Firm
-----------------------------------------
Rosen Law Firm, a global investor rights law firm, continues to
investigate potential securities claims on behalf of shareholders
of Bayerische Motoren Werke AG (OTC: BMWYY, BAMXF) resulting from
allegations that BMW may have issued materially misleading business
information to the investing public.
On December 23, 2019, the Wall Street Journal reported that the SEC
is investigating BMW's sales practices, specifically, whether BMW
engaged in a practice known as "sales punching." Sales punching
occurs when a company boosts sales figures by having dealers
register cars as sold when the vehicles are still on car lots.
As a result of this news, BMWYY's share price fell $0.36, or 1.3%
to close at $26.96 on December 23, 2019, while BAMXF's share price
fell $1.25, or 1.5%, to close at $80.60 that same day.
Then, on September 24, 2020, BMW agreed to a settlement with the
SEC regarding the "sales punching" investigation. The settlement
included fines of up to $18 million. On this news, BMWYY share
prices fell $0.51, or 2.2%, to close at $23.07 the next day, while
BAMXF share prices fell $2.54, or 3.55%, to close at $68.91 the
next day.
Rosen Law Firm is preparing a class action lawsuit to recover
losses suffered by BMW investors. If you purchased shares of BMW
please visit the firm's website at
http://www.rosenlegal.com/cases-register-1749.htmlto join the
class action. You may also contact Phillip Kim of Rosen Law Firm
toll free at 866-767-3653 or via email at pkim@rosenlegal.com or
cases@rosenlegal.com.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation. Rosen Law Firm was Ranked No. 1
by ISS Securities Class Action Services for number of securities
class action settlements in 2017. The firm has been ranked in the
top 3 each year since 2013. Rosen Law Firm has achieved the largest
ever securities class action settlement against a Chinese Company.
Rosen Law Firm's attorneys are ranked and recognized by numerous
independent and respected sources. Rosen Law Firm has secured
hundreds of millions of dollars for investors. Attorney
Advertising. Prior results do not guarantee a similar outcome. [GN]
BIOMARIN PHARMA: Glancy Prongay Reminds of Nov. 24 Deadline
-----------------------------------------------------------
Glancy Prongay & Murray LLP ("GPM") reminds investors of the
upcoming November 24, 2020 deadline to file a lead plaintiff motion
in the class action filed on behalf of investors who purchased or
otherwise acquired BioMarin Pharmaceuticals, Inc. ("BioMarin" or
the "Company") (NASDAQ: BMRN) securities between February 28, 2020
and August 18, 2020, inclusive (the "Class Period").
If you suffered a loss on your BioMarin investments or would like
to inquire about potentially pursuing claims to recover your loss
under the federal securities laws, you can submit your contact
information at
https://www.glancylaw.com/cases/biomarin-pharmaceuticals-inc/. You
can also contact Charles H. Linehan, of GPM at 310-201-9150,
Toll-Free at 888-773-9224, or via email at
shareholders@glancylaw.com to learn more about your rights.
BioMarin is a biotechnology company that develops and
commercializes therapies for people with serious and
life-threatening rare diseases and medical conditions. The
Company's product candidates include, as well as others,
valoctocogene roxaparvovec, an investigational adeno-associated
virus ("AAV") gene therapy, which is in Phase 3 clinical
development for the treatment of patients with severe hemophilia
A.
On August 19, 2020, BioMarin announced receipt of a Complete
Response Letter ("CRL") from the U.S. Food and Drug Administration
("FDA") regarding the Company's Biologics License Application
("BLA") for valoctocogene roxaparvovec. Therein, the FDA concluded
that the "differences between Study 270-201 (Phase 1/2) and the
Phase 3 study limited its ability to rely on the Phase 1/2 study to
support durability of effect." As a result, the FDA recommended
that BioMarin "complete the Phase 3 Study and submit two-year
follow-up safety and efficacy data on all study participants."
On this news, the Company's stock price fell $41.82 per share, or
35%, to close at $76.72 per share on August 19, 2020, thereby
injuring investors.
The complaint filed in this class action alleges that throughout
the Class Period, Defendants made materially false and/or
misleading statements and/or failed to disclose material adverse
facts about the Company's business, operations, and prospects.
Specifically, Defendants failed to disclose to investors that: (1)
the disparities between the Phase 1/2 and Phase 3 study of
valoctocogene roxaparvovec limited the reliability of the Phase 1/2
study to support valoctocogene roxaparvovec's durability of effect;
(2) as a result, it was foreseeable that the FDA would not approve
the BLA for valoctocogene roxaparvovec without additional data; and
(3) that, as a result of the foregoing, Defendants' positive
statements about the Company's busines, operations, and prospects
were materially misleading and/or lacked a reasonable basis.
If you purchased or otherwise acquired BioMarin securities, you may
move the Court no later than November 24, 2020 to ask the Court to
appoint you as lead plaintiff. To be a member of the Class you need
not take any action at this time; you may retain counsel of your
choice or take no action and remain an absent member of the Class.
If you wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests
with respect to these matters, please contact Charles Linehan,
Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles
California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by
email to shareholders@glancylaw.com, or visit our website at
www.glancylaw.com. If you inquire by email please include your
mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules. [GN]
BIOMARIN PHARMA: Hagens Berman Reminds of Nov. 24 Deadline
----------------------------------------------------------
Hagens Berman urges BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
investors to contact the firm now. A securities fraud class
action has been filed and certain investors may have valuable
claims.
Class Period: Feb. 28, 2020 – Aug. 18, 2020
Lead Plaintiff Deadline: Nov. 24, 2020
Visit: www.hbsslaw.com/investor-fraud/BMRN
Contact An Attorney Now: BMRN@hbsslaw.com
844-916-0895
BioMarin Pharmaceutical (BMRN) Securities Class Action:
The complaint alleges that Defendants' statements misrepresented
and concealed material information about BioMarin's valoctocogene
roxaparvovec product candidate, potentially the first gene therapy
approved by the U.S. FDA for hemophilia in the U.S.
Specifically, throughout the Class Period, Defendants misstated or
omitted to disclose that (1) differences between the phase 1/2 and
phase 3 study of valoctocogene roxaparvovec limited the reliability
of the phase 1/2 study to support valoctocogene roxaparvovec's
durability of effect, and (2) as a result, it was foreseeable that
the FDA would not approve BioMarin's Biologics License Application
("BLA") for valoctocogene roxaparvovec without additional data.
Investors allegedly began to learn the truth on Aug. 19, 2020, when
BioMarin announced it received the FDA's complete response letter
("CRL") to the BLA indicating the FDA recommended the company
submit additional data upon completion of the phase 3 study since
the difference between the phase 1/2 and phase 3 studies limited
the FDA's ability to rely on the phase 1/2 study to support the
durability of effect.
Analysts at Guggenheim were shocked by the Company's disclosure,
noting "[t]his news came as a negative surprise to us in light of
mgt commentary and other launch-related prep (by BMRN and other
payers) and pushes out a potential Roctavian approval until
~2022."
This news drove the price of BioMarin shares down over 35% that
day.
"We're focused on investors' losses and proving Defendants misled
investors about the phase 1/2 reliability for the BLA," said Reed
Kathrein, the Hagens Berman partner leading the investigation.
If you are a BioMarin investor or may assist the firm's
investigation, click here to discuss your legal rights with Hagens
Berman.
Whistleblowers: Persons with non-public information regarding
BioMarin should consider their options to help in the investigation
or take advantage of the SEC Whistleblower program. Under the new
program, whistleblowers who provide original information may
receive rewards totaling up to 30 percent of any successful
recovery made by the SEC. For more information, call Reed Kathrein
at 844-916-0895 or email BMRN@hbsslaw.com.
About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight
cities around the country and eighty attorneys. The firm represents
investors, whistleblowers, workers and consumers in complex
litigation. More about the firm and its successes is located at
hbsslaw.com. [GN]
BIOMARIN PHARMA: Schall Law Firm Reminds of Nov. 24 Deadline
------------------------------------------------------------
The Schall Law Firm, a national shareholder rights litigation firm,
on Sept. 29 announced the filing of a class action lawsuit against
BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ:
BMRN) for violations of Sections 10(b) and 20(a) of the Securities
Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the
U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between February
28, 2020 and August 18, 2020, inclusive (the "Class Period"), are
encouraged to contact the firm before November 24, 2020.
We also encourage you to contact Brian Schall of the Schall Law
Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at
310-301-3335, to discuss your rights free of charge. You can also
reach us through the firm's website at www.schallfirm.com, or by
email at brian@schallfirm.com.
The class, in this case, has not yet been certified, and until
certification occurs, you are not represented by an attorney. If
you choose to take no action, you can remain an absent class
member.
According to the Complaint, the Company made false and misleading
statements to the market. BioMarin's Phase 3 trial of valoctocogene
roxaparvovec differed from its Phase 1/2 trial, which lowered the
reliability of the earlier study's data on durability of effect.
This put the Company at risk of the FDA not approving the BLA for
valoctocogene roxaparvovec without the submission of additional
supporting data. Based on these facts, the Company's public
statements were false and materially misleading throughout the
class period. When the market learned the truth about BioMarin,
investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder
rights litigation.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and rules of ethics.
Contacts:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com [GN]
CABOT OIL: Robbins Geller Files Securities Class Action
-------------------------------------------------------
Robbins Geller Rudman & Dowd LLP
(https://www.rgrdlaw.com/cases-cabot-oil-gas-corporation-class-action-lawsuit.html)
on Oct. 5 disclosed that it filed a class action on behalf of an
institutional investor seeking to represent purchasers of Cabot Oil
& Gas Corporation (NYSE:COG) common stock during the period between
October 23, 2015 and June 12, 2020 (the "Class Period"). This
action was filed in the Middle District of Pennsylvania and is
captioned Delaware County Employees Retirement System v. Cabot Oil
& Gas Corporation, No. 20-cv-1815.
The Private Securities Litigation Reform Act of 1995 permits any
investor who purchased Cabot Oil stock during the Class Period to
seek appointment as lead plaintiff in the Cabot Oil class action
lawsuit. A lead plaintiff acts on behalf of all other class members
in directing the Cabot Oil class action lawsuit. The lead plaintiff
can select a law firm of its choice to litigate the Cabot Oil class
action lawsuit. An investor's ability to share in any potential
future recovery of the Cabot Oil class action lawsuit is not
dependent upon serving as lead plaintiff. If you wish to serve as
lead plaintiff in the Cabot Oil class action lawsuit, you must move
the Court no later than 60 days from August 13, 2020. If you wish
to discuss the Cabot Oil class action lawsuit or have any questions
concerning this notice or your rights or interests, please contact
plaintiff's counsel, Brian E. Cochran of Robbins Geller, at
800/449-4900 or 619/231-1058 or via e-mail at bcochran@rgrdlaw.com.
You can view a copy of the complaint as filed at
https://www.rgrdlaw.com/cases-cabot-oil-gas-corporation-class-action-lawsuit.html.
The Cabot Oil class action lawsuit charges Cabot Oil and certain of
its officers with violations of the Securities Exchange Act of
1934. Cabot Oil is an independent oil and gas company that explores
for, exploits, develops, produces, and markets oil and gas
properties in the United States, with a primary focus on the
Marcellus Shale in Susquehanna County, Pennsylvania.
The complaint alleges that throughout the Class Period, defendants
made false and misleading statements and/or failed to disclose
that: (i) Cabot Oil had inadequate environmental controls and
procedures and/or failed to properly mitigate known issues related
to those controls and procedures; (ii) Cabot Oil failed to fix
faulty gas wells that were polluting Pennsylvania's water supplies
through stray gas migration; and (iii) Cabot Oil continually
downplayed its potential civil and/or criminal liabilities with
respect to environmental matters. These issues were foreseeably
likely to subject Cabot Oil to increased governmental scrutiny and
enforcement, as well as increased reputational and financial harm,
and would also materially impact Cabot Oil's financial results.
Defendants' false statements and omissions caused Cabot Oil stock
to trade at artificially inflated prices throughout the Class
Period.
On July 26, 2019, Cabot Oil filed its quarterly report on Form 10-Q
with the SEC for the quarter ended June 30, 2019. The Form 10-Q
disclosed that the Company had received two proposed Consent Order
and Agreements related to two Notices of Violation it had received
from the Pennsylvania Department of Environmental Protection two
years earlier (in June and November 2017) for failure to prevent
the migration of gas into fresh groundwater sources in the area
surrounding Susquehanna County, Pennsylvania. As a result of this
news, the price of Cabot Oil stock declined 12%.
Then, on June 15, 2020, following a grand jury investigation, the
Pennsylvania Attorney General's office charged Cabot Oil with 15
criminal counts due to its failure to fix the faulty gas wells that
had polluted Pennsylvania's water supplies through stray gas
migration. In announcing the charges, Pennsylvania's Attorney
General, Josh Shapiro, emphasized that defendants ‘"put their
bottom line ahead of the health and safety of our neighbors'" and
that ‘"Cabot knows what they've done.'" On this news, the price
of Cabot Oil stock declined more than 3%.
The plaintiff is represented by Robbins Geller, which has extensive
experience in prosecuting investor class actions including actions
involving financial fraud.
Robbins Geller Rudman & Dowd LLP is one of the world's leading law
firms representing investors in securities litigation. With 200
lawyers in 9 offices, Robbins Geller has obtained many of the
largest securities class action recoveries in history. For seven
consecutive years, ISS Securities Class Action Services has ranked
the Firm in its annual SCAS Top 50 Report as one of the top law
firms in the world in both amount recovered for shareholders and
total number of class action settlements. Robbins Geller attorneys
have helped shape the securities laws and have recovered tens of
billions of dollars on behalf of aggrieved victims. Beyond securing
financial recoveries for defrauded investors, Robbins Geller also
specializes in implementing corporate governance reforms, helping
to improve the financial markets for investors worldwide. Robbins
Geller attorneys are consistently recognized by courts,
professional organizations and the media as leading lawyers in the
industry. Please visit http://www.rgrdlaw.comfor more
information.
Contacts
Robbins Geller Rudman & Dowd LLP
Brian E. Cochran, 800-449-4900
bcochran@rgrdlaw.com [GN]
CELSION CORPORATION: Faces Spar Class Suit Over Stock Price Drop
----------------------------------------------------------------
SHLOMO SPAR, Individually and On Behalf of All Others Similarly
Situated v. CELSION CORPORATION, MICHAEL H. TARDUGNO, JEFFREY W.
CHURCH, and NICHOLAS BORYS, Case No. 1:20-cv-15228 (D.N.J., Oct.
29, 2020), is a federal securities class action on behalf of a
class consisting of all persons and entities other than the
Defendants that purchased or otherwise acquired Celsion securities
between November 2, 2015 and July 10, 2020, both dates inclusive,
seeking to recover damages caused by the Defendants' violations of
the federal securities laws and to pursue remedies under Sections
10(b) and 20(a) of the Securities Exchange Act of 1934, against the
Company and certain of its top officials.
In February 2014, Celsion announced that the U.S. Food and Drug
Administration ("FDA") had reviewed and provided clearance for the
Company's planned pivotal, double-blind, placebo-controlled Phase
III trial of ThermoDox in combination with radio frequency ablation
("RFA") in primary liver cancer, also known as hepatocellular
carcinoma ("HCC"), called the "OPTIMA Study." The trial design was
purportedly based on a comprehensive analysis of data from the
Company's Phase III HEAT Study, which purportedly demonstrated that
treatment with ThermoDox resulted in a 55% improvement in overall
survival ("OS") in a substantial number of HCC patients that
received an optimized RFA treatment.
The OPTIMA Study was expected to enroll 550 patients globally, with
up to 100 sites in the U.S., Europe, China and Asia Pacific, to
evaluate ThermoDox in combination with RFA. The primary endpoint
for the trial was OS, and the statistical plan called for two
interim efficacy analyses by an independent Data Monitoring
Committee ("DMC").
The Plaintiff contends that the Defendants made materially false
and misleading statements regarding the Company's business,
operational and compliance policies.
On July 13, 2020, Celsion announced that "it ha[d] received a
recommendation from the independent [DMC] to consider stopping the
global Phase III OPTIMA Study of ThermoDox (TM) in combination with
[RFA] for the treatment of [t]he [HCC], or primary liver cancer."
(TM) According to the Company, recommendation was made following
the second pre-planned interim safety and efficacy analysis by the
DMC on July 9, 2020, which "found that the pre-specified boundary
for stopping the trial for futility of 0.900 was crossed with an
actual value."
On this news, Celsion's stock price fell $2.29 per share, or
63.97%, to close at $1.29 per share on July 13, 2020.
As a result of the Defendants' wrongful acts and omissions, and the
precipitous decline in the market value of the Company's
securities, the Plaintiff and other Class members have suffered
significant losses and damages.
Celsion was founded in 1982 and is headquartered in Lawrenceville,
New Jersey. Celsion is an integrated development clinical stage
oncology drug company that focuses on the development and
commercialization of directed chemotherapies, DNA-mediated
immunotherapy, and RNA-based therapies for the treatment of cancer.
Celsion's lead product candidate is ThermoDox, a heat-activated
liposomal encapsulation of doxorubicin that is in Phase III
clinical development for treating primary liver cancer.[BN]
The Plaintiff is represented by:
Gustavo F. Bruckner, Esq.
Jeremy A. Lieberman, Esq.
J. Alexander Hood II, Esq.
Patrick V. Dahlstrom, Esq.
POMERANTZ LLP
600 Third Avenue
New York, NY 10016
Telephone: (212) 661-1100
Facsimile: (917) 463-1044
E-mail: gfbruckner@pomlaw.com
jalieberman@pomlaw.com
ahood@pomlaw.com
pdahlstrom@pomlaw.com
CHEMOURS COMPANY: Lifshitz Law Probes Firm
------------------------------------------
Lifshitz Law Firm announces investigation into possible breaches of
fiduciary duty by certain of The Chemours Company (NYSE: CC)'s
officers and/or directors. The investigation relates to a
securities class action lawsuit alleging that certain officers of
the company made false and misleading statements beginning in
February 2017 relating to accrued reserves for its environmental
liabilities.
If you are a CC investor, and would like additional information
about our investigation, please complete the Information Request
Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780
or e-mail at info@jlclasslaw.com.
ATTORNEY ADVERTISING.(C) 2020 Lifshitz Law Firm, P.C. The law firm
responsible for this advertisement is Lifshitz Law Firm, P.C., 821
Franklin Avenue, Suite 209, Garden City, New York 11530, Tel:
(516)493-9780. Prior results do not guarantee or predict a similar
outcome with respect to any future matter. [GN]
COGNIZANT TECHNOLOGY: Suit Dismissal Bid Denied, Lifshitz Says
--------------------------------------------------------------
Lifshitz Law Firm, P.C. announces that on June 5, 2020, the Court
issued an Order denying Cognizant Technology Solutions Corporation
(NASDAQ: CTSH)' Motion to Dismiss a securities class action
alleging that Defendants made materially false and misleading
statements concerning a bribery scheme at the core of CTSH's
business.
If you are a CTSH investor, and would like additional information
about our investigation, please complete the Information Request
Form.
ATTORNEY ADVERTISING.(C) 2020 Lifshitz Law Firm, P.C. The law firm
responsible for this advertisement is Lifshitz Law Firm, P.C., 821
Franklin Avenue, Suite 209, Garden City, New York 11530, Tel:
(516)493-9780. Prior results do not guarantee or predict a similar
outcome with respect to any future matter. [GN]
COLONY CREDIT: Bronstein Gewirtz Reminds of November 9 Deadline
---------------------------------------------------------------
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class
action lawsuit has been filed against Colony Credit Real Estate,
Inc. ("Colony Credit" or the "Company") (NYSE: CLNC) and certain of
its officers, on behalf of shareholders who purchased or otherwise
acquired the common stock of Colony Credit Real Estate, Inc. f/k/a/
Colony NorthStar Credit Real Estate, Inc. ("Colony Credit" or the
"Company") pursuant and/or traceable to the Company's Registration
Statement and Prospectus (collectively, the "Registration
Statement") issued in connection with the combination of Colony
NorthStar, Inc. and NorthStar Real Estate Income Trust, Inc. and
NorthStar Real Estate Income II, Inc. on or about February 1, 2018
(the "Merger"). Such investors are encouraged to join this case by
visiting the firm's site: www.bgandg.com/clnc.
This class action seeks to recover damages against Defendants for
alleged violations of the federal securities laws under the
Securities Exchange Act of 1933.
The Complaint alleges the Registration Statement was materially
false and misleading and omitted to state: (1) that the credit
quality of certain of Colony Credit's assets had deteriorated prior
to the Merger and were continuing to deteriorate at the time of the
Merger; (2) that certain of the Company's loans, including four
loans of approximately $261 million related to a New York hotel,
were substantially impaired, there was insufficient collateral to
secure the loans, and it was unlikely that the loans would be
repaid; (3) that, as a result, the valuation attributed to certain
of the Company's assets was overstated; (4) that, certain of the
assets contributed as part of the Merger were of substantially
lower value than reflected in the Company's financial statements
and the Registration Statement; (5) that, as a result, the
Company's financial condition, including its book value, was
materially overstated; and (6) that, as a result of the foregoing,
the positive statements in the Registration Statement about the
Company's business, operations, and prospects were materially
misleading and/or lacked a reasonable basis
A class action lawsuit has already been filed. If you wish to
review a copy of the Complaint you can visit the firm's site:
www.bgandg.com/clnc or you may contact Peretz Bronstein, Esq. or
his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz
& Grossman, LLC at 212-697-6484. If you suffered a loss in Colony
Credit you have until November 9, 2020 to request that the Court
appoint you as lead plaintiff. Your ability to share in any
recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not guarantee
similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com [GN]
COUSIN JENNY'S: Chinn et al. Sue Over Unlawful Retention of Tips
----------------------------------------------------------------
NELLYA CHINN and PAIGE SMITH, individually, and on behalf of others
similarly situated, Plaintiff v. COUSIN JENNY'S, INC., d/b/a COUSIN
JENNY'S CORNISH PASTIES, a Michigan corporation and JERILYN J.
DeBOER, Defendants, Case No. 1:20-cv-01037 (W.D. Mich., October 28,
2020) is a collective and class action complaint brought against
the Defendants for their alleged willful, intentional, and repeated
violations of the Fair Labor Standards Act (FLSA).
According to the complaint, although the Plaintiffs and others
similarly situated Front of the House Employees received an hourly
wage from the Defendants, they were unlawfully deprived of their
tips/gratuities by the Defendants due to its unlawful policy of
confiscating all tips left for them by customers.
In addition, the Plaintiffs demanded the return of all confiscated
tips by sending a letter to the Defendants on August 24, 2020, but
the Defendants ignored the Plaintiffs' request.
The Plaintiffs were employed by the Defendants as hourly-paid Front
of the House Employees in the Traverse City restaurant.
Cousin Jenny's, Inc., d/b/a Cousin Jenny's Cornish Pastries,
operates a restaurant in Traverse City, Michigan that specializes
in comfort food. [BN]
The Plaintiffs are represented by:
Charles R. Ash, IV, Esq.
SOMMERS SCHWARTZ, P.C.
One Towne Square, Suite 1700
Southfield, MI 48076
Tel: (248) 355-0300
E-mail: crash@sommerspc.com
CREDIT ACCEPTANCE: Kahn Swick Reminds of December 1 Deadline
------------------------------------------------------------
Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney
General of Louisiana, Charles C. Foti, Jr., remind investors that
they have until December 1, 2020 to file lead plaintiff
applications in a securities class action lawsuit against Credit
Acceptance Corporation (NASDAQ: CACC), if they purchased the
Company's shares between November 1, 2019 and August 28, 2020,
inclusive (the "Class Period"). This action is pending in the
United States District Court for the Eastern District of Michigan.
What You May Do
If you purchased shares of Credit Acceptance and would like to
discuss your legal rights and how this case might affect you and
your right to recover for your economic loss, you may, without
obligation or cost to you, contact KSF Managing Partner Lewis Kahn
toll-free at 1-877-515-1850 or via email ( ), or visit [To enable
links contact MENAFN] to learn more. If you wish to serve as a lead
plaintiff in this class action, you must petition the Court by
December 1, 2020 .
About the Lawsuit
Credit Acceptance and certain of its executives are charged with
failing to disclose material information during the Class Period,
violating federal securities laws.
On August 28, 2020, the Attorney General of Massachusetts filed a
lawsuit against the Company for allegedly unfair and deceptive
automobile loans it made to thousands of Massachusetts consumers,
providing its investors with false and/or misleading information
regarding the asset-backed securitizations offered, and for unfair
debt collection practices.
On this news, the price of Credit Acceptance's shares plummeted.
The case is Palm Tran, Inc. Amalgamated Transit Union Local 1577
Pension Plan V. Credit Acceptance Corporation, et al, 20-cv-12698.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General
Charles C. Foti, Jr., is one of the nation's premier boutique
securities litigation law firms. KSF serves a variety of clients -
including public institutional investors, hedge funds, money
managers and retail investors - in seeking to recover investment
losses due to corporate fraud and malfeasance by publicly traded
companies. KSF has offices in New York, California and Louisiana.
[GN]
CREDIT ACCEPTANCE: Kirby McInerney Reminds of Dec. 1 Deadline
-------------------------------------------------------------
The law firm of Kirby McInerney LLP reminds investors that a class
action lawsuit has been filed in the U.S. District Court for the
District of Michigan on behalf of those who acquired Credit
Acceptance Corporation ("Credit Acceptance" or the "Company")
(NASDAQ: CACC) securities during the period from November 1, 2019
through August 28, 2020, inclusive (the "Class Period"). Investors
have until December 1, 2020 to apply to the Court to be appointed
as lead plaintiff in the lawsuit.
According to the Complaint, the Company made false and misleading
statements to the market. Credit Acceptance used high-risk loans to
top off loan pools that it packaged and securitized. The Company
made subprime loans at high interest rates to borrowers it knew
could not repay them. The Company's hidden finance charges raised
the interest rate of these loans above the usury rate ceiling set
by state law. The Company used aggressive and illegal measures to
collect debt from its defaulted borrowers. Based on these facts,
the Company's public statements were false and materially
misleading throughout the class period. When the market learned the
truth about Credit Acceptance, investors suffered damages.
If you acquired Credit Acceptance securities, have information, or
would like to learn more about these claims, please contact Thomas
W. Elrod of Kirby McInerney at 212-371-6600, by email at
investigations@kmllp.com, or by filling out this contact form, to
discuss your rights or interests with respect to these matters
without any cost to you.
Kirby McInerney is a New York-based plaintiffs' law firm
concentrating in securities, antitrust, and whistleblower
litigation. The firm's efforts on behalf of shareholders in
securities litigation have resulted in recoveries totaling billions
of dollars. Additional information about the firm can be found at
Kirby McInerney's website: www.kmllp.com. [GN]
CREDIT ACCEPTANCE: Rosen Law Reminds of Dec. 1 Deadline
-------------------------------------------------------
Rosen Law Firm, a global investor rights law firm, announces the
filing of a class action lawsuit on behalf of purchasers of the
securities of Credit Acceptance Corporation (NASDAQ: CACC) between
November 1, 2019 and August 28, 2020, inclusive (the "Class
Period"). The lawsuit seeks to recover damages for Credit
Acceptance investors under the federal securities laws.
To join the Credit Acceptance class action, go to
http://www.rosenlegal.com/cases-register-1851.htmlor call Phillip
Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or
cases@rosenlegal.com for information on the class action.
The complaint filed in this class action alleges that throughout
the Class Period, Defendants made materially false and/or
misleading statements, as well as failed to disclose material
adverse facts about the Company's business, operations, and
prospects. Specifically, Defendants failed to disclose to investors
that: (1) the Company was topping off the pools of loans that they
packaged and securitized with higher-risk loans; (2) Credit
Acceptance was making high-interest subprime auto loans to
borrowers that the Company knew borrowers would be unable to repay;
(3) the borrowers were subject to hidden finance charges, resulting
in loans exceeding the usury rate ceiling mandated by state law;
(4) Credit Acceptance took excessive and illegal measures to
collect debt from defaulted borrowers; (5) as a result, the Company
was likely to face regulatory scrutiny and possible penalties from
various regulators or lawsuits; and (6) as a result of the
foregoing, Defendant's positive statements about the Company's
business, operations, and adherence to appropriate laws and
regulations were materially misleading and/or lacked a reasonable
basis.
A class action lawsuit has already been filed. If you wish to serve
as lead plaintiff, you must move the Court no later than December
1, 2020. A lead plaintiff is a representative party acting on
behalf of other class members in directing the litigation. If you
wish to join the litigation, go to
http://www.rosenlegal.com/cases-register-1851.htmlor to discuss
your rights or interests regarding this class action, please
contact Phillip Kim, Esq. of Rosen Law Firm toll free at
866-767-3653 or via e-mail at pkim@rosenlegal.com or
cases@rosenlegal.com.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS
IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN
ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN
ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S
ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT
UPON SERVING AS LEAD PLAINTIFF.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation. Rosen Law Firm was Ranked No. 1
by ISS Securities Class Action Services for number of securities
class action settlements in 2017. The firm has been ranked in the
top 3 each year since 2013. Rosen Law Firm has achieved the largest
ever securities class action settlement against a Chinese Company.
Rosen Law Firm's attorneys are ranked and recognized by numerous
independent and respected sources. Rosen Law Firm has secured
hundreds of millions of dollars for investors. Attorney
Advertising. Prior results do not guarantee a similar outcome. [GN]
ERIC CHURCH: Hayden Sues Over Unpaid Overtime and Retaliation
-------------------------------------------------------------
MARY BETH HAYDEN, on behalf of herself and all similarly situated
employees, Plaintiff v. ERIC CHURCH and KATHERINE CHURCH,
Defendants, Case No. 3:20-cv-00926 (M.D. Tenn., October 28, 2020)
brings this collective action complaint against the Defendants for
their alleged breach of contract under North Carolina law and
violations of the Fair Labor Standards Act (FLSA).
The Plaintiff started working for the Defendants as a domestic
service worker in the position known as Estate Manager/Personal
Assistant on July 9, 2019.
According to the complaint, the Plaintiff and other similarly
situated employees regularly worked more than 40 hours per
workweek, but were not paid by the Defendants for their lawfully
earned overtime compensation for hours worked over 40 in a workweek
at one and one-half times their regular rates of pay because they
were misclassified by the Defendants as exempt from overtime
compensation.
The Plaintiff asserts that she was immediately terminated by
Defendant Katherine Church when she complained about the
surveillance camera, which she discovered installed near the
temporary sleeping quarters for female employees at the Defendants'
Banner Elk home. The surveillance camera was allegedly capturing
images of the Plaintiff and other female employees in various
stages of undress.
Eric Church is a world-famous country music star. Katherine Church
is Eric Church's wife and a music publisher. [BN]
The Plaintiff is represented by:
Charles P. Yezbak, III, Esq.
N. Chase Teeples, Esq.
YEZBK LAW OFFICES PLLC
2021 Richard Jones Road, Suite 310-A
Nashville, TN 37215
Tel: (615) 250-2000
E-mail: yezbak@yezbaklaw.com
teeples@yezbaklaw.com
EVOLUS INC: Glancy Prongay Reminds of Dec. 15 Deadline
------------------------------------------------------
Glancy Prongay & Murray LLP ("GPM"), a leading national rights
firm, announces that a class action lawsuit has been filed on
behalf of investors who purchased or otherwise acquired Evolus,
Inc.("Evolus" or the "Company") (NASDAQ: EOLS) securities between
February 1, 2019 and July 6, 2020, inclusive (the "Class Period").
Evolus investors have until December 15, 2020 to file a lead
plaintiff motion.
If you suffered a loss on your Evolus investments or would like to
inquire about potentially pursuing claims to recover your loss
under the federal securities laws, you can submit your contact
information at https://www.glancylaw.com/cases/evolus-inc/. You can
also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free
at 888-773-9224, or via email at shareholders@glancylaw.com to
learn more about your rights.
Evolus is a direct competitor with Botox, which is manufactured by
Allergan plc and Allergan Inc. (collectively, "Allergan") and
distributed by Medytox Inc. ("Medytox"). Botox has been the gold
standard of the industry since its approval by the U.S. Food and
Drug Administration ("FDA") more than twenty years ago.
On July 6, 2020, the Initial Final Determination was issued by the
U.S. International Trade Commission ("ITC") in a case brought by
Allergan and Medytox against Evolus, asserting that Evolus stole
certain trade secrets to develop Jeuveau™. The ITC Judge
determined that the Company misappropriated the botulinum toxin
strain as well as the manufacturing processes that led to its
development and manufacture. As a result, the ITC Judge recommended
a ten-year long ban on the Company's ability to import Jeuveau™
into the United States and a ten-year long cease and desist order
preventing Evolus from selling Jeuveau™ in the United States.
On this news, the Company's share price declined significantly,
falling 37% over the course of two trading days, to close at $3.35
on July 8, 2020, thereby injuring investors.
The complaint filed in this class action alleges that throughout
the Class Period, Defendants made materially false and/or
misleading statements, as well as failed to disclose material
adverse facts about the Company's business, operations, and
prospects. Specifically, Defendants failed to disclose to
investors: (1) that the real source of botulinum toxin bacterial
strain, along with the manufacturing processes used to develop
Jeuveau, originated with and were misappropriated from Medytox; (2)
that sufficient evidentiary support existed for the allegations
that the Company misappropriated certain trade secrets relating to
the botulin toxin strain and the manufacturing processes for the
development of Jeuveau; (3) as a result, the Company faced a real
threat of regulatory and/or court action, barring the import,
marketing, and sale of Jeuveau; (4) which in turn seriously
threatened Evolus' ability to commercialize Jeuveau in the United
States and generate revenue; and (5) that any revenues generated
from the sale of Jeuveau were based on Evolus' unlawful actions,
including the misappropriation of trade secrets and secret
manufacturing processes belonging to Allergan and Medytox; and (6)
that, as a result, the Company's public statements were materially
false and misleading at all relevant times.
If you purchased or otherwise acquired Evolus securities during the
Class Period, you may move the Court no later than December 15,
2020 to request appointment as lead plaintiff in this putative
class action lawsuit. To be a member of the class action you need
not take any action at this time; you may retain counsel of your
choice or take no action and remain an absent member of the class
action. If you wish to learn more about this class action, or if
you have any questions concerning this announcement or your rights
or interests with respect to the pending class action lawsuit,
please contact Charles Linehan, Esquire, of GPM, 1925 Century Park
East, Suite 2100, Los Angeles, California 90067 at 310-201-9150,
Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com,
or visit our website at www.glancylaw.com. If you inquire by email
please include your mailing address, telephone number and number of
shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules. [GN]
FLUIDIGM CORP: Bernstein Liebhard Reminds of November 20 Deadline
-----------------------------------------------------------------
Bernstein Liebhard, a nationally acclaimed investor rights law
firm, reminds investors of the deadline to file a lead plaintiff
motion in a securities class action that has been filed on behalf
of investors that purchased or acquired the securities of Fluidigm
Corporation ("Fluidigm" or the "Company") (NASDAQ: FLDM) between
February 7, 2019, and November 5, 2019(the "Class Period"). The
lawsuit filed in the United States District Court for the Northern
District of California alleges violations of the Securities
Exchange Act of 1934.
If you purchased Fluidigm securities, and/or would like to discuss
your legal rights and options please visit FLDM Shareholder Class
Action Lawsuit or contact Matthew E. Guarnero toll free at (877)
779-1414 or MGuarnero@bernlieb.com.
The complaint alleges that throughout the Class Period, defendants
made false and/or misleading statements and/or failed to disclose
that: (1) that Fluidigm was experiencing longer sales cycles; (2)
that, as a result, Fluidigm's revenue was reasonably likely to
decline; and (3) that, as a result of the foregoing, Defendants'
positive statements about the Company's business, operations, and
prospects were materially misleading and/or lacked a reasonable
basis.
On November 5, 2019, after the market closed, Fluidigm reported
that third quarter 2019 revenue declined 8.5% year-over-year
primarily due to mass cytometry instrument sales. On this news, the
Company's share price fell $2.60, or 51% to close at $2.51 per
share on November 6, 2019.
If you wish to serve as lead plaintiff, you must move the Court no
later than November 20, 2020. A lead plaintiff is a representative
party acting on behalf of other class members in directing the
litigation. Your ability to share in any recovery doesn't require
that you serve as lead plaintiff. If you choose to take no action,
you may remain an absent class member.
If you purchased Fluidigm securities, and/or would like to discuss
your legal rights and options please visit
https://www.bernlieb.com/cases/fluidigmcorporation-fldm-shareholder-class-action-lawsuit-stock-fraud-312/apply/
contact Matthew E. Guarnero toll free at (877) 779-1414 or
MGuarnero@bernlieb.com.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion
for its clients. In addition to representing individual investors,
the Firm has been retained by some of the largest public and
private pension funds in the country to monitor their assets and
pursue litigation on their behalf. As a result of its success
litigating hundreds of lawsuits and class actions, the Firm has
been named to The National Law Journal's "Plaintiffs' Hot List"
thirteen times and listed in The Legal 500 for ten consecutive
years.
Contact Information:
Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
MGuarnero@bernlieb.com [GN]
GARRETT MOTION: Federman & Sherwood Reminds of Nov. 24 Deadline
---------------------------------------------------------------
Federman & Sherwood disclosed that on September 25, 2020, a class
action lawsuit was filed in the United States District Court for
the Southern District of New York against Garrett Motion, Inc.
(NYSE: GTX) (OTC: GTXMQ). The complaint alleges violations of
federal securities laws, Sections 10(b) and 20(a) of the Securities
Exchange Act of 1934 and Rule 10b-5, including allegations of
issuing a series of material or false misrepresentations to the
market which had the effect of artificially inflating the market
price during the Class Period, which is October 1, 2018 through
September 28, 2020.
To learn how to participate in this action, please visit
https://www.federmanlaw.com/blog/federman-sherwood-announces-the-filing-of-a-securities-class-action-lawsuit-against-garrett-motion-inc/
Plaintiff seeks to recover damages on behalf of all Garrett Motion,
Inc. shareholders who purchased common stock during the Class
Period and are therefore a member of the Class as described above.
You may move the Court no later than Tuesday, November 24, 2020 to
serve as a lead plaintiff for the entire Class. However, in order
to do so, you must meet certain legal requirements pursuant to the
Private Securities Litigation Reform Act of 1995.
If you wish to discuss this action, obtain further information and
participate in this or any other securities litigation, or should
you have any questions or concerns regarding this notice or
preservation of your rights, please contact:
Robin Hester
FEDERMAN & SHERWOOD
10205 North Pennsylvania Avenue
Oklahoma City, OK 73120
Email to: rkh@federmanlaw.com
Or, visit the firm's website at www.federmanlaw.com [GN]
GARRETT MOTION: Levi & Korsinsky Reminds of November 24 Deadline
----------------------------------------------------------------
The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired
securities of Garrett Motion Inc. ("Garrett Motion") (NYSE: GTX)
between October 1, 2018 and September 18, 2020. You are hereby
notified that a securities class action lawsuit has been commenced
in the the United States District Court for the Southern District
of New York. To get more information go to:
https://www.zlk.com/pslra-1/garrett-motion-inc-loss-submission-form?prid=9830&wire=5
or contact Joseph E. Levi, Esq. either via email at
jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is
no cost or obligation to you.
The complaint alleges that throughout the class period Defendants
issued materially false and/or misleading statements and/or failed
to disclose that: (1) due to its agreement to indemnify and
reimburse Honeywell for certain asbestos-related liability, Garrett
was saddled with an unsustainable level of debt; (2) as a result,
Garrett had a highly leveraged capital structure that posed
significant challenges to its overall strategic and financial
flexibility; (3) as a result of the foregoing, Garrett's ability to
gain or hold market share was impaired; (4) as a result of the
foregoing, the Company was reasonably likely to seek bankruptcy
protection; and (5) as a result of the foregoing, Defendants'
positive statements about the Company's business, operations, and
prospects were materially misleading and/or lacked a reasonable
basis.
If you suffered a loss in Garrett Motion you have until November
24, 2020 to request that the Court appoint you as lead plaintiff.
Your ability to share in any recovery doesn't require that you
serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in
New York, California, Connecticut, and Washington D.C. The firm's
attorneys have extensive expertise and experience representing
investors in securities litigation and have recovered hundreds of
millions of dollars for aggrieved shareholders. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com [GN]
GOHEALTH INC: Wolf Haldenstein Reminds of November 20 Deadline
--------------------------------------------------------------
Wolf Haldenstein Adler Freeman & Herz LLP on Oct. 5 disclosed that
it has filed a federal securities class action lawsuit against
GoHealth, Inc. ("GoHealth" or the "Company") (NASDAQ: GOCO). The
class action, filed in the United States District Court for the
Northern District of Illinois, Eastern Division, and docketed under
1:20-cv-05765, is on behalf of a class consisting of all persons
other than Defendants who purchased or otherwise acquired GoHealth
Class A common stock pursuant and/or traceable to the registration
statement issued in connection with GoHealth's July 2020 initial
public offering (the "IPO"). Wolf Haldenstein is seeking to pursue
remedies under the Securities Act of 1933 (the "Securities Act")
against GoHealth, certain of GoHealth's officers and directors, and
the private equity sponsor of the IPO and its affiliates.
All investors who purchased shares of GoHealth and incurred losses
are urged to contact the firm immediately at classmember@whafh.com
or (800) 575-0735 or (212) 545-4774. You may obtain additional
information concerning the action or join the case on our website,
www.whafh.com.
If you have incurred losses in the shares of against GoHealth., you
may, no later than November 20, 2020, request that the Court
appoint you lead plaintiff of the proposed class. Please contact
Wolf Haldenstein to learn more about your rights as an investor in
the shares of GoHealth.
On June 19, 2020, GoHealth filed a registration statement with the
United States Securities and Exchange Commission ("SEC") for the
IPO on Form S-1 (the "Registration Statement"), which was used to
sell to the investing public 43.5 million shares of GoHealth Class
A common stock at $21 per share, for total gross proceeds of $913.5
million.
Our complaint alleges that the Offering Materials for the IPO were
negligently prepared and, as a result, contained untrue statements
of material fact, omitted material facts necessary to make the
statements contained therein not misleading, and failed to make
necessary disclosures required under the rules and regulations
governing their preparation. Specifically, the Offering Materials
failed to disclose that at the time of the IPO:
* the Medicare insurance industry was undergoing a period of
elevated churn, which had begun in the first half of 2020;
* GoHealth suffered from a higher risk of customer churn as a
result of its unique business model and limited carrier base;
* GoHealth suffered from degradations in customer persistency
and retention as a result of elevated industry churn,
vulnerabilities that arose from the Company's concentrated carrier
business model, and GoHealth's efforts to expand into new
geographies, develop new carrier partnerships and worsening product
mix;
* GoHealth had entered into materially less favorable revenue
sharing arrangements with its external sales agents; and
* these adverse financial and operational trends were internally
projected by GoHealth to continue and worsen following the IPO.
Since the July 2020 IPO, the price of GoHealth Class A common stock
has suffered significant price declines. By September 15, 2020,
GoHealth Class A common stock closed at just $12.53 per share --
over 40% below the $21 per share price investors paid for the stock
in the IPO nearly two months prior.
Wolf Haldenstein has extensive experience in the prosecution of
securities class actions and derivative litigation in state and
federal trial and appellate courts across the country. The firm
has attorneys in various practice areas; and offices in New York,
Chicago and San Diego. The reputation and expertise of this firm
in shareholder and other class litigation has been repeatedly
recognized by the courts, which have appointed it to major
positions in complex securities multi-district and consolidated
litigation.
If you wish to discuss this action or have any questions regarding
your rights and interests in this case, please immediately contact
Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at
classmember@whafh.com, or visit our website at www.whafh.com.
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules. [GN]
HALLMARK FINANCIAL: Hagens Berman Files Amended Class Action
------------------------------------------------------------
Hagens Berman, the preeminent plaintiffs' class action law firm, as
Lead Counsel, on Oct. 6 disclosed that the court-appointed Lead
Plaintiff represented by the firm has filed an amended complaint in
the securities fraud class action lawsuit pending against Hallmark
and certain of its senior executives. The firm encourages
individuals with relevant, non-public information regarding
Hallmark to contact the firm now.
Hallmark Financial Services, Inc. (HALL) Securities Class Action:
The action, captioned Schulze v. Hallmark Financial Services, Inc.,
et al., No. 3:20-cv-1130-X, was filed in the United States District
Court for the Northern District of Texas on May 5, 2020, on behalf
of all investors who purchased or otherwise acquired the
publicly-traded common stock of Hallmark during the period from
March 5, 2019, through March 17, 2020, inclusive (the "Class
Period").
If you have information regarding Hallmark's alleged fraud, Hagens
Berman wants to hear from you. Individuals with non-public
information regarding Hallmark are encouraged to contact the firm
by emailing HALL@hbsslaw.com or by calling 844-916-0895.
As alleged in the Amended Complaint, throughout the Class Period,
Defendants misrepresented and concealed that: (1) Hallmark
deliberately and systematically manipulated and understated loss
reserves in order to overstate its reported net income during the
Class Period; and (2) lacked effective internal accounting controls
to prevent such manipulation.
Investors began to learn the truth, according to the complaint,
through a series of disclosures beginning on Mar. 2, 2020, when
Hallmark announced it was exiting the Binding Primary Commercial
Auto business and reported a $63.8 million loss development for
prior underwriting years.
Then, on Mar. 11, 2020, Hallmark announced it had dismissed its
independent auditor BDO over a "disagreement" concerning the
Company's estimated reserves for unpaid losses and loss adjustment
expenses throughout 2019.
Finally, on Mar. 17, 2020, Hallmark disclosed a letter from BDO to
the SEC revealing that BDO had expanded significantly the scope of
its audit on Jan. 31, 2020, with respect to the matters of
disagreement, and that "a substantial portion the requests had not
been received and/or tested prior to our termination."
These disclosures caused Hallmark shares to decline over 75%
between Mar. 2 and Mar. 18, 2020.
On July 22, 2020, Hagens Berman was named lead counsel in the case
by the Honorable Brantley Starr, with Steve Berman, managing
partner and co-founder of firm, serving as the lead trial counsel.
For more information about the case visit:
http://www.hbsslaw.com/cases/HALL
About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight
cities around the country and eighty attorneys. The firm represents
investors, whistleblowers, workers and consumers in complex
litigation. More about the firm and its successes is located at
hbsslaw.com. [GN]
HONEYWELL INTERNATIONAL: Suit Dismissal Bid Denied, Lifshitz Says
------------------------------------------------------------------
Lifshitz Law Firm, P.C. announces that on May 18, 2020, the Court
issued an Order denying Honeywell International Inc. (NASDAQ: HON)'
Motion to Dismiss a securities class action alleging that
Defendants made materially false and misleading statements
regarding Honeywell's business, operational and compliance
policies.
If you are a HON investor, and would like additional information
about our investigation, please complete the Information Request
Form.
ATTORNEY ADVERTISING.(C) 2020 Lifshitz Law Firm, P.C. The law firm
responsible for this advertisement is Lifshitz Law Firm, P.C., 821
Franklin Avenue, Suite 209, Garden City, New York 11530, Tel:
(516)493-9780. Prior results do not guarantee or predict a similar
outcome with respect to any future matter. [GN]
HUAZHU GROUP: Rosen Law Firm Investigates Securities Claims
-----------------------------------------------------------
Rosen Law Firm, a global investor rights law firm, continues to
investigate potential securities claims on behalf of shareholders
of Huazhu Group Limited (NASDAQ: HTHT) resulting from allegations
that Huazhu Group may have issued materially misleading business
information to the investing public.
On September 21, 2020, the investment analyst Bonitas Research
issued a report on the Company which alleged that Huazhu Group
"lied about the ownership of its hotel portfolio to produce fake
financials." The report also stated that Bonitas' "fieldwork"
"confirmed that Huazhu secretly supported operating costs of
franchisee hotels owned by undisclosed current Huazhu employees &
other undisclosed related parties (‘off-book hotels')." Bonitas
further asserted that it "believe[s] that Huazhu concealed
operating expenses using undisclosed related party transactions to
artificially inflate Huazhu's reported profits[,]" and that it
"calculate[s] that Huazhu's fake profits manifested as RMB 2
billion (US$ 300 million) of fake PP&E on its CYE'19 balance
sheet."
On this news, Huazhu Group's American depositary share ("ADS")
price fell $1.54, or over 3.6%, to close at $40.48 per ADS on
September 21, 2020, thereby injuring investors.
Rosen Law Firm is preparing a class action lawsuit to recover
losses suffered by Huazhu Group's investors. If you purchased ADSs
of Huazhu Group, please visit the firm's website at
http://www.rosenlegal.com/cases-register-1949.htmlto join the
class action. You may also contact Phillip Kim of Rosen Law Firm
toll free at 866-767-3653 or via email at pkim@rosenlegal.com or
cases@rosenlegal.com.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation. Rosen Law Firm was Ranked No. 1
by ISS Securities Class Action Services for number of securities
class action settlements in 2017. The firm has been ranked in the
top 3 each year since 2013. Rosen Law Firm has achieved the largest
ever securities class action settlement against a Chinese Company.
Rosen Law Firm's attorneys are ranked and recognized by numerous
independent and respected sources. Rosen Law Firm has secured
hundreds of millions of dollars for investors.
Attorney Advertising. Prior results do not guarantee a similar
outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com [GN]
INFINITY FASTENERS: Rendon Labor Suit Removed to E.D. California
----------------------------------------------------------------
The case styled ERIC RENDON, on behalf of himself and all others
similarly situated v. INFINITY FASTENERS, INC. and DOES 1-50, Case
No. 20CECG02019, was removed from the Superior Court of the State
of California in and for the County of Fresno to the U.S. District
Court for the Eastern District of California on October 29, 2020.
The Clerk of Court for the Eastern District of California assigned
Case No. 1:20-cv-01538-DAD-BAM to the proceeding.
The case arises from the Defendant's alleged violations of the
California Labor Code and the California's Business and Professions
Code including retaliation for work-related complaints, withholding
of wages, failure to timely pay final wages, failure to reimburse
business expenses, and unfair business practices.
Infinity Fasteners, Inc. is a supplier of fasteners, headquartered
in Lenexa, Kansas. [BN]
The Defendant is represented by:
Kellie M. Murphy, Esq.
Kristen M. Caprino, Esq.
JOHNSON SCHACHTER & LEWIS
A Professional Law Corporation
Harvard Square
2180 Harvard Street, Suite 560
Sacramento, CA 95815
Telephone: (916) 921-5800
Facsimile: (916) 921-0247
E-mail: kellie@jsl-law.com/kristen@jsl-law.com
JOERNS HEALTHCARE: Fails to Pay Proper Overtime, Brooks Claims
--------------------------------------------------------------
ROGER BROOKS, individually, and on behalf of himself and other
similarly situated current and former employees, Plaintiff v.
JOERNS HEALTHCARE, LLC, a Delaware Limited Liability Company,
Defendant, Case No. 2:20-cv-00224 (E.D. Tenn., October 28, 2020)
brings this collective action complaint against the Defendant for
its alleged violation of the Fair Labor Standards Act.
The Plaintiff, who was employed by the Defendant as an hourly-paid
Field Service Technician, claims that despite regularly working in
excess of 40 hours per within weekly pay periods, the Defendant did
not compensate him and other similarly situated current and former
employees for all their compensable overtime hours at the
applicable FLSA overtime rates of pay.
According to the complaint, the Defendant had a common plans,
policies, and practices of requiring them to work "off-the-clock"
without compensating them for such "off-the-clock" work; and
automatically "editing-out" a 30-minute meal periods for which
times they were not compensated at the applicable FLSA overtime
rates of pay.
Joerns Healthcare, LLC is a fully integrated provider of services
and products to post-acute care facilities. [BN]
The Plaintiff is represented by:
Gordon E. Jackson, Esq.
J. Russ Bryant, Esq.
Robert E. Turner, Esq.
JACKSON, SHIELDS, YEISER, HOLT
OWEN & BRYANT
Attorneys at Law
262 German Oak Drive
Memphis, TN 38018
Tel: (901) 754-8001
Fax: (901) 754-8524
E-mail: gjackson@jsyc.com
rbryant@jsyc.com
rturner@jsyc.com
LAS VEGAS SANDS: Bronstein Gewirtz Reminds of Dec. 21 Deadline
--------------------------------------------------------------
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class
action lawsuit has been filed against Las Vegas Sands Corp. ("Las
Vegas Sands" or the "Company") (NYSE:LVS) and certain of its
officers, on behalf of shareholders who purchased or otherwise
acquired Las Vegas Sands securities between February 27, 2016 and
September 15, 2020, both dates inclusive (the "Class Period"). Such
investors are encouraged to join this case by visiting the firm's
site: www.bgandg.com/lvs.
This class action seeks to recover damages against Defendants for
alleged violations of the federal securities laws under the
Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants
made materially false and misleading statements and omitted to
disclose material facts regarding the Company's business and
operations. Specifically the complaint alleges that Defendants made
false and or misleading statements and/or failed to disclose that:
(1) weaknesses existed in Marina Bay Sands' casino control measures
pertaining to fund transfers; (2) the Marina Bay Sands' casino was
consequently prone to illicit fund transfers that implicated, among
other issues, the transfer of customer funds to unauthorized
persons and potential breaches in the Company's anti-money
laundering procedures; (3) the foregoing foreseeably increased the
risk of litigation against the Company, as well as investigation
and increased oversight by regulatory authorities; (4) Las Vegas
Sands had inadequate disclosure controls and procedures; (5)
consequently, all the foregoing issues were untimely disclosed; and
(6) as a result, the Company's public statements were materially
false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to
review a copy of the Complaint you can visit the firm's site:
www.bgandg.com/lvs or you may contact Peretz Bronstein, Esq. or his
Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz &
Grossman, LLC at 212-697-6484. If you suffered a loss in Las Vegas
Sands you have until December 21, 2020 to request that the Court
appoint you as lead plaintiff. Your ability to share in any
recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not guarantee
similar outcomes. [GN]
LAS VEGAS SANDS: Gainey McKenna Reminds of Dec. 21 Deadline
-----------------------------------------------------------
Gainey McKenna & Egleston announces that a class action lawsuit has
been filed against Las Vegas Sands Corp. ("Las Vegas Sands" or the
"Company") (NYSE: LVS) in the United States District Court for the
District of Nevada on behalf of those who purchased or acquired the
securities of Las Vegas Sands between February 27, 2016 and
September 15, 2020, inclusive (the "Class Period"). The lawsuit
seeks to recover damages for Las Vegas Sands investors under the
federal securities laws.
The Complaint alleges that Defendants made false and/or misleading
statements and/or failed to disclose that: (1) Marina Bay Sands, a
Las Vegas Sands resort in Singapore, casino control measures
pertaining to fund transfers had weaknesses; (2) the Marina Bay
Sands' casino was consequently prone to illicit fund transfers that
implicated, among other issues, the transfer of customer funds to
unauthorized persons and potential breaches in the Company's
anti-money laundering procedures; (3) the foregoing foreseeably
increased the risk of litigation against the Company, as well as
investigation and increased oversight by regulatory authorities;
(4) Las Vegas Sands had inadequate disclosure controls and
procedures; (5) consequently, all the foregoing issues were
untimely disclosed; and (6) as a result, the Company's public
statements were materially false and misleading at all relevant
times. When the true details entered the market, the lawsuit claims
that investors suffered damages.
Investors who purchased or otherwise acquired shares of Las Vegas
Sands during the Class Period should contact the Firm prior to the
December 21, 2020 lead plaintiff motion deadline. A lead plaintiff
is a representative party acting on behalf of other class members
in directing the litigation. If you wish to discuss your rights or
interests regarding this class action, please contact Thomas J.
McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna &
Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com
or gegleston@gme-law.com.
Please visit our website at http://www.gme-law.comfor more
information about the firm. [GN]
LAS VEGAS SANDS: Rosen Law Reminds of Dec. 21 Deadline
------------------------------------------------------
Rosen Law Firm, a global investor rights law firm, announces the
filing of a class action lawsuit on behalf of purchasers of the
securities of Las Vegas Sands Corp. (NYSE: LVS) between February
27, 2016 and September 15, 2020, inclusive (the "Class Period").
The lawsuit seeks to recover damages for Las Vegas Sands investors
under the federal securities laws.
To join the Las Vegas Sands class action, go to
http://www.rosenlegal.com/cases-register-1948.htmlor call Phillip
Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or
cases@rosenlegal.com for information on the class action.
According to the lawsuit, defendants throughout the Class Period
made false and/or misleading statements and/or failed to disclose
that: (1) Marina Bay Sands, a Las Vegas Sands resort in Singapore,
casino control measures pertaining to fund transfers had
weaknesses; (2) the Marina Bay Sands' casino was consequently prone
to illicit fund transfers that implicated, among other issues, the
transfer of customer funds to unauthorized persons and potential
breaches in the Company's anti-money laundering procedures; (3) the
foregoing foreseeably increased the risk of litigation against the
Company, as well as investigation and increased oversight by
regulatory authorities; (4) Las Vegas Sands had inadequate
disclosure controls and procedures; (5) consequently, all the
foregoing issues were untimely disclosed; and (6) as a result, the
Company's public statements were materially false and misleading at
all relevant times. When the true details entered the market, the
lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve
as lead plaintiff, you must move the Court no later than December
21, 2020. A lead plaintiff is a representative party acting on
behalf of other class members in directing the litigation. If you
wish to join the litigation, go to
http://www.rosenlegal.com/cases-register-1948.htmlor to discuss
your rights or interests regarding this class action, please
contact Phillip Kim, Esq. of Rosen Law Firm toll free at
866-767-3653 or via e-mail at pkim@rosenlegal.com or
cases@rosenlegal.com.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS
IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN
ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN
ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S
ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT
UPON SERVING AS LEAD PLAINTIFF.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation. Rosen Law Firm was Ranked No. 1
by ISS Securities Class Action Services for number of securities
class action settlements in 2017. The firm has been ranked in the
top 3 each year since 2013. Rosen Law Firm has achieved the largest
ever securities class action settlement against a Chinese Company.
Rosen Law Firm's attorneys are ranked and recognized by numerous
independent and respected sources. Rosen Law Firm has secured
hundreds of millions of dollars for investors. Attorney
Advertising. Prior results do not guarantee a similar outcome. [GN]
LOOP INDUSTRIES: Howard G. Smith Reminds of Dec. 14 Deadline
------------------------------------------------------------
Law Offices of Howard G. Smith reminds investors of the upcoming
December 14, 2020 deadline to file a lead plaintiff motion in the
class action filed on behalf of investors who purchased Loop
Industries, Inc. ("Loop" or the "Company") (NASDAQ: LOOP)
securities between September 24, 2018 and October 12, 2020,
inclusive (the "Class Period").
Investors suffering losses on their Loop investments are encouraged
to contact the Law Offices of Howard G. Smith to discuss their
legal rights in this class action at 888-638-4847 or by email to
howardsmith@howardsmithlaw.com.
On October 13, 2020, Hindenburg Research published a report
alleging, among other things, that "Loop's scientists, under
pressure from CEO Daniel Solomita, were tacitly encouraged to lie
about the results of the company's process internally." The report
also stated that "Loop's previous claims of breaking PET down to
its base chemicals at a recovery rate of 100% were 'technically and
industrially impossible,'" according to a former employee.
Moreover, the report alleged that "Executives from a division of
key partner Thyssenkrupp, who Loop entered into a 'global alliance
agreement' with in December 2018, told us their partnership is on
'indefinite' hold and that Loop 'underestimated' both costs and
complexities of its process."
On this news, Loop's share price fell $3.78, or over 32%, to close
at $7.83 per share on October 13, 2020, thereby damaging
investors.
The complaint filed alleges that throughout the Class Period,
Defendants made materially false and/or misleading statements, as
well as failed to disclose material adverse facts about the
Company's business, operations, and prospects. Specifically,
Defendants failed to disclose to investors: (1) that Loop
scientists were encouraged to misrepresent the results of Loop's
purportedly proprietary process; (2) that Loop did not have the
technology to break PET down to its base chemicals at a recovery
rate of 100%; (3) that, as a result, the Company was unlikely to
realize the purported benefits of Loop's announced partnerships
with Indorama and Thyssenkrupp; and (4) that, as a result of the
foregoing, Defendants' positive statements about the Company's
business, operations, and prospects were materially misleading
and/or lacked a reasonable basis.
If you purchased Loop securities, have information or would like to
learn more about these claims, or have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Howard G. Smith, Esquire, of Law Offices of
Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem,
Pennsylvania, 19020 by telephone at (215) 638-4847, toll-free at
(888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or
visit our website at www.howardsmithlaw.com. [GN]
LOOP INDUSTRIES: Robbins LLP Reminds of Dec. 14 Deadline
--------------------------------------------------------
Shareholder rights law firm Robbins LLP announces that a purchaser
of Loop Industries, Inc. (NASDAQ: LOOP) has filed a class action
complaint against the company's officers for alleged violations of
the Securities Exchange Act of 1934 between September 24, 2018 and
October 12, 2020. Loop Industries, Inc. claims to own proprietary
technology that can be used to depolymerize waste polyethylene
terephthalate (PET) plastics and polyester fibers into base
building blocks.
Loop Industries, Inc. (LOOP) Accused of Deceiving Consumers and
Investors
According to the complaint, during the class period, the company
falsely touted the strength of Loop's technological and operational
profile. On October 13, 2020, Hidenburg Research published a report
titled "Loop Industries: Former Employees and Plastics Experts Blow
The Whistle On This ‘Recycled' Smoke And Mirrors Show." According
to the report, Loop Industries' scientists were under pressure from
CEO Daniel Solomita to lie about the results of the company's
process. Hidenburg also alleged that the Company did not have the
proprietary process or technology to break PET down to its base
chemicals at a recovery rate of 100% and that it would have been
'technically and industrially impossible' to do so. The report
purported that a key partner Tysenkrupp put an indefinite hold on
their global alliance agreement as Loop 'underestimated' both costs
and complexities of its process. On this news, Loop's stock dropped
32% to close at $7.83 and has yet to recover.
If you purchased Loop Industries, Inc. (LOOP) securities between
September 24, 2018 and October 12, 2020, you have until December
14, 2020, to ask the court to appoint you lead plaintiff for the
class.
Lauren Levi
Tel No: (800) 350-6003
E-mail: llevi@robbinsllp.com
Robbins LLP is a nationally recognized leader in shareholder rights
law. To be notified if a class action against Loop Industries, Inc.
settles or to receive free alerts about companies engaged in
wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar
outcome. [GN]
LOOP INDUSTRIES: Rosen Law Reminds of Dec. 14 Deadline
------------------------------------------------------
Rosen Law Firm, a global investor rights law firm, announces the
filing of a class action lawsuit on behalf of purchasers of the
securities of Loop Industries, Inc. (NASDAQ: LOOP) between
September 24, 2018 and October 12, 2020, inclusive (the "Class
Period"). The lawsuit seeks to recover damages for Loop investors
under the federal securities laws.
To join the Loop class action, go to
http://www.rosenlegal.com/cases-register-1969.htmlor call Phillip
Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or
cases@rosenlegal.com for information on the class action.
According to the lawsuit, defendants throughout the Class Period
made false and/or misleading statements and/or failed to disclose
that: (1) Loop scientists were encouraged to misrepresent the
results of Loop's purportedly proprietary process; (2) Loop did not
have the technology to break PET down to its base chemicals at a
recovery rate of 100%; (3) as a result, the Company was unlikely to
realize the purported benefits of Loop's announced partnerships
with Indorama and Thyssenkrupp; and (4) as a result of the
foregoing, defendants' positive statements about Loop's business,
operations, and prospects were materially misleading and/or lacked
a reasonable basis. When the true details entered the market, the
lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve
as lead plaintiff, you must move the Court no later than December
14, 2020. A lead plaintiff is a representative party acting on
behalf of other class members in directing the litigation. If you
wish to join the litigation, go to
http://www.rosenlegal.com/cases-register-1969.htmlor to discuss
your rights or interests regarding this class action, please
contact Phillip Kim, Esq. of Rosen Law Firm toll free at
866-767-3653 or via e-mail at pkim@rosenlegal.com or
cases@rosenlegal.com.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS
IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN
ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN
ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S
ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT
UPON SERVING AS LEAD PLAINTIFF.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation. Rosen Law Firm was Ranked No. 1
by ISS Securities Class Action Services for number of securities
class action settlements in 2017. The firm has been ranked in the
top 3 each year since 2013. Rosen Law Firm has achieved the largest
ever securities class action settlement against a Chinese Company.
Rosen Law Firm's attorneys are ranked and recognized by numerous
independent and respected sources. Rosen Law Firm has secured
hundreds of millions of dollars for investors. Attorney
Advertising. Prior results do not guarantee a similar outcome [GN]
MEI PHARMA: Lifshitz Law Probes Firm
------------------------------------
Lifshitz Law Firm announces investigation into possible breaches of
fiduciary duty by certain of MEI Pharma, Inc. (NasdaqGS: MEIP)'s
directors. The investigation relates to a securities class action
lawsuit alleging that certain officers of the company made false
and misleading statements relating to Pracinostat's potential
efficacy and likelihood of meeting its primary endpoint of overall
survival.
If you are an MEIP investor, and would like additional information
about our investigation, please complete the Information Request
Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780
or e-mail at info@jlclasslaw.com.
ATTORNEY ADVERTISING.(C) 2020 Lifshitz Law Firm, P.C. The law firm
responsible for this advertisement is Lifshitz Law Firm, P.C., 821
Franklin Avenue, Suite 209, Garden City, New York 11530, Tel:
(516)493-9780. Prior results do not guarantee or predict a similar
outcome with respect to any future matter. [GN]
MICROSOFT CORP: Website Inaccessible to Blind Users, Romero Claims
------------------------------------------------------------------
JOSUE ROMERO, on behalf of himself and all others similarly
situated, Plaintiff v. MICROSOFT CORPORATION, Defendant, Case No.
1:20-cv-09083 (S.D.N.Y., October 29, 2020) is a class action
against the Defendant for violations of the Americans with
Disabilities Act, the New York State Human Rights Law, the New York
State Civil Rights Law, and the New York City Human Rights Law.
According to the complaint, the Defendant has failed to design,
construct, maintain, and operate its Website to be fully accessible
to and independently usable by the Plaintiff and other blind or
visually-impaired persons. The Defendant's Website, www.xbox.com,
contains access barriers which hinder the Plaintiff and Class
members to enjoy the benefits of its online goods, content, and
services offered to the general public through the Website. These
access barriers include, but not limited to: (1) lack of
alternative text (alt-text), or a text equivalent, which prevents
screen readers from accurately vocalizing a description of the
graphics; (2) empty links that contain no text causing the function
or purpose of the link to not be presented to the user; (3)
redundant links where adjacent links go to the same Uniform
Resource Locator (URL) address, which results in additional
navigation and repetition for keyboard and screen-reader users; and
(4) linked images missing alt-text, which causes problems if an
image within a link contains no text and that image does not
provide alt-text.
The Plaintiff and Class members seek permanent injunction to cause
a change in the Defendant's corporate policies, practices, and
procedures so that the Defendant's Website will become and remain
accessible to blind and visually-impaired individuals.
Microsoft Corporation is a video game console company that operates
and distributes its products throughout the United States,
including New York. [BN]
The Plaintiff is represented by:
Joseph H. Mizrahi, Esq.
COHEN & MIZRAHI LLP
300 Cadman Plaza West, 12th Fl.
Brooklyn, NY 11201
Telephone: (929) 575-4175
Facsimile: (929) 575-4195
E-mail: Joseph@cml.legal
NEXTCURE INC: Bernstein Liebhard Reminds of Nov. 20 Deadline
------------------------------------------------------------
Bernstein Liebhard, a nationally acclaimed investor rights law
firm, reminds investors of the deadline to file a lead plaintiff
motion in a securities class action that has been filed on behalf
of investors that: (i) purchased or acquired the securities of
NextCure, Inc. ("NextCure" or the "Company") (NASDAQ: NXTC)
securities between November 5, 2019 to July 14, 2020; and (ii)
purchased or acquired NextCure common stock pursuant to or
traceable to the Company's Registration Statement on Form S-1 which
was filed with and declared effective by the SEC on November 12,
and November 14, 2019. The lawsuit filed in the United States
District Court for the Southern District of New York alleges
violations of the Securities Act of 1933 and the Securities
Exchange Act of 1934.
If you purchased NextCure securities, and/or would like to discuss
your legal rights and options please visit NXTC Shareholder Class
Action Lawsuit or contact Matthew E. Guarnero toll free at (877)
779-1414 or MGuarnero@bernlieb.com.
Throughout the Class Period, Defendants misled investors regarding
its leading treatment candidate, NC318, which was a first-in-class
immunomedicine targeting a novel immunomodulatory receptor, called
Siglec-15, or S15, particularly in patients with advanced or
metastatic solid tumors.
On July 13, 2020, NextCure made a shocking admission. Specifically,
in a press release entitled, "NextCure provides an Interim update
of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and
Announces Departure Chief Medical Officer," NextCure announced that
the Company was no longer planning to "advance the nonsmall cell
lung cancer (NSCLC) and ovarian cancer cohorts in the stage 2
portion of the Simon 2-stage trial," citing "clinical response
data" and "current enrollment criteria." The July 13, 2020
announcement continued, stating, in relevant part, "The analysis of
biomarker data for these cohorts has been delayed and is not yet
complete. The company will evaluate whether to pursue additional
monotherapy studies in NSCLC and ovarian cancer after a review of
that information."
On this news, NextCure's shares, which had closed at $17.88 per
share on July 10, 2020, dropped over 54% the next trading day to
close at $8.15 per share on July 13, 2020 on unusually high trading
volume.
If you wish to serve as lead plaintiff, you must move the Court no
later than November 20, 2020. A lead plaintiff is a representative
party acting on behalf of other class members in directing the
litigation. Your ability to share in any recovery doesn't require
that you serve as lead plaintiff. If you choose to take no action,
you may remain an absent class member.
If you purchased NextCure securities, and/or would like to discuss
your legal rights and options please visit
https://www.bernlieb.com/cases/nextcureinc-nxtc-shareholder-class-action-lawsuit-stock-fraud-313/apply/
contact Matthew E. Guarnero toll free at (877) 779-1414 or
MGuarnero@bernlieb.com.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion
for its clients. In addition to representing individual investors,
the Firm has been retained by some of the largest public and
private pension funds in the country to monitor their assets and
pursue litigation on their behalf. As a result of its success
litigating hundreds of lawsuits and class actions, the Firm has
been named to The National Law Journal's "Plaintiffs' Hot List"
thirteen times and listed in The Legal 500 for ten consecutive
years.
ATTORNEY ADVERTISING. © 2020 Bernstein Liebhard LLP. The law firm
responsible for this advertisement is Bernstein Liebhard LLP, 10
East 40th Street, New York, New York 10016, (212) 779-1414. The
lawyer responsible for this advertisement in the State of
Connecticut is Michael S. Bigin. Prior results do not guarantee or
predict a similar outcome with respect to any future matter. [GN]
NIKOLA CORP: Bernstein Liebhard Reminds of November 16 Deadline
---------------------------------------------------------------
Bernstein Liebhard, a nationally acclaimed investor rights law
firm, reminds investors of the deadline to file a lead plaintiff
motion in a securities class action that has been filed on behalf
of investors that purchased or acquired the securities of Nikola
Corporation ("Nikola" or the "Company") (Nasdaq: NKLA) between June
4, 2020 and September 9, 2020 (the "Class Period"). The lawsuit
filed in the United States District Court for the Eastern District
of New York alleges violations of the Securities Exchange Act of
1934.
If you purchased Nikola securities, and/or would like to discuss
your legal rights and options please visit Nikola Shareholder
Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414
or MGuarnero@bernlieb.com.
According to the Complaint, the Company made false and misleading
statements to the market. Nikola's founder, Trevor Milton,
materially misrepresented the Company's technology and business.
The Company's profitability and business prospects were massively
overstated. Based on these facts, the Company's public statements
were false and materially misleading throughout the class period.
On September 10, 2020, Hindenburg Research issued a report titled:
"Nikola: How to parlay an Ocean of Lies into a Partnership with the
Largest Auto OEM in America." In that report Hindenburg claimed
that it "gathered extensive evidence-including recorded phone
calls, text messages, private emails, and behind-the-scenes
photographs detailing dozens of false statements by the Company's
founder Trevor Milton."
On this news the Company's stock price fell during intraday trading
on September 10, 2020.
If you wish to serve as lead plaintiff, you must move the Court no
later than November 16, 2020. A lead plaintiff is a representative
party acting on behalf of other class members in directing the
litigation. Your ability to share in any recovery doesn't require
that you serve as lead plaintiff. If you choose to take no action,
you may remain an absent class member.
If you purchased Nikola securities, and/or would like to discuss
your legal rights and options please visit
https://www.bernlieb.com/cases/nikolacorporation-nkla-shareholder-class-action-lawsuit-stock-fraud-307/apply/
contact Matthew E. Guarnero toll free at (877) 779-1414 or
MGuarnero@bernlieb.com.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion
for its clients. In addition to representing individual investors,
the Firm has been retained by some of the largest public and
private pension funds in the country to monitor their assets and
pursue litigation on their behalf. As a result of its success
litigating hundreds of lawsuits and class actions, the Firm has
been named to The National Law Journal's "Plaintiffs' Hot List"
thirteen times and listed in The Legal 500 for ten consecutive
years.
Contact Information
Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
MGuarnero@bernlieb.com [GN]
NIKOLA CORP: ClaimsFiler Reminds of November 16 Deadline
--------------------------------------------------------
ClaimsFiler, a FREE shareholder information service, reminds
investors of pending deadlines in the following securities class
action lawsuits:
Nikola Corporation (NKLA, NKLAW) f/k/a VectoIQ Acquisition Corp.
(VTIQ, VTIQW, VTIQU)
Class Period: 3/3/2020 - 9/20/2020
Lead Plaintiff Motion Deadline: November 16, 2020
SECURITIES FRAUD
To learn more, visit
https://www.claimsfiler.com/cases/view-nikola-corporation-securities-litigation
BioMarin Pharmaceutical Inc. (BMRN)
Class Period: 2/28/2020 - 8/18/2020
Lead Plaintiff Motion Deadline: November 24, 2020
SECURITIES FRAUD
To learn more, visit
https://www.claimsfiler.com/cases/view-biomarin-pharmaceutical-inc-securities-litigation
Peabody Energy Corp. (BTU)
Class Period: 4/3/2017 - 10/28/2019
Lead Plaintiff Motion Deadline: November 27, 2020
SECURITIES FRAUD
To learn more, visit
https://www.claimsfiler.com/cases/view-peabody-energy-corporation-securities-litigation
If you purchased shares of the above companies and would like to
discuss your legal rights and your right to recover for your
economic loss, you may, without obligation or cost to you, contact
us toll-free (844) 367-9658 or visit the case links above.
If you wish to serve as a Lead Plaintiff in the class action, you
must petition the Court on or before the Lead Plaintiff Motion
deadline.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information
source to help retail investors recover their share of billions of
dollars from securities class action settlements. At
ClaimsFiler.com, investors can: (1) register for free to gain
access to information and settlement websites for various
securities class action cases so they can timely submit their own
claims; (2) upload their portfolio transactional data to be
notified about relevant securities cases in which they may have a
financial interest; and (3) submit inquiries to the Kahn Swick &
Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com [GN]
NIKOLA CORP: Johnson Fistel Reminds of Nov. 16 Deadline
-------------------------------------------------------
Shareholder rights law firm Johnson Fistel, LLP reminds investors
that a class action lawsuit has been filed against Nikola
Corporation ("Nikola or the "Company") (NASDAQ: NKLA) on behalf of
all purchasers of common stock during the period between March 3,
2020 and September 15, 2020, inclusive (the "Class Period").
If you wish to serve as a lead plaintiff, you must move the Court
no later than November 16, 2020. If you want to discuss this action
or have any questions concerning this notice, please contact lead
analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If you
email, please include your phone number.
The complaint alleges that during the Class Period, defendants
throughout the Class Period made false and misleading statements
and failed to disclose that: (1) VectoIQ did not engage in proper
due diligence regarding its merger with Nikola; (2) Nikola
overstated its "in-house" design, manufacturing, and testing
capabilities; (3) Nikola overstated its hydrogen production
capabilities; (4) as a result, Nikola overstated its ability to
lower the cost of hydrogen fuel; (5) Nikola founder and Executive
Chairman, Trevor Milton, tweeted a misleading "test" video of the
Company's Nikola Two truck; (6) the work experience and background
of key Nikola employees, including Mr. Milton, had been overstated
and obfuscated; (7) Nikola did not have five Tre trucks completed;
and (8) as a result, defendants' public statements were materially
false and misleading at all relevant times. According to the suit,
these true details were disclosed by a market research firm.
On September 14, 2020, media outlets reported Nikola is facing a
probe by the SEC and the DOJ. Then on September 20, 2020, Nikola
announced that Trevor Milton, its founder stepped down as executive
chairman.
About Johnson Fistel
Johnson Fistel, LLP is a nationally recognized shareholder rights
law firm with offices in California, New York and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonfistel.com.Attorney advertising. Past results do
not guarantee future outcomes.
Jim Baker
Johnson Fistel, LLP
Tel No: 619-814-4471
E-mail: jimb@johnsonfistel.com [GN]
NIKOLA CORP: Kessler Topaz Reminds of November 16 Deadline
----------------------------------------------------------
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Nikola
Corporation (NASDAQ:NKLA)(NASDAQ:NKLAW) ("Nikola") investors that a
securities fraud class action lawsuit has been filed in the United
States District Court for the District of Arizona against Nikola on
behalf of those who purchased or otherwise acquired Nikola
securities between March 3, 2020 and September 20, 2020, inclusive
(the "Class Period").
Important Deadline Reminder: Investors who purchased or otherwise
acquired Nikola securities during the Class Period may, no later
than November 16, 2020, seek to be appointed as a lead plaintiff
representative of the class. For additional information or to learn
how to participate in this litigation please click
https://www.ktmc.com/nikola-corporation-class-action?utm_source=PR&utm_medium=link&utm_campaign=nikola.
According to the complaint, Nikola operates as an integrated zero
emissions transportation systems provider, which designs and
manufactures battery-electric and hydrogen-electric vehicles,
electric vehicle drivetrains, vehicle components, energy storage
systems, and hydrogen fueling station infrastructure. The merger of
VectoIQ and Nikola closed on June 3, 2020.
The Class Period commences on March 3, 2020 when Nikola issued a
press release entitled, "Nikola Corporation, a Global Leader in
Zero Emissions Transportation Solutions, to Be Listed on NASDAQ
Through a Merger with VectoIQ." In connection with the merger
announcement, Nikola released an investor presentation on March 3,
2020, which touted Nikola founder and Executive Chairman Trevor R.
Milton's ("Milton") experience in the clean energy and technology
field and Nikola's hydrogen production capabilities.
The complaint alleges that, on September 10, 2020, before market
hours, Hindenburg Research published a report describing, among
other things, how: (i) Nikola claims to design key components in
house, but they appear to simply be buying or licensing them from
third parties; (ii) Nikola has not produced hydrogen; (iii) a
spokesman for Powercell AB, a hydrogen fuel cell technology company
that formerly partnered with Nikola, called Nikola's battery and
hydrogen fuel cell claims "hot air"; (iv) Nikola staged a "test"
video for its Nikola Two (a prototype truck); (v) some of Nikola's
team, including Milton, are not experts and do not have relevant
experience; and (vi) Nikola did not have five Tre trucks completed.
Following this news, shares of Nikola fell $10.24, or 24%, over the
next two trading days, to close at $32.13 per share on September
11, 2020.
Then, on September 15, 2020, before trading hours, Hindenburg
Research published another report, focused on Nikola's responses
and nonresponses to its initial report, entitled "We View Nikola's
Response As a Tacit Admission of Securities Fraud." Following this
news, shares of Nikola fell $2.96, or 8%, to close at $32.83 per
share on September 15, 2020.
Finally, on September 20, 2020, Nikola issued a press release
entitled "Nikola Board of Directors Announces Leadership
Transition: Trevor Milton Steps Down as Executive Chairman; Stephen
Girsky Appointed Chairman of the Board." Following this news, the
price of Nikola's shares fell in pre-market trading on September
21, 2020, further damaging investors.
The complaint alleges that throughout the Class Period, the
defendants made false and/or misleading statements and/or failed to
disclose that: (1) VectoIQ did not engage in proper due diligence
regarding its merger with Nikola; (2) Nikola overstated its
"in-house" design, manufacturing, and testing capabilities; (3)
Nikola overstated its hydrogen production capabilities; (4) as a
result, Nikola overstated its ability to lower the cost of hydrogen
fuel; (5) Milton tweeted a misleading "test" video of the Nikola
Two truck; (6) the work experience and background of key Nikola
employees, including Milton, had been overstated and obfuscated;
(7) Nikola did not have five Tre trucks completed; and (8) as a
result, the defendants' public statements were false and/or
misleading at all relevant times.
If you wish to discuss this securities fraud class action lawsuit
or have any questions concerning this notice or your rights or
interests with respect to this litigation, please contact Kessler
Topaz Meltzer & Check (James Maro, Jr., Esq. or Adrienne Bell,
Esq.) at (844) 877-9500 (toll free) or (610) 667-7706, or via
e-mail at info@ktmc.com.
Nikola investors may, no later than November 16, 2020, seek to be
appointed as a lead plaintiff representative of the class through
Kessler Topaz Meltzer & Check, or other counsel, or may choose to
do nothing and remain an absent class member. A lead plaintiff is a
representative party who acts on behalf of all class members in
directing the litigation. In order to be appointed as a lead
plaintiff, the Court must determine that the class member's claim
is typical of the claims of other class members, and that the class
member will adequately represent the class. Your ability to share
in any recovery is not affected by the decision of whether or not
to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check prosecutes class actions in state and
federal courts throughout the country involving securities fraud,
breaches of fiduciary duties and other violations of state and
federal law. Kessler Topaz Meltzer & Check is a driving force
behind corporate governance reform, and has recovered billions of
dollars on behalf of institutional and individual investors from
the United States and around the world. The firm represents
investors, consumers and whistleblowers (private citizens who
report fraudulent practices against the government and share in the
recovery of government dollars). The complaint in this action was
not filed by Kessler Topaz Meltzer & Check. For more information
about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 877-9500 (toll free)
(610) 667-7706
info@ktmc.com [GN]
NIKOLA CORP: Lifshitz Law Probes Firm
-------------------------------------
Lifshitz Law Firm announces investigation into possible breaches of
fiduciary duty by certain of Nikola Corporation (NasdaqGS: NKLA)'s
officers and/or directors. The investigation relates to a
securities class action lawsuit alleging that certain officers of
the company made false and misleading statements that VectoIQ did
not engage in proper due diligence regarding its merger with
Nikola.
If you are a NKLA investor, and would like additional information
about our investigation, please complete the Information Request
Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780
or e-mail at info@jlclasslaw.com.
ATTORNEY ADVERTISING.(C) 2020 Lifshitz Law Firm, P.C. The law firm
responsible for this advertisement is Lifshitz Law Firm, P.C., 821
Franklin Avenue, Suite 209, Garden City, New York 11530, Tel:
(516)493-9780. Prior results do not guarantee or predict a similar
outcome with respect to any future matter. [GN]
NIKOLA CORPORATION: Rosen Law Reminds of Nov. 16 Deadline
---------------------------------------------------------
Rosen Law Firm, a global investor rights law firm, reminds
purchasers of the securities of Nikola Corporation (NASDAQ: NKLA,
NKLAW), f/k/a VectoIQ Acquisition Corp. (NASDAQ: VTIQ, VTIQW,
VTIQU), between March 3, 2020 and September 20, 2020, inclusive
(the "Class Period"), of the important November 16, 2020 lead
plaintiff deadline in the securities class action commenced by the
firm. The lawsuit seeks to recover damages for Nikola investors
under the federal securities laws.
To join the Nikola class action, go to
http://www.rosenlegal.com/cases-register-1943.htmlor call Phillip
Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or
cases@rosenlegal.com for information on the class action.
According to the lawsuit, defendants throughout the Class Period
made false and/or misleading statements and/or failed to disclose
that: (1) VectoIQ did not engage in proper due diligence regarding
its merger with Nikola; (2) Nikola overstated its "in-house"
design, manufacturing, and testing capabilities; (3) Nikola
overstated its hydrogen production capabilities; (4) as a result,
Nikola overstated its ability to lower the cost of hydrogen fuel;
(5) Nikola founder and Executive Chairman, Trevor Milton, tweeted a
misleading "test" video of the Company's Nikola Two truck; (6) the
work experience and background of key Nikola employees, including
Mr. Milton, had been overstated and obfuscated; (7) Nikola did not
have five Tre trucks completed; and (8) as a result, defendants'
public statements were materially false and/or misleading at all
relevant times. When the true details entered the market, the
lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve
as lead plaintiff, you must move the Court no later than November
16, 2020. A lead plaintiff is a representative party acting on
behalf of other class members in directing the litigation. If you
wish to join the litigation, go to
http://www.rosenlegal.com/cases-register-1943.htmlor to discuss
your rights or interests regarding this class action, please
contact Phillip Kim, Esq. of Rosen Law Firm toll free at
866-767-3653 or via e-mail at pkim@rosenlegal.com or
cases@rosenlegal.com.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS
IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN
ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN
ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S
ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT
UPON SERVING AS LEAD PLAINTIFF.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation. Rosen Law Firm was Ranked No. 1
by ISS Securities Class Action Services for number of securities
class action settlements in 2017. The firm has been ranked in the
top 3 each year since 2013. Rosen Law Firm has achieved the largest
ever securities class action settlement against a Chinese Company.
Rosen Law Firm's attorneys are ranked and recognized by numerous
independent and respected sources. Rosen Law Firm has secured
hundreds of millions of dollars for investors. Attorney
Advertising. Prior results do not guarantee a similar outcome. [GN]
NORTHSTAR LOCATION: Hirsch Sues Over Unlawful Debt Collection
--------------------------------------------------------------
MAYER HIRSCH, individually and on behalf of all others similarly
situated, Plaintiff v. NORTHSTAR LOCATION SERVICES, LLC and JOHN
DOES 1-25, Defendants, Case No. 1:20-cv-05197 (E.D.N.Y., October
28, 2020) is a class action complaint brought against the
Defendants for their alleged violation of the Fair Debt Collection
Practices At.
The Plaintiff has a debt that was allegedly incurred to Barclays
Bank Delaware.
According to the complaint, the Defendant contracted with the
Barclays Bank Delaware to collect the alleged debt. Subsequently,
the Defendant sent the Plaintiff a collection letter on or about
December 6, 2019. However, the letter confused the Plaintiff
because there was no settlement offer indicated, and yet it
demanded the Plaintiff to call to discuss a settlement option and
to consult a tax advisor about the tax consequences if not
immediately settled.
The Plaintiff asserts that the letter is false and deceptive
because he was unable to determine what the settlement offer is and
the need to consult a tax advisor.
Northstar Location Services, LLC is a debt collector. [BN]
The Plaintiff is represented by:
Raphael Deutsch, Esq.
STEIN SAKS, PLLC
285 Passaic Street
Hackensack, NJ 07601
Tel: (201) 282-6500
Fax: (201) 282-6501
E-mail: rdeutsch@steinsakslegal.com
ONESPAN INC: Portnoy Law Reminds of Class Action
------------------------------------------------
The Portnoy Law Firm advises investors that a class action lawsuit
has been filed on behalf of OneSpan, Inc. (NASDAQ: OSPN) investors
that acquired shares between May 9, 2018, and August 11, 2020.
Investors had until October 19, 2020 to seek an active role in this
litigation.
Investors are encouraged to contact attorney Lesley F. Portnoy, to
determine eligibility to participate in this action, by phone
310-692-8883 or email, or click here to join the case.
On August 11, 2020, OneSpan admitted that it would fail to file its
quarterly report for the period ending June 30, 2020, in a timely
manner. The Company also disclosed that it had overstated revenues
in the past. Based on this news, shares of OneSpan fell by nearly
40% on August 12, 2020.
A class action lawsuit has already been filed. If you wish to serve
as lead plaintiff, you must move the Court no later than October
19, 2020.
Please visit our website to review more information and submit your
transaction information.
The Portnoy Law Firm represents investors in pursuing claims
arising from corporate wrongdoing. The Firm's founding partner has
recovered over $5.5 billion for aggrieved investors. Attorney
advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
E-mail: lesley@portnoylaw.com [GN]
PEABODY ENERGY: Frank R. Cruz Reminds of November 27 Deadline
-------------------------------------------------------------
The Law Offices of Frank R. Cruz reminds investors that a class
action lawsuit has been filed on behalf of Peabody Energy
Corporation shareholders. Investors have until the deadline listed
below to file a lead plaintiff motion.
Investors suffering losses on their investments are encouraged to
contact The Law Offices of Frank R. Cruz to discuss their legal
rights in the class action at 310-914-5007 or by email to
fcruz@frankcruzlaw.com.
Peabody Energy Corporation (NYSE: BTU)
Class Period: April 3, 2017 - October 28, 2019
Lead Plaintiff Deadline: November 27, 2020
Shareholders with $250,000 losses or more are encouraged to contact
the firm
The complaint alleges that Defendants made materially false and/or
misleading statements, as well as failed to disclose material
adverse facts about the Company's business, operations, and
prospects. Specifically, Defendants failed to disclose to investors
that: (1) Peabody had failed to implement adequate safety controls
at the North Goonyella mine to prevent the risk of a spontaneous
combustion event; (2) Peabody failed to follow its own safety
procedures; (3) as a result, the North Goonyella mine was at a
heightened risk of shutdown; (4) Peabody's low-cost plan to restart
operations at the North Goonyella mine posed unreasonable safety
and environmental risks; (5) the Queensland Mines Inspectorate
("QMI"), the Australian body responsible for ensuring acceptable
health and safety standards, would likely mandate a safer,
cost-prohibitive approach; (6) as a result, there would be major
delays in reopening the North Goonyella mine and restarting coal
production; and (5) that, as a result, of the foregoing,
Defendants' statements about the Peabody's business, operations,
and prospects were materially misleading and/or lacked a reasonable
basis.
To be a member of these class action, you need not take any action
at this time; you may retain counsel of your choice or take no
action and remain an absent member of the class action. If you
wish to learn more about the class action, or if you have any
questions concerning this announcement or your rights or interests
with respect to these matters, please contact Frank R. Cruz, of The
Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100,
Los Angeles, California 90067 at 310-914-5007, by email to
info@frankcruzlaw.com, or visit our website at
www.frankcruzlaw.com. If you inquire by email please include your
mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules. [GN]
PEABODY ENERGY: Glancy Prongay Reminds of November 27 Deadline
--------------------------------------------------------------
Glancy Prongay & Murray LLP ("GPM") reminds investors of the
upcoming November 27, 2020 deadline to file a lead plaintiff motion
in the class action filed on behalf of investors who purchased or
otherwise acquired Peabody Energy Corporation ("Peabody" or the
"Company") (NYSE: BTU) common stock between April 3, 2017 and
October 28, 2019, inclusive (the "Class Period").
If you suffered a loss on your Peabody investments or would like to
inquire about potentially pursuing claims to recover your loss
under the federal securities laws, you can submit your contact
information at
https://www.glancylaw.com/cases/peabody-energy-corporation/. You
can also contact Charles H. Linehan, of GPM at 310-201-9150,
Toll-Free at 888-773-9224, or via email at
shareholders@glancylaw.com to learn more about your rights.
Peabody is the largest coal mining company in the world with 23
coal mines organized into six business segments. Its largest
segment is the Australian Metallurgical Mining segment, which
accounted for 23.1% of Peabody's revenue in 2016. Peabody's most
profitable operation is the North Goonyella mine, which is within
the Australian Metallurgical Mining segment, and in 2017, the mine
generated 20% of the Company's total operating profit.
On September 28, 2018, Peabody announced that it did "not expect
any production from North Goonyella in the fourth quarter of 2018"
due to a fire occurring within the mine.
On this news, the Company's stock price fell $5.54, or over 13%, to
close at $35.64 per share on September 28, 2018, thereby injuring
investors.
Then, on February 6, 2019, Peabody reported disappointing financial
results for fourth quarter 2018 due to remediation costs and lack
of production at the North Goonyella mine. The Company also
announced that production would not resume at the mine until the
"early months of 2020."
On this news, the Company's stock price fell $3.80, or 11%, to
close at $32.05 per share on February 6, 2019, thereby injuring
investors further.
Then, on October 29, 2019, Peabody disclosed that operations at the
North Goonyella mine would not resume for three or more years due
to local regulators' strict restrictions.
On this news, the Company's stock price fell $3.56, or 22%, to
close at $12.48 per share on October 29, 2019, thereby injuring
investors further.
The complaint filed in this class action alleges that Defendants
made materially false and/or misleading statements, as well as
failed to disclose material adverse facts about the Company's
business, operations, and prospects. Specifically, Defendants
failed to disclose to investors that: (1) the Company had failed to
implement adequate safety controls at the North Goonyella mine to
prevent the risk of a spontaneous combustion event; (2) the Company
failed to follow its own safety procedures; (3) as a result, the
North Goonyella mine was at a heightened risk of shutdown; (4) the
Company's low-cost plan to restart operations at the North
Goonyella mine posed unreasonable safety and environmental risks;
(5) the Australian body responsible for ensuring acceptable health
and safety standards, the Queensland Mines Inspectorate ("QMI"),
would likely mandate a safer, cost-prohibitive approach; (6) as a
result, there would be major delays in reopening the North
Goonyella mine and restarting coal production; and (5) that, as a
result of the foregoing, Defendants' statements about the Company's
business, operations, and prospects were materially misleading
and/or lacked a reasonable basis.
If you purchased or otherwise acquired Peabody common stock during
the Class Period, you may move the Court no later than November 27,
2020 to ask the Court to appoint you as lead plaintiff. To be a
member of the Class you need not take any action at this time; you
may retain counsel of your choice or take no action and remain an
absent member of the Class. If you wish to learn more about this
action, or if you have any questions concerning this announcement
or your rights or interests with respect to these matters, please
contact Charles Linehan, Esquire, of GPM, 1925 Century Park East,
Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free
at 888-773-9224, by email to shareholders@glancylaw.com, or visit
our website at www.glancylaw.com. If you inquire by email please
include your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Contacts:
Glancy Prongay and Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
www.glancylaw.com
shareholders@glancylaw.com [GN]
PINTEC TECHNOLOGY: Frank R. Cruz Reminds of November 30 Deadline
----------------------------------------------------------------
The Law Offices of Frank R. Cruz reminds investors that a class
action lawsuit has been filed on behalf of Pintec Technology
shareholders. Investors have until the deadline listed below to
file a lead plaintiff motion.
Investors suffering losses on their investments are encouraged to
contact The Law Offices of Frank R. Cruz to discuss their legal
rights in the class action at 310-914-5007 or by email to
fcruz@frankcruzlaw.com.
Pintec Technology Holdings Limited (NASDAQ: PT)
Class Period: October 2018 IPO
Lead Plaintiff Deadline: November 30, 2020
The complaint alleges that the Registration Statement was false and
misleading and omitted to state material facts. Specifically,
Defendants failed to disclose to investors: (1) that Pintec
erroneously recorded revenue earned from certain technical service
fee on a net basis, rather than a gross basis; (2) that there were
material weaknesses in the Company's internal control over
financial reporting related to cash advances outside the normal
course of business to Jimu Group, a related party, and to a
non-routine loan financing transaction with a third-party entity,
Plutux Labs; (3) that, as a result of the foregoing, Pintec's
financial results for fiscal 2017 and 2018 had been misstated; and
(4) that, as a result of the foregoing, Defendants' positive
statements about the Pintec's business, operations, and prospects,
were materially misleading and/or lacked a reasonable basis.
To be a member of these class action, you need not take any action
at this time; you may retain counsel of your choice or take no
action and remain an absent member of the class action. If you
wish to learn more about the class action, or if you have any
questions concerning this announcement or your rights or interests
with respect to these matters, please contact Frank R. Cruz, of The
Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100,
Los Angeles, California 90067 at 310-914-5007, by email to
info@frankcruzlaw.com, or visit our website at
www.frankcruzlaw.com. If you inquire by email please include your
mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules. [GN]
PINTEC TECHNOLOGY: Levi & Korsinsky Reminds of Nov. 30 Deadline
---------------------------------------------------------------
Levi & Korsinsky, LLP on Oct. 5 disclosed that class action
lawsuits have commenced on behalf of shareholders of the following
publicly-traded companies. Shareholders interested in serving as
lead plaintiff have until the deadlines listed to petition the
court. Further details about the cases can be found at the links
provided. There is no cost or obligation to you.
PT Shareholders Click Here:
https://www.zlk.com/pslra-1/pintec-technology-holdings-limited-loss-form?prid=9790&wire=1
TCMD Shareholders Click Here:
https://www.zlk.com/pslra-1/tactile-systems-technology-inc-loss-submission-form?prid=9790&wire=1
GTX Shareholders Click Here:
https://www.zlk.com/pslra-1/garrett-motion-inc-loss-submission-form?prid=9790&wire=1
* ADDITIONAL INFORMATION BELOW *
Pintec Technology Holdings Limited (NASDAQ:PT)
This lawsuit is on behalf of shareholders who purchased PT
securities pursuant and/or traceable to the registration statement
and prospectus issued in connection with the Company's October 2018
initial public offering.
Lead Plaintiff Deadline: November 30, 2020
TO LEARN MORE, VISIT:
https://www.zlk.com/pslra-1/pintec-technology-holdings-limited-loss-form?prid=9790&wire=1
According to the filed complaint, (1) the Company erroneously
recorded revenue earned from certain technical service fee on a net
basis, rather than a gross basis; (2) there were material
weaknesses in Pintec's internal control over financial reporting
related to cash advances outside the normal course of business to
Jimu Group, a related party, and to a non-routine loan financing
transaction with a third-party entity, Plutux Labs; (3) as a result
of the foregoing, the Company's financial results for fiscal 2017
and 2018 had been misstated; and (4) as a result of the foregoing,
Defendants' positive statements about the Company's business,
operations, and prospects, were materially misleading and/or lacked
a reasonable basis.
Tactile Systems Technology, Inc. (NASDAQ:TCMD)
TCMD Lawsuit on behalf of: investors who purchased May 7, 2018 -
June 8, 2020
Lead Plaintiff Deadline: November 30, 2020
TO LEARN MORE, VISIT:
https://www.zlk.com/pslra-1/tactile-systems-technology-inc-loss-submission-form?prid=9790&wire=1
According to the filed complaint, during the class period, Tactile
Systems Technology, Inc. made materially false and/or misleading
statements and/or failed to disclose that: (1) while Tactile
publicly touted a $4 plus billion or $5 plus billion market
opportunity, in truth, the total addressable market for Tactile's
pneumatic compression devices was materially smaller; (2) to induce
sales growth and share gains, Tactile and/or its employees were
engaged in illicit and illegal sales and marketing activities in
violation of applicable federal and state rules and public payer
regulations; (3) the foregoing illicit and illegal sales and
marketing activities increased the risk of a Medicare audit of
Tactile's claims and criminal and civil liability; (4) Tactile's
revenues were in part the product of unlawful conduct and thus
unsustainable; and that as a result of the foregoing, (5)
Defendants' public statements, including Tactile's year-over-year
revenue growth, the purported growth drivers, and the effectiveness
of Tactile's internal controls over financial reporting were
materially false and misleading at all relevant times.
Garrett Motion Inc. (NYSE:GTX)
GTX Lawsuit on behalf of: investors who purchased October 1, 2018 -
September 18, 2020
Lead Plaintiff Deadline: November 24, 2020
TO LEARN MORE, VISIT:
https://www.zlk.com/pslra-1/garrett-motion-inc-loss-submission-form?prid=9790&wire=1
According to the filed complaint, during the class period, Garrett
Motion Inc. made materially false and/or misleading statements
and/or failed to disclose that: (1) due to its agreement to
indemnify and reimburse Honeywell for certain asbestos-related
liability, Garrett was saddled with an unsustainable level of debt;
(2) as a result, Garrett had a highly leveraged capital structure
that posed significant challenges to its overall strategic and
financial flexibility; (3) as a result of the foregoing, Garrett's
ability to gain or hold market share was impaired; (4) as a result
of the foregoing, the Company was reasonably likely to seek
bankruptcy protection; and (5) as a result of the foregoing,
Defendants' positive statements about the Company's business,
operations, and prospects were materially misleading and/or lacked
a reasonable basis.
You have until the lead plaintiff deadlines to request that the
court appoint you as lead plaintiff. Your ability to share in any
recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in
New York, California, Connecticut, and Washington D.C. The firm's
attorneys have extensive expertise and experience representing
investors in securities litigation and have recovered hundreds of
millions of dollars for aggrieved shareholders. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com [GN]
PORTLAND GENERAL: Grant & Eisenhofer Reminds of Class Action
------------------------------------------------------------
Grant & Eisenhofer P.A. announces that a lawsuit has been filed in
the District of Oregon on behalf of shareholders of Portland
General Electric Company ("PGE") and certain officers of PGE
(collectively, "Defendants") alleging that Defendants violated
federal securities laws. The lawsuit, captioned Public Employees'
Retirement System of Mississippi v. Portland General Electric Co.,
et al., is pending under docket number 3:20-cv-01786 and seeks
rescission and damages.
The proposed class includes all persons who purchased shares of
PGE's common stock between February 13, 2020 and August 24, 2020
(the "Class Period"). The Class Period expands the class period
asserted in two other complaints filed against PGE in the District
of Oregon, both of which limit participation to those shareholders
who purchased PGE shares from April 24, 2020 through August 24,
2020 (Hessel v. Portland General Electric Co., et al., No.
3:20-cv-01523; Cannataro v. Portland General Electric Co., et al.,
No. 3:20-cv-01583). Shareholders have until November 2, 2020 to
petition the Court for lead plaintiff status.
The complaint alleges that PGE made materially false and/or
misleading statements and/or failed to disclose that: (1) PGE
lacked effective internal controls over its trading practices in
the wholesale energy markets; (2) PGE personnel entered energy
trades during 2020, with increasing volume accumulating late in the
second quarter and into the third quarter, that created significant
negative financial exposure for PGE; (3) as a result, PGE was
reasonably likely to incur significant losses and had issued
materially misleading statements or statements which lacked a
reasonable basis regarding PGE's business, operations, and
prospects. The federal securities claims are brought under Sections
10(b) and 20(a) of the Securities Exchange Act of 1934, 15 U.S.C.
Sec 78j, 78t, and Rule 10b-5 promulgated thereunder.
Pursuant to the Private Securities Litigation Reform Act, 15 U.S.C.
§ 78u-4(a)(3)(A)(i)(II), any shareholder who purchased PGE shares
during the Class Period and which seeks to serve as lead plaintiff
of the proposed class shall, no later than November 2, 2020, move
the Court for appointment as lead plaintiff and approval of lead
plaintiff's selection of lead counsel. No class has yet been
certified in the above action. Until a class is certified, you are
not represented by counsel unless you retain a lawyer. You may
retain counsel of your choice. You may also remain an absent class
member and do nothing at this point. Your ability to share in any
potential future recovery is not dependent upon serving as lead
plaintiff.
For additional information about this lawsuit, please contact
Daniel L. Berger, Esq. by telephone at 646-722-8500 or via email at
dberger@gelaw.com. There is no cost or obligation to you.
Grant & Eisenhofer P.A. is a nationally recognized law firm which
has recovered billions of dollars on behalf of clients. The firm's
attorneys have extensive experience representing investors in
securities litigation. This notice may be considered attorney
advertising in some jurisdictions under the applicable law and
rules of ethics. Prior results do not guarantee similar outcomes
[GN].
QUTOUTIAO INC: Frank R. Cruz Reminds of Class Action
----------------------------------------------------
The Law Offices of Frank R. Cruz reminds investors of the upcoming
October 19, 2020 deadline to file a lead plaintiff motion in the
class action filed on behalf of investors who acquired Qutoutiao
Inc. ("Qutoutiao" or "the Company") (NASDAQ: QTT): (a) American
Depositary Shares ("ADSs" or "shares") pursuant and/or traceable to
the Company's September 2018 initial public offering ("IPO" or the
"Offering"); and/or (b) securities between September 14, 2018 and
July 15, 2020, inclusive (the "Class Period").
In September 2018, the Company completed its IPO, selling 13.8
million ADSs at $7.00 per share.
On December 10, 2019, Wolfpack Research published a report,
alleging among other things, that the Company had overstated its
revenues by recording non-existent advances from advertising
customers. Moreover, the report alleged that Qutoutiao replaced its
third-party advertising agent with a related party, thereby
bypassing the agent's oversight and allowing the Company to
"perpetrate the unmitigated ad fraud that [Wolfpack] observed in
[its] sample."
On this news, the Company's share price fell $0.12, nearly 4%, to
close at $2.86 per share on December 11, 2019, on unusually heavy
trading volume.
On July 15, 2020, hosts of a consumer rights gala stated that
Qutoutiao had allowed ads on its platform promoting exaggerated or
impossible claims from weight-loss products. For example, one such
ad offered free weight-loss products valued at $14,300 that would
help users lose more than 30 pounds a month.
On this news, the Company's share price fell $0.85, or 23%, to
close at $2.84 per share on July 16, 2020, on unusually heavy
trading volume.
The complaint filed in this class action alleges that Defendants
made materially false and/or misleading statements, as well as
failed to disclose material adverse facts about the Company's
business, operations, and prospects. Specifically, Defendants
failed to disclose to investors: (1) that Qutoutiao replaced its
advertising agent with a related party, thereby bypassing
third-party oversight of the content and quality of the
advertisements; (2) that the Company placed advertisements on its
mobile app for products whose claims could not be substantiated and
thus were considered false advertisements under applicable
regulations; (3) that, as a result, the Company would face
increasing regulatory scrutiny and reputational harm; (4) that, as
a result, the Company's advertising revenue was reasonably likely
to decline; and (5) that, as a result of the foregoing, Defendants'
positive statements about the Company's business, operations, and
prospects, were materially misleading and/or lacked a reasonable
basis.
If you purchased or otherwise acquired Qutoutiao securities during
the Class Period, you may move the Court no later than October 19,
2020 to request appointment as lead plaintiff in this putative
class action lawsuit. To be a member of the class action you need
not take any action at this time; you may retain counsel of your
choice or take no action and remain an absent member of the class
action. If you wish to learn more about this class action, or if
you have any questions concerning this announcement or your rights
or interests with respect to the pending class action lawsuit,
please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz,
1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067
at 310-914-5007, by email to info@frankcruzlaw.com, or visit our
website at www.frankcruzlaw.com. If you inquire by email please
include your mailing address, telephone number, and number of
shares purchased. [GN]
REATA PHARMACEUTICALS: Kehoe Law Announces Securities Class Action
------------------------------------------------------------------
Kehoe Law Firm, P.C. is investigating potential securities claims
on behalf of investors of Reata Pharmaceuticals, Inc. ("Reata" or
the "Company") (NASDAQ: RETA) to determine whether the Company
engaged in securities fraud or other unlawful business practices.
Reata investors who purchased, or otherwise acquired, the Company's
securities between October 15, 2019 and August 7, 2020, both dates
inclusive (the "Class Period"), and suffered losses greater than
$100,000 are encouraged to complete Kehoe Law Firm's Securities
Class Action Questionnaire or contact Michael Yarnoff, Esq., (215)
792-6676, Ext. 804, myarnoff@kehoelawfirm.com,
securities@kehoelawfirm.com, to discuss the securities
investigation or potential legal claims.
A class action lawsuit was filed against Reata and certain of its
officers in United States District Court, Eastern District of
Texas, seeking to recover damages by the Reata Defendants' alleged
violations of federal securities laws and to pursue remedies under
Sections 10(b) and 20(a) of the Securities Exchange Act of 1934,
and Rule 10b-5 promulgated thereunder, against the Company and
certain of its top officials.
According to the class action complaint, "Reata is a clinical stage
biopharmaceutical company that develops novel therapeutics for
patients with serious or life-threatening diseases by targeting
molecular pathways that regulate cellular metabolism and
inflammation."
Omaveloxolone, according to the complaint, is "[a]mong Reata's drug
candidates under development . . . which is in Phase 2 clinical
development to treat Friedreich's ataxia ('FA'). Following the
announcement of positive data from the MOXIe Part 2 study of
omaveloxolone for FA in October 2019, the Company represented that
it would seek submission for marketing approval of omaveloxolone
for the treatment of FA in the [United States] with the U.S. Food
and Drug Administration ('FDA')."
Throughout the Class Period, the Reata Defendants, allegedly, made
materially false and misleading statements regarding the Company's
business, operational, and compliance policies. The Reata
Defendants, according to the complaint, made false and/or
misleading statements and/or failed to disclose that: (i) the MOXIe
Part 2 study results were insufficient to support a single study
marketing approval of omaveloxolone for the treatment of FA in the
United States without additional evidence; (ii) as a result, it was
foreseeable that the FDA would not accept marketing approval of
omaveloxolone for the treatment of FA in the U.S. based on the
MOXIe Part 2 study results; and (iii) as a result, the Reata's
public statements were materially false and misleading at all
relevant times.
Kehoe Law Firm, P.C., with offices in New York and Philadelphia, is
a multidisciplinary, plaintiff–side law firm dedicated to
protecting investors from securities fraud, breaches of fiduciary
duties, and corporate misconduct. Combined, the partners at Kehoe
Law Firm have served as Lead Counsel or Co-Lead Counsel in cases
that have recovered more than $10 billion on behalf of
institutional and individual investors. [GN]
ROYAL CARIBBEAN: Bernstein Liebhard Reminds of Dec. 7 Deadline
--------------------------------------------------------------
Bernstein Liebhard, a nationally acclaimed investor rights law
firm, reminds investors of the deadline to file a lead plaintiff
motion in a securities class action that has been filed on behalf
of investors that purchased or acquired the securities of Royal
Caribbean Cruises Ltd. ("Royal Caribbean" or the "Company") (NYSE:
RCL) between February 4, 2020 and March 17, 2020 (the "Class
Period"). The lawsuit filed in the United States District Court for
the Southern District of Florida alleges violations of the
Securities Exchange Act of 1934.
If you purchased Royal Caribbean securities, and/or would like to
discuss your legal rights and options please visit Royal Caribbean
Shareholder Lawsuit or contact Matthew E. Guarnero toll free at
(877) 779-1414 or MGuarnero@bernlieb.com.
The complaint alleges that the Defendants throughout the Class
Period made false and/or misleading statements and failed to
disclose material adverse facts about the Company's decrease in
bookings outside China and its inadequate policies and procedures
to prevent the spread of COVID-19 on its ships. Specifically,
regarding global bookings, Royal Caribbean made statements that:
(1) misled investors to believe that any issue related to COVID-19
was relatively insignificant; (2) falsely assured investors that
bookings outside China were strong with no signs of a slowdown; and
(3) failed to disclose that the Company was experiencing material
declines in bookings globally due to customer concerns over
COVID-19. Additionally, regarding safety procedures, the Company
made statements that: (1) falsely assured investors that it
implemented rigorous safety protocols; (2) such protocols were
expected to ultimately contain the spread of the virus; and (3)
failed to disclose that its ships were following grossly inadequate
protocols that would foster the spread of COVID-19 and pose a
substantial risk to passengers and crews.
The full impact of the Company's false and misleading statements
and/or omissions was revealed, as analysts downgraded the Company's
stock and slashed their price targets, reflecting the true value of
Royal Caribbean stock. On March 18, 2020, prior to the opening of
the stock market, Stifel cut its one-year price target on Royal
Caribbean from $161 to $40
On this news, Royal Caribbean's stock price dropped $5.33 per
share, or 19.27% to close at $22.33 per share on March 18, 2020.
If you wish to serve as lead plaintiff, you must move the Court no
later than December 7, 2020. A lead plaintiff is a representative
party acting on behalf of other class members in directing the
litigation. Your ability to share in any recovery doesn't require
that you serve as lead plaintiff. If you choose to take no action,
you may remain an absent class member.
If you purchased Royal Caribbean securities, and/or would like to
discuss your legal rights and options please visit
https://www.bernlieb.com/cases/royalcaribbeancruisesltd-rcl
shareholder-class-action-lawsuit-fraud-323/apply/ contact Matthew
E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion
for its clients. In addition to representing individual investors,
the Firm has been retained by some of the largest public and
private pension funds in the country to monitor their assets and
pursue litigation on their behalf. As a result of its success
litigating hundreds of lawsuits and class actions, the Firm has
been named to The National Law Journal's "Plaintiffs' Hot List"
thirteen times and listed in The Legal 500 for ten consecutive
years.
ATTORNEY ADVERTISING. (C) 2020 Bernstein Liebhard LLP. The law firm
responsible for this advertisement is Bernstein Liebhard LLP, 10
East 40th Street, New York, New York 10016, (212) 779-1414. The
lawyer responsible for this advertisement in the State of
Connecticut is Michael S. Bigin. Prior results do not guarantee or
predict a similar outcome with respect to any future matter.
Matthew E. Guarnero
Bernstein Liebhard LLP
Tel No: (877) 779-1414
E-mail: MGuarnero@bernlieb.com [GN]
ROYAL CARIBBEAN: Glancy Prongay Reminds of Dec. 7 Deadline
----------------------------------------------------------
Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder
rights law firm, announces that a class action lawsuit has been
filed on behalf of investors who purchased or otherwise acquired
Royal Caribbean Cruises Ltd. ("Royal Caribbean" or the "Company")
(NYSE: RCL) securities between February 4, 2020 and March 17, 2020,
inclusive (the "Class Period"). Royal Caribbean investors have
until December 7, 2020 to file a lead plaintiff motion.
If you suffered a loss on your Royal Caribbean investments or would
like to inquire about potentially pursuing claims to recover your
loss under the federal securities laws, you can submit your contact
information at
https://www.glancylaw.com/cases/royal-caribbean-cruises-ltd/.
You can also contact Charles H. Linehan, of GPM at 310-201-9150,
Toll-Free at 888-773-9224, or via email at
shareholders@glancylaw.com to learn more about your rights.
On February 25, 2020, Royal Caribbean disclosed that the COVID-19
pandemic would adversely impact its earnings by $0.90 per share.
On this news, the Company's share price fell $12.55, or 14%, to
close at $77.00 per share on February 27, 2020.
On March 10, 2020, Royal Caribbean withdrew its 2020 financial
guidance, increased its revolving credit facility by $550 million,
and announced that it would take cost-cutting actions due to the
continued spread of COVID-19.
On this news, the Company's share price fell $7.30, or 14%, to
close at $44.37 per share on March 11, 2020.
On March 11, 2020, Royal Caribbean's largest competitor, Carnival
Corporation, announced a 60-day suspension of all operations, which
prompted concerns that Royal Carribean's safety procedures were not
as "aggressive" as claimed. At the same time, Royal Caribbean also
cancelled two cruises.
On this news, the Company's share price fell $14.10, or 32%, to
close at $30.27 per share on March 12, 2020.
On March 18, 2020, Stifel cut its one-year price target on Royal
Caribbean from $161 to $40.
On this news, the Company's share price fell $5.33, or 19% to close
at $22.33 per share on March 18, 2020.
The complaint alleges that throughout the Class Period, the
Defendants made false and/or misleading statements and failed to
disclose material adverse facts about the Company's decrease in
bookings outside China and its faulty policies and procedures to
prevent the circulation of COVID-19 on its cruise ships.
Specifically, regarding worldwide bookings, Royal Caribbean made
announcements that: (1) misled investors to believe that any issue
related to COVID-19 was relatively insignificant; (2) falsely
assured investors that bookings outside China were strong with no
signs of a slowdown; and (3) failed to disclose that the Company
was undergoing material declines in bookings globally due to
customer concerns over COVID-19.
Additionally, regarding safety procedures, the Company made
announcements that: (1) falsely assured investors that it
implemented rigorous safety procedures; (2) such procedures were
expected to ultimately contain the circulation of COVID-19; and (3)
failed to disclose that its cruise ships were following grossly
inadequate procedures that would facilitate the circulation of
COVID-19 and pose a substantial risk to passengers and crews; and
(4) as a result of the foregoing, Defendants' positive statements
about the Company's business, operations, and prospects were
materially misleading and/or lacked a reasonable basis.
If you purchased Royal Caribbean securities during the Class
Period, you may move the Court no later than December 7, 2020 to
ask the Court to appoint you as lead plaintiff. To be a member of
the Class you need not take any action at this time; you may retain
counsel of your choice or take no action and remain an absent
member of the Class. If you wish to learn more about this action,
or if you have any questions concerning this announcement or your
rights or interests with respect to these matters, please contact
Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite
2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at
888-773-9224, by email to shareholders@glancylaw.com, or visit our
website at www.glancylaw.com. If you inquire by email please
include your mailing address, telephone number and number of shares
purchased. [GN]
ROYAL CARIBBEAN: Howard G. Smith Announces Securities Class Action
------------------------------------------------------------------
Law Offices of Howard G. Smith announces that a class action
lawsuit has been filed on behalf of investors who purchased Royal
Caribbean Cruises Ltd. ("Royal Caribbean" or the "Company") (NYSE:
RCL) securities between February 4, 2020 and March 17, 2020,
inclusive (the "Class Period"). Royal Caribbean investors have
until December 7, 2020 to file a lead plaintiff motion.
Investors suffering losses on their Royal Caribbean investments are
encouraged to contact the Law Offices of Howard G. Smith to discuss
their legal rights in this class action at 888-638-4847 or by email
to howardsmith@howardsmithlaw.com.
On February 25, 2020, Royal Caribbean disclosed that the COVID-19
pandemic would adversely impact its earnings by $0.90 per share.
On this news, the Company's share price fell $12.55, or 14%, to
close at $77.00 per share on February 27, 2020.
On March 10, 2020, Royal Caribbean withdrew its 2020 financial
guidance, increased its revolving credit facility by $550 million,
and announced that it would take cost-cutting actions due to the
continued spread of COVID-19.
On this news, the Company's share price fell $7.30, or 14%, to
close at $44.37 per share on March 11, 2020.
On March 11, 2020, Royal Caribbean's largest competitor, Carnival
Corporation, announced a 60-day suspension of all operations, which
prompted concerns that Royal Carribean's safety procedures were not
as "aggressive" as claimed. At the same time, Royal Caribbean also
cancelled two cruises.
On this news, the Company's share price fell $14.10, or 32%, to
close at $30.27 per share on March 12, 2020.
On March 18, 2020, Stifel cut its one-year price target on Royal
Caribbean from $161 to $40.
On this news, the Company's share price fell $5.33, or 19% to close
at $22.33 per share on March 18, 2020.
The complaint filed in this class action alleges that throughout
the Class Period, the Defendants made false and/or misleading
statements and failed to disclose material adverse facts about
Royal Caribbean's decrease in bookings outside China and its faulty
policies and protocols to prevent the spread of COVID-19 on its
ships. Specifically, regarding global bookings, Royal Caribbean
made statements that: (1) misled investors to believe that any
issue related to COVID-19 was relatively inconsequential; (2)
falsely assured investors that bookings outside China were robust
with no signs of a slowdown; and (3) failed to disclose that Royal
Caribbean was undergoing material declines in bookings worldwide
due to client concerns over COVID-19.
Furthermore, regarding safety protocols, the Company made
statements that: (1) falsely assured investors that it implemented
thorough safety protocols; (2) such measures were expected to
ultimately contain the spread of COVID-19; and (3) failed to
disclose that its ships were following grossly inadequate
procedures that would enable the spread of COVID-19 and pose a
substantial risk to passengers and crews; and (4) as a result of
the foregoing, Defendants' positive statements about the Company's
business, operations, and prospects were materially misleading
and/or lacked a reasonable basis.
If you purchased Royal Caribbean securities, have information or
would like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Howard G. Smith, Esquire,
of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847,
toll-free at (888) 638-4847, or by email to
howardsmith@howardsmithlaw.com, or visit our website at
www.howardsmithlaw.com.
Howard G. Smith, Esquire
Law Offices of Howard G. Smith
Tel No: 215-638-4847
888-638-4847
E-mail: howardsmith@howardsmithlaw.com [GN]
ROYAL CARIBBEAN: Rosen Law Reminds of December 7 Deadline
---------------------------------------------------------
Rosen Law Firm, a global investor rights law firm, announces the
filing of a class action lawsuit on behalf of purchasers of the
securities of Royal Caribbean Cruises Ltd. (NYSE: RCL) between
February 4, 2020 and March 17, 2020, inclusive (the "Class
Period"). The lawsuit seeks to recover damages for Royal Caribbean
investors under the federal securities laws.
To join the Royal Caribbean class action, go to
http://www.rosenlegal.com/cases-register-1966.htmlor call Phillip
Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or
cases@rosenlegal.com for information on the class action.
According to the lawsuit, defendants throughout the Class Period
made materially false and/or misleading statements and/or failed to
disclose material adverse facts about the Company. Regarding global
bookings, Royal Caribbean made statements that: (1) misled
investors to believe that any issue related to COVID-19 was
relatively insignificant; (2) falsely assured investors that
bookings outside China were strong with no signs of a slowdown; and
(3) failed to disclose that the Company was experiencing material
declines in bookings globally due to customer concerns over
COVID-19. Additionally, regarding safety procedures, the Company
made statements that: (1) falsely assured investors that it
implemented rigorous safety protocols; (2) such protocols were
expected to ultimately contain the spread of COVID-19; and (3)
failed to disclose that its ships were following grossly inadequate
protocols that would foster the spread of COVID-19 and pose a
substantial risk to passengers and crews. When the true details
entered the market, the lawsuit claims that investors suffered
damages.
A class action lawsuit has already been filed. If you wish to serve
as lead plaintiff, you must move the Court no later than December
7, 2020. A lead plaintiff is a representative party acting on
behalf of other class members in directing the litigation. If you
wish to join the litigation, go to
http://www.rosenlegal.com/cases-register-1966.htmlor to discuss
your rights or interests regarding this class action, please
contact Phillip Kim, Esq. of Rosen Law Firm toll free at
866-767-3653 or via e-mail at pkim@rosenlegal.com or
cases@rosenlegal.com.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS
IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN
ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN
ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S
ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT
UPON SERVING AS LEAD PLAINTIFF.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation. Rosen Law Firm was Ranked No. 1
by ISS Securities Class Action Services for number of securities
class action settlements in 2017. The firm has been ranked in the
top 3 each year since 2013. Rosen Law Firm has achieved the largest
ever securities class action settlement against a Chinese Company.
Rosen Law Firm's attorneys are ranked and recognized by numerous
independent and respected sources. Rosen Law Firm has secured
hundreds of millions of dollars for investors. Attorney
Advertising. Prior results do not guarantee a similar outcome. [GN]
SOCIAL CAPITAL: Chaplin Suit Challenges Merger With Clover Health
-----------------------------------------------------------------
PAUL CHAPLIN, on behalf of himself and those similarly situated,
Plaintiff v. SOCIAL CAPITAL HEDOSOPHIA HOLDINGS CORP. III, CHAMATH
PALIHAPITIYA, IAN OSBORNE, JACQUELINE D. RESES and JAMES RYANS,
Defendants, Case No. 655802/2020 (N.Y. Sup. Ct., New York Cty.,
October 29, 2020) is a class action against the Defendants for
breach of fiduciary duties and for aiding and abetting the Board of
Directors' breaches of fiduciary duties.
The case arises from the Defendants' approval of the proposed
acquisition of Social Capital by Clover Health Investments Corp. to
the detriment of Social Capital's stockholders. The merger
agreement will cause Social Capital's shareholder interests to be
significantly diluted and they will own only 18.7% of the combined
company, while existing Clover Health shareholders will own the
vast majority, or 67.6%. Moreover, the Defendants caused to be
filed with the Securities and Exchange Commission (SEC) the
materially deficient Registration Statement in an effort to solicit
stockholders to vote their Social Capital shares in favor of the
proposed transaction. The Registration Statement is materially
deficient and deprives Social Capital stockholders of the
information they need to make an intelligent, informed and rational
decision of whether to vote their shares in favor of the proposed
transaction.
Social Capital Hedosophia Holdings Corp. III is a special purpose
acquisition company, with its principal executive offices located
at 317 University Ave, Suite 200, Palo Alto, California. [BN]
The Plaintiff is represented by:
Evan J. Smith, Esq.
BRODSKY & SMITH, LLC
240 Mineola Boulevard
Mineola, NY 11501
Telephone: (516) 741-4977
Facsimile: (561) 741-0626
TACTILE SYSTEMS: Bernstein Liebhard Reminds of Nov. 30 Deadline
---------------------------------------------------------------
Bernstein Liebhard, a nationally acclaimed investor rights law
firm, announces that a securities class action has been filed on
behalf of investors that purchased or acquired the securities of
Tactile Systems Technology, Inc. ("TCMD" or the "Company") (NASDAQ:
TCMD) between May 7, 2018 and June 8, 2020 (the "Class Period").
The lawsuit filed in the United States District Court for the
District of Minnesota alleges violations of the Securities Exchange
Act of 1934.
If you purchased Tactile securities, and/or would like to discuss
your legal rights and options please visit TCMD Shareholder Lawsuit
or contact Matthew E. Guarnero toll free at (877) 779-1414 or
MGuarnero@bernlieb.com.
The complaint alleges that throughout the Class Period, defendants
made false and/or misleading statements and/or failed to disclose
that: (1) while Tactile publicly touted a $4 plus billion or $5
plus billion market opportunity, in truth, the total addressable
market for Tactile's PCDs was materially smaller; (2) to induce
sales growth and share gains, Tactile and/or its employees were
engaged in illicit and illegal sales and marketing activities in
violation of applicable federal and state rules and public payer
regulations; (3) the foregoing illicit and illegal sales and
marketing activities increased the risk of a Medicare audit of
Tactile's claims and criminal and civil liability; (4) Tactile's
revenues were in part the product of unlawful conduct and thus
unsustainable; and that as a result of the foregoing (5)
Defendants' public statements, including Tactile's year-over-year
revenue growth, the purported growth drivers, and the effectiveness
of Tactile's internal controls over financial reporting were
materially false and misleading at all relevant times.
On June 8, 2020, research firm OSS Research published a scathing
report about the Company entitled "Strong Sell on Tactile Systems:
Bloated Stock Needs Compression Therapy." In the report, OSS
Research accused Tactile of (1) overstating its total addressable
market by nearly $4.7 billion, (2) using a "‘daisy-chaining
kick-back scheme' that has resulted in rampant overprescribing and
rapid market share gains at the expense of patients, insurers and
the public," and (3) concealing Medicare audits resulting in
denials, for failure to establish medical necessity, of a whopping
71% of Tactile's submitted claims.
On this news, the Company's stock price fell $6.05, or 11.69%, from
its June 8, 2020 opening price of $51.72 per share to a June 9,
2020 close of $45.67.
If you wish to serve as lead plaintiff, you must move the Court no
later than November 30, 2020. A lead plaintiff is a representative
party acting on behalf of other class members in directing the
litigation. Your ability to share in any recovery doesn't require
that you serve as lead plaintiff. If you choose to take no action,
you may remain an absent class member.
If you purchased Tactile securities, and/or would like to discuss
your legal rights and options please visit
https://www.bernlieb.com/cases/tactilesystemstechnologyinc-tcmd-shareholder-class-action-lawsuit-stock-fraud-317/apply/
or contact Matthew E. Guarnero toll free at (877) 779-1414 or
MGuarnero@bernlieb.com.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion
for its clients. In addition to representing individual investors,
the Firm has been retained by some of the largest public and
private pension funds in the country to monitor their assets and
pursue litigation on their behalf. As a result of its success
litigating hundreds of lawsuits and class actions, the Firm has
been named to The National Law Journal's "Plaintiffs' Hot List"
thirteen times and listed in The Legal 500 for ten consecutive
years.
Contacts
Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
MGuarnero@bernlieb.com [GN]
TACTILE SYSTEMS: Frank R. Cruz Reminds of November 30 Deadline
--------------------------------------------------------------
The Law Offices of Frank R. Cruz reminds investors that a class
action lawsuit has been filed on behalf of Tactile Systems
Technology, Inc. shareholders. Investors have until the deadline
listed below to file a lead plaintiff motion.
Investors suffering losses on their investments are encouraged to
contact The Law Offices of Frank R. Cruz to discuss their legal
rights in the class action at 310-914-5007 or by email to
fcruz@frankcruzlaw.com.
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
Class Period: May 7, 2018 - June 8, 2020
Lead Plaintiff Deadline: November 30, 2020
The complaint alleges that Defendants made materially false and/or
misleading statements, as well as failed to disclose material
adverse facts about the Company's business, operations, and
prospects. Specifically, Defendants failed to disclose to investors
that: (1) while Tactile publicly touted a $4 plus billion or $5
plus billion market opportunity, in fact, the total addressable
market for Tactile's medical devices was materially smaller; (2) to
induce sales growth and share gains, the Company and/or its
employees were engaged in illicit and illegal sales and marketing
activities in violation of applicable federal and state rules and
public payer regulations; (3) the foregoing illicit and illegal
sales and marketing activities increased the risk of a Medicare
audit of the Tactile's claims and criminal and civil liability; (4)
Tactile's profits were in part the product of unlawful conduct and
thus unsustainable; and that as a result of the foregoing, (5) the
Companys' public statements, including its year-over-year revenue
growth and the purported growth drivers, were materially false and
misleading at all relevant times; and (6) that, as a result of the
foregoing, the Defendants' statements about the Company's business,
operations, and prospects were materially misleading and/or lacked
a reasonable basis.
To be a member of these class action, you need not take any action
at this time; you may retain counsel of your choice or take no
action and remain an absent member of the class action. If you
wish to learn more about the class action, or if you have any
questions concerning this announcement or your rights or interests
with respect to these matters, please contact Frank R. Cruz, of The
Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100,
Los Angeles, California 90067 at 310-914-5007, by email to
info@frankcruzlaw.com, or visit our website at
www.frankcruzlaw.com. If you inquire by email please include your
mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules. [GN]
TACTILE SYSTEMS: Hagens Berman Reminds of November 30 Deadline
--------------------------------------------------------------
On September 29, 2020, leading shareholder rights law firm Hagens
Berman filed a securities fraud class action in the U.S. District
Court for the District of Minnesota against Tactile Systems
Technology (NASDAQ: TCMD) and certain of the Company's current and
former senior executives (collectively, "Defendants") on behalf of
investors in Tactile securities between May 7, 2018 and June 8,
2020 (the "Class Period") for violations of federal securities
laws.
If you are a shareholder who has suffered a material loss on your
Tactile investment, submit your losses now.
The complaint filed by Hagens Berman is the first and only action
filed on behalf of Tactile investors, and is based on an extensive
proprietary investigation and a careful evaluation of the merits of
this case.
Class Period:
May 7, 2018 - June 8, 2020
Lead Plaintiff Deadline:
Nov. 30, 2020
Visit:
www.hbsslaw.com/investor-fraud/TCMD
Contact An Attorney Now:
TCMD@hbsslaw.com
844-916-0895
Tactile's Alleged Fraud:
Headquartered in Minneapolis, Minnesota, Tactile is a medical
technology company that develops and provides medical devices for
the at home treatment of lymphedema and venous insufficiency. A
material portion of Tactile's annual revenues come in the form of
reimbursement from public third party payers, such as Medicare, the
Veterans Administration and certain Medicaid programs in the United
States. Accordingly, Tactile's compliance with applicable federal
and state rules and public payer regulations is critical to the
Company's success.
Based on a proprietary investigation conducted by Hagens Berman,
the complaint alleges that Defendants violated the securities laws
by misrepresenting and concealing that: (1) while Tactile publicly
touted a $4 plus billion or $5 plus billion market opportunity, in
truth, the total addressable market for Tactile's medical devices
was materially smaller; (2) to induce sales growth and share gains,
Tactile and/or its employees were engaged in illicit and illegal
sales and marketing activities in violation of applicable federal
and state rules and public payer regulations; (3) the foregoing
illicit and illegal sales and marketing activities increased the
risk of a Medicare audit of Tactile's claims and criminal and civil
liability; (4) Tactile's revenues were in part the product of
unlawful conduct and thus unsustainable; and that as a result of
the foregoing, (5) Defendants' public statements, including its
year-over-year revenue growth and the purported growth drivers,
were materially false and misleading at all relevant times.
The truth began to emerge on March 20, 2019, when an amended
federal Qui Tam complaint filed against Tactile by one of the
Company's competitors was unsealed, which contained detailed
allegations of illegal sales practices on the part of Tactile,
causing the Company to submit fraudulent claims to Medicare and the
VA. Then, on February 21, 2020, the court issued an order in the
Qui Tam Action, denying Tactile's motion to dismiss in its
entirety. Finally, on June 8, 2020, research firm OSS Research
published a scathing report about the Company, accusing Tactile of
using a "‘daisy-chaining' kickback scheme that has resulted in
rampant overprescribing and rapid market share gains at the expense
of patients, insurers and the public." All told, these disclosures
caused Tactile securities to decline precipitously, wiping out
significant shareholder value.
If you are a shareholder who purchased TCMD securities during the
class period, you have until Nov. 30, 2020, to ask the Court to
appoint you as Lead Plaintiff for the class. A copy of the
Complaint can be obtained here. Click here to discuss your legal
rights with Hagens Berman.
"We're focused on investors' losses and proving Tactile deceived
investors by engaging in illegal marketing schemes to induce sales
growth," said Reed Kathrein, the Hagens Berman partner leading the
investigation.
Lead Plaintiff Process: The Private Securities Litigation Reform
Act of 1995 permits any investor who purchased TCMD securities
during the Class Period to seek appointment as lead plaintiff. A
lead plaintiff acts on behalf of all other class members in
directing the litigation. The lead plaintiff can select a law firm
of its choice. An investor's ability to share in any potential
future recovery is not dependent upon serving as lead plaintiff. If
you wish to serve as Lead Plaintiff for the Class, you must file a
motion with the Court no later than Nov. 30, 2020, which is the
first business day on which the U.S. District Court for the
District of Minnesota is open that is 60 days after the publication
date of Sept. 29, 2020. Any member of the proposed Class may move
the Court to serve as Lead Plaintiff through counsel of their
choice. Members may also choose to do nothing and remain part of
the proposed Class.
Whistleblowers: Persons with non-public information regarding
Tactile should consider their options to help in the investigation
or take advantage of the SEC Whistleblower program. Under the new
program, whistleblowers who provide original information may
receive rewards totaling up to 30 percent of any successful
recovery made by the SEC. For more information, call Reed Kathrein
at 844-916-0895 or email TCMD@hbsslaw.com.
About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight
cities around the country and eighty attorneys. The firm represents
investors, whistleblowers, workers and consumers in complex
litigation. More about the firm and its successes is located at
hbsslaw.com. [GN]
TACTILE SYSTEMS: Rosen Law Firm Reminds of November 30 Deadline
---------------------------------------------------------------
Rosen Law Firm, a global investor rights law firm, on Oct. 5
announced the filing of a class action lawsuit on behalf of
purchasers of the securities of Tactile Systems Technology, Inc.
(NASDAQ: TCMD) between May 7, 2018 and June 8, 2020, inclusive (the
"Class Period"). The lawsuit seeks to recover damages for Tactile
investors under the federal securities laws.
To join the Tactile class action, go to
http://www.rosenlegal.com/cases-register-1872.htmlor call Phillip
Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or
cases@rosenlegal.com for information on the class action.
The complaint filed in this class action alleges that throughout
the Class Period, defendants made materially false and/or
misleading statements, as well as failed to disclose material
adverse facts about the Company's business, operations, and
prospects. Specifically, defendants failed to disclose to investors
that: (1) while Tactile publicly touted a $4 plus billion or $5
plus billion market opportunity, in truth, the total addressable
market for Tactile's medical devices was materially smaller; (2) to
induce sales growth and share gains, Tactile engaged in illegal
sales and marketing activities; (3) Tactile's revenues were in part
the product of unlawful conduct and thus unsustainable; and (4) as
a result, defendants' public statements were materially false and
misleading at all relevant times. When the true details entered the
market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve
as lead plaintiff, you must move the Court no later than November
30, 2020. A lead plaintiff is a representative party acting on
behalf of other class members in directing the litigation. If you
wish to join the litigation, go to
http://www.rosenlegal.com/cases-register-1872.htmlor to discuss
your rights or interests regarding this class action, please
contact Phillip Kim, Esq. of Rosen Law Firm toll free at
866-767-3653 or via e-mail at pkim@rosenlegal.com or
cases@rosenlegal.com.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS
IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN
ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN
ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S
ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT
UPON SERVING AS LEAD PLAINTIFF.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation. Rosen Law Firm was Ranked No. 1
by ISS Securities Class Action Services for number of securities
class action settlements in 2017. The firm has been ranked in the
top 3 each year since 2013. Rosen Law Firm has achieved the largest
ever securities class action settlement against a Chinese Company.
Rosen Law Firm's attorneys are ranked and recognized by numerous
independent and respected sources. Rosen Law Firm has secured
hundreds of millions of dollars for investors. Attorney
Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com [GN]
TEVA PHARMA: Rosen Law Reminds of Nov. 23 Deadline
--------------------------------------------------
Rosen Law Firm, a global investor rights law firm, reminds the
purchasers of the securities of Teva Pharmaceuticals Industries
Limited (NYSE: TEVA) between October 29, 2015 and August 18, 2020,
inclusive (the "Class Period"), of the important November 23, 2020
lead plaintiff deadline in securities class action. The lawsuit
seeks to recover damages for Teva investors under the federal
securities laws.
To join the Teva class action, go to
http://www.rosenlegal.com/cases-register-1956.htmlor call Phillip
Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or
cases@rosenlegal.com for information on the class action.
The complaint alleges that throughout the Class Period, Defendants
made materially false and misleading statements regarding Teva's
business, operational, and compliance policies. Specifically,
Defendants made false and/or misleading statements and/or failed to
disclose that: (1) Teva had made substantial illegal kickback
payments to charitable foundations to cover Medicare co-payment
obligations of patients taking Copaxone; (2) accordingly, Teva's
revenues derived from Copaxone were in part the product of unlawful
conduct and thus unsustainable; (3) the foregoing misconduct
subjected Teva to a foreseeable risk of heightened regulatory
scrutiny and enforcement, as well as reputational harm when the
truth became known; and (4) as a result, defendants' public
statements were materially false and misleading at all relevant
times. When the true details entered the market, the lawsuit claims
that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve
as lead plaintiff, you must move the Court no later than November
23, 2020. A lead plaintiff is a representative party acting on
behalf of other class members in directing the litigation. If you
wish to join the litigation, go to
http://www.rosenlegal.com/cases-register-1956.htmlor to discuss
your rights or interests regarding this class action, please
contact Phillip Kim, Esq. of Rosen Law Firm toll free at
866-767-3653 or via e-mail at pkim@rosenlegal.com or
cases@rosenlegal.com.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS
IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN
ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN
ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S
ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT
UPON SERVING AS LEAD PLAINTIFF.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation. Rosen Law Firm was Ranked No. 1
by ISS Securities Class Action Services for number of securities
class action settlements in 2017. The firm has been ranked in the
top 3 each year since 2013. Rosen Law Firm has achieved the largest
ever securities class action settlement against a Chinese Company.
Rosen Law Firm's attorneys are ranked and recognized by numerous
independent and respected sources. Rosen Law Firm has secured
hundreds of millions of dollars for investors. Attorney
Advertising. Prior results do not guarantee a similar outcome. [GN]
TURQUOISE HILL: Robbins Geller Reminds of Dec. 14 Deadline
----------------------------------------------------------
Robbins Geller Rudman & Dowd LLP announces that a class action
lawsuit has been filed in the Southern District of New York on
behalf of purchasers or acquirers of Turquoise Hill Resources Ltd.
(NYSE:TRQ) securities between July 17, 2018 and July 31, 2019,
inclusive (the "Class Period"). The case is captioned Franchi v.
Turquoise Hill Resources Ltd., No. 20-cv-08585, and is assigned to
Judge Lewis J. Liman. The Turquoise Hill class action lawsuit
charges Turquoise Hill, certain of its executives, as well as Rio
Tinto PLC, Rio Tinto Limited and Rio Tinto International Holdings,
Inc. (together, "Rio Tinto"), and certain of Rio Tinto's executives
with violations of the Securities Exchange Act of 1934.
The Private Securities Litigation Reform Act of 1995 permits any
investor who purchased Turquoise Hill securities during the Class
Period to seek appointment as lead plaintiff in the Turquoise Hill
class action lawsuit. A lead plaintiff will act on behalf of all
other class members in directing the Turquoise Hill class action
lawsuit. The lead plaintiff can select a law firm of its choice to
litigate the Turquoise Hill class action lawsuit. An investor's
ability to share in any potential future recovery of the Turquoise
Hill class action lawsuit is not dependent upon serving as lead
plaintiff. If you wish to serve as lead plaintiff of the Turquoise
Hill class action lawsuit or have questions concerning your rights
regarding the Turquoise Hill class action lawsuit, please provide
your information here or contact counsel, J.C. Sanchez of Robbins
Geller, at 800/449-4900 or 619/231-1058 or via e-mail at
jsanchez@rgrdlaw.com. Lead plaintiff motions for the Turquoise Hill
class action lawsuit must be filed with the court no later than
December 14, 2020.
Turquoise Hill is an international mining company focused on the
operation and development of the Oyu Tolgoi copper-gold mine in
Southern Mongolia, which is Turquoise Hill's principal and only
material resource property. Through its subsidiaries, Rio Tinto
owns 50.8% of Turquoise Hill. Rio Tinto PLC subsidiary Rio Tinto
International Holdings, Inc. is also the manager of the Oyu Tolgoi
project, including having responsibility for its development and
construction.
The Turquoise Hill class action lawsuit alleges that during the
Class Period defendants made false and/or misleading statements
and/or failed to disclose that: (i) the progress of underground
development at Oyu Tolgoi was not proceeding as planned; (ii) there
were significant undisclosed underground stability issues that
called into question the design of the mine and the projected cost
and timing of production; (iii) Turquoise Hill's publicly disclosed
estimates of the cost, date of completion, and dates for production
from the underground mine were not achievable; (iv) the development
capital required for the underground development of Oyu Tolgoi
would cost substantially more than a billion dollars over what
Turquoise Hill had represented; and (v) Turquoise Hill would
require additional financing and/or equity to complete the
project.
On February 26, 2019, Turquoise Hill shocked the financial markets
by disclosing in a press release that, although "the [Oyu Tolgoi]
project cost was expected to remain within the $5.3 billion
budget," a review had determined that "there was an increasingly
likely risk of a further delay to sustainable first production
beyond Q3'21." In the press release, Turquoise Hill attributed the
"likely risk" to productivity delays in completing Shaft 2 and
"challenging ground conditions that have had a direct impact on the
project's critical path." On this news, Turquoise Hill's common
stock price fell nearly 13%.
Then, on July 15, 2019, Turquoise Hill issued a press release
announcing a further delay and that the underground project would
cost substantially more than Turquoise Hill had repeatedly stated
during the Class Period. Sustainable first production from the
underground development of Oyu Tolgoi would now be delayed by
another 9 to 21 months until May 2022 to June 2023, and "the
development capital spend for the project may increase by $1.2 to
$1.9 billion over the $5.3 billion previously disclosed." On this
news, Turquoise Hill's common stock price fell nearly 44%.
Finally, on July 31, 2019, Turquoise Hill disclosed that it had
taken a $600 million impairment charge and a substantial "deferred
income tax recognition adjustment" tied to the Oyu Tolgoi project,
and that it had suffered a loss in the second quarter. The next
day, Rio Tinto also revealed that it too had taken an impairment
charge related to the Oyu Tolgoi project of $800 million. On this
news, Turquoise Hill's common stock price fell more than 8%,
further damaging investors.
Robbins Geller Rudman & Dowd LLP is one of the world's leading law
firms representing investors in securities class action litigation.
With 200 lawyers in 9 offices, Robbins Geller has obtained many of
the largest securities class action recoveries in history. For
seven consecutive years, ISS Securities Class Action Services has
ranked the Firm in its annual SCAS Top 50 Report as one of the top
law firms in the world in both amount recovered for shareholders
and total number of class action settlements. Robbins Geller
attorneys have helped shape the securities laws and have recovered
tens of billions of dollars on behalf of aggrieved victims. Beyond
securing financial recoveries for defrauded investors, Robbins
Geller also specializes in implementing corporate governance
reforms, helping to improve the financial markets for investors
worldwide. Robbins Geller attorneys are consistently recognized by
courts, professional organizations, and the media as leading
lawyers in the industry. Please visit http://www.rgrdlaw.comfor
more information.
J.C. Sanchez
Robbins Geller Rudman & Dowd LLP
Tel No: 800-449-4900
E-mail: jsanchez@rgrdlaw.com [GN]
TURQUOISE HILL: Schall Law Announces Securities Class Action
------------------------------------------------------------
The Schall Law Firm, a national shareholder rights litigation firm,
announces the filing of a class-action lawsuit against Turquoise
Hill Resources Ltd. ("Turquoise Hill" or "the Company") (NYSE:TRQ)
for violations of 10(b) and 20(a) of the Securities Exchange Act of
1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities
and Exchange Commission.
Investors who purchased the Company's securities between July 17,
2018 and July 31, 2019, inclusive (the "Class Period"), are
encouraged to contact the firm before December 14, 2020.
We also encourage you to contact Brian Schall of the Schall Law
Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at
310-301-3335, to discuss your rights free of charge. You can also
reach us through the firm's website at www.schallfirm.com, or by
email at brian@schallfirm.com.
The class, in this case, has not yet been certified, and until
certification occurs, you are not represented by an attorney. If
you choose to take no action, you can remain an absent class
member.
According to the Complaint, the Company made false and misleading
statements to the market. Turquoise Hill suffered stability issues
at its Oyu Tolgoi copper-gold mine in Mongolia that were far more
severe than represented. The Company's estimates of the cost of
completion and production schedule were impossible to achieve. The
Company's purported "challenging ground conditions" made its
production estimates beyond its capabilities. In fact, the Company
would require additional financing to complete the project. Based
on these facts, the Company's public statements were false and
materially misleading throughout the class period. When the market
learned the truth about Turquoise Hill, investors suffered
damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder
rights litigation.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and rules of ethics. [GN]
ULTRA PETROLEUM Portnoy Law Reminds of Nov. 9 Deadline
------------------------------------------------------
The Portnoy Law Firm advises investors that a class action lawsuit
has been filed on behalf of Ultra Petroleum Corporation (OTCMKTS:
UPLCQ) investors that acquired shares between April 13, 2017 and
August 8, 2019. Investors have until November 9, 2020 to seek an
active role in this litigation.
Investors are encouraged to contact attorney Lesley F. Portnoy , to
determine eligibility to participate in this action, by phone
310-692-8883 or email.
This lawsuit charges certain current and former officers and/or
directors of Ultra Petroleum with violations of the Securities
Exchange Act of 1934. Ultra Petroleum is an oil and gas development
company with its primary assets in the Jonah and Pinedale fields of
southwest Wyoming's Green River Basin. Over 80% of the Company's
revenues have historically been derived from the development and
sale of natural gas. On May 14, 2020, Ultra Petroleum filed for
bankruptcy protection. Ultra Petroleum is not named as a defendant
in the action.
In April 2017, at the beginning of the Class Period, Ultra
Petroleum exited a court-supervised reorganization under Chapter 11
of the U.S. Bankruptcy Code. According to defendants, Ultra
Petroleum was "in growth mode" at the point it exited the
bankruptcy. Ultra stated that the it was prepared to maximize the
value of its substantial oil and gas deposits (which they valued at
$4.19 billion, which included $1.5 billion of proved undeveloped
reserves) by way of ramped up production in 2017 and 2018, and that
it was set to produce between 290 and 300 billion cubic feet
equivalent ("Bcfe") in 2017, with 25% production growth over these
figures in 2018. Ultra represented that they had the financial and
production flexibility to withstand even a low-commodity-price
environment and was in preparation to ramp up well development with
10 rigs operating by 2018 on the back of an estimated $788 million
capital budget. Accretive to this plan was the launch of a
horizontal well drilling program, which Ultra executives claimed
was set to greatly expand the production capabilities of the
Ultra's existing wells.
The complaint alleges that these and similar statements issued by
Ultra during the Class Period were misleading and materially false.
Throughout the Class Period, Ultra, inter alia : (i) materially
overstated the value of Ultra oil and gas reserves; (ii) materially
misrepresented their ability increase production as well as its
financial flexibility; (iii) failed to disclose extreme sensitivity
of Ultra to even a modest decline in natural gas prices; and (iv)
concealed significant setbacks in the Ultra's vaunted horizontal
well drilling program.
Then, soon after exiting bankruptcy at the beginning in August
2017, Ultra Petroleum began issuing a series of revelations that
demonstrated that it was not capable of increasing production by
any meaningful amount and that its wells were worth a fraction of
the values that had been previously represented. Finally, on August
9, 2019, Ultra Petroleum announced disappointing results for the
second quarter of 2019, announcing that total revenues had
decreased 18% for the quarter, that Ultra's horizontal well program
had been effectively halted, and that it was lowering its 2019
projected capital investments to a range of $260 million to $290
million and annual production to a range of 238 to 244 Bcfe. The
price of Ultra Petroleum stock declined 31% on this news to just
$0.09 per share, continuing to fall to just $0.01 per share, 99%
below the stock's Class Period high. On August 22, 2019, Ultra
Petroleum stock was delisted. And in May 2020, the Ultra was forced
to enter bankruptcy proceedings once more in order to seek a
court-ordered reorganization.
A class action lawsuit has already been filed. If you wish to serve
as lead plaintiff, you must move the Court no later than November
9, 2020.
Please visit our website to review more information and submit your
transaction information.
The Portnoy Law Firm represents investors in pursuing claims
arising from corporate wrongdoing. The Firm's founding partner has
recovered over $5.5 billion for aggrieved investors. Attorney
advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Tel No: 310-692-8883
E-mail: lesley@portnoylaw.com [GN]
ULTRA PETROLEUM: Wolf Haldenstein Reminds of Class Action
---------------------------------------------------------
Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein")
announces that a federal securities class action lawsuit has been
filed in the United States District Court for the District of
Colorado against Ultra Petroleum Corp. ("Ultra Petroleum" or the
"Company") (OTC: UPLCQ) and certain of its officers, on behalf of
shareholders who purchased or otherwise acquired Ultra Petroleum
securities between April 13, 2017 and August 8, 2019, both dates
inclusive (the "Class Period").
All investors who purchased shares of Ultra Petroleum Corp. and
incurred losses are urged to contact the firm immediately at
classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may
obtain additional information concerning the action or join the
case on our website, www.whafh.com.
If you have incurred losses in the shares of Ultra Petroleum Corp.,
you may, no later than November 2, 2020, request that the Court
appoint you lead plaintiff of the proposed class.
On August 9, 2019, Ultra issued a press release announcing its
second-quarter 2019 financial and operating results. The Company
disclosed that total revenues for the quarter had decreased by 18%
to $155.4 million, compared to $190.1 million during the second
quarter of 2018. Ultra's press release advised investors that the
Company's once-vaunted horizontal well program had been effectively
halted and also lowered the Company's 2019 projected capital
investments to a range of $260 million to $290 million and annual
production to a range of 3239 to 244 billion cubic feet
equivalent.
On this news, Ultra's stock price fell 31% to close at $0.09 per
share on an unusually high volume of nearly 14 million shares
traded. On August 22, 2019, NASDAQ formally delisted Ultra stock.
Wolf Haldenstein has extensive experience in the prosecution of
securities class actions and derivative litigation in state and
federal trial and appellate courts across the country. The firm has
attorneys in various practice areas; and offices in New York,
Chicago and San Diego. The reputation and expertise of this firm in
shareholder and other class litigation has been repeatedly
recognized by the courts, which have appointed it to major
positions in complex securities multi-district and consolidated
litigation.
If you wish to discuss this action or have any questions regarding
your rights and interests in this case, please immediately contact
Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at
classmember@whafh.com, or visit our website at www.whafh.com. [GN]
UNITED STATES: NUL, NFHA Balk at Trump's EO on Diversity Trainings
------------------------------------------------------------------
NATIONAL URBAN LEAGUE and NATIONAL FAIR HOUSING ALLIANCE, on behalf
of themselves and all others similarly situated, Plaintiffs v.
DONALD J. TRUMP, in his official capacity as President of the
United States; EUGENE SCALIA, in his official capacity as United
States Secretary of Labor; and U.S. DEPARTMENT OF LABOR,
Defendants, Case No. 1:20-cv-03121 (D.D.C., October 29, 2020) is a
class action against the Defendants for violations of the First and
Fifth Amendments to the United States Constitution.
According to the complaint, the Executive Order (EO) 13950 issued
by U.S. President Donald Trump on September 22, 2020 prohibits the
Plaintiffs and Class members from discussing and promoting concepts
like, among other things, systemic race and sex discrimination and
implicit race and sex biases in the workplace, which violates the
guarantees of Free Speech, Equal Protection, and Due Process under
the United States Constitution. The Plaintiffs allege that EO 13950
imposes the inaccurate and ahistorical viewpoints of the Trump
Administration on federal contractors and grantees simply because
President Trump disagrees with the Protected Speech. The EO 13950
prohibits any federal contractor from engaging in speech, including
the provision of certain training to its employees, that may foster
belief in certain concepts that President Trump has deemed
divisive, but which are widely-accepted, historically-based
concepts that have been used for years in trainings and programs
across the country in corporate, public sector, and educational
settings. As a result of this prohibition, the Plaintiffs are
prevented from creating and maximizing economic efficiencies by
ensuring the satisfaction and inclusivity of all their employees,
and reaping the full benefits of a diverse and productive
workforce.
The National Urban League (NUL) is a nonpartisan historic civil
rights organization headquartered in New York, New York.
The National Fair Housing Alliance (NFHA) is a non-profit
corporation headquartered in Washington, D.C. [BN]
The Plaintiffs are represented by:
Sherrilyn Ifill, Esq.
Janai Nelson, Esq.
Samuel Spital, Esq.
Jin Hee Lee, Esq.
Monique Lin-Luse, Esq.
Amber Koonce, Esq.
NAACP LEGAL DEFENSE AND EDUCATIONAL FUND, INC.
40 Rector St., 5th Floor
New York, NY 10006
Telephone: (212) 965-2200
Facsimile: (212) 226-7592
E-mail: sspital@naacpldf.org
- and –
Ajmel Quereshi, Esq.
NAACP LEGAL DEFENSE AND EDUCATIONAL FUND, INC.
700 14th Street N.W., Ste.600
Washington, DC 20005
Telephone: (202) 682-1300
WRAP TECHNOLOGIES: Rosen Law Firm Reminds of November 23 Deadline
-----------------------------------------------------------------
Rosen Law Firm, a global investor rights law firm, reminds
purchasers of the securities of Wrap Technologies, Inc. (NASDAQ:
WRTC) between July 31, 2020 and September 23, 2020, inclusive (the
"Class Period") of the important November 23, 2020 lead plaintiff
deadline in the case commenced by the firm. The lawsuit seeks to
recover damages for Wrap investors under the federal securities
laws.
To join the Wrap class action, go to
http://www.rosenlegal.com/cases-register-1953.htmlor call Phillip
Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or
cases@rosenlegal.com for information on the class action.
According to the lawsuit, defendants throughout the Class Period
made false and/or misleading statements and/or failed to disclose
that: (1) Wrap had concealed the results of the LAPD BolaWrap pilot
program, which demonstrated that the BolaWrap was ineffective,
expensive, and sparingly used in the field; and (2) as a result,
defendants' public statements were materially false and/or
misleading at all relevant times. When the true details entered the
market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve
as lead plaintiff, you must move the Court no later than November
23, 2020. A lead plaintiff is a representative party acting on
behalf of other class members in directing the litigation. If you
wish to join the litigation, go to
http://www.rosenlegal.com/cases-register-1953.htmlor to discuss
your rights or interests regarding this class action, please
contact Phillip Kim, Esq. of Rosen Law Firm toll free at
866-767-3653 or via e-mail at pkim@rosenlegal.com or
cases@rosenlegal.com.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS
IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN
ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN
ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S
ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT
UPON SERVING AS LEAD PLAINTIFF.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation. Rosen Law Firm was Ranked No. 1
by ISS Securities Class Action Services for number of securities
class action settlements in 2017. The firm has been ranked in the
top 3 each year since 2013. Rosen Law Firm has achieved the largest
ever securities class action settlement against a Chinese Company.
Rosen Law Firm's attorneys are ranked and recognized by numerous
independent and respected sources. Rosen Law Firm has secured
hundreds of millions of dollars for investors. Attorney
Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com [GN]
YAYYO INC: Lifshitz Law Probes Firm
-----------------------------------
Lifshitz Law Firm announces investigation into possible securities
law violations by certain of YayYo, Inc. (Other OTC: YAYO)'s
officers and/or directors. The investigation relates to a
securities class action lawsuit alleging that certain officers made
false and/or misleading statements relating to El-Batrawi continued
to exercise supervision, authority, and control over YayYo, and was
intimately involved, on a day-to-day basis, with the business,
operations, and finances of the Company, including assisting the
Underwriter Defendants in marketing YayYo's IPO.
If you are a YAYO investor, and would like additional information
about our investigation, please complete the Information Request
Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780
or e-mail at info@jlclasslaw.com.
ATTORNEY ADVERTISING.(C) 2020 Lifshitz Law Firm, P.C. The law firm
responsible for this advertisement is Lifshitz Law Firm, P.C., 821
Franklin Avenue, Suite 209, Garden City, New York 11530, Tel:
(516)493-9780. Prior results do not guarantee or predict a similar
outcome with respect to any future matter. [GN]
YAYYO INC: Wolf Haldenstein Reminds of November 9 Deadline
----------------------------------------------------------
Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") on
Oct. 5 disclosed that a federal securities class action lawsuit has
been filed on behalf of investors who purchased YayYo, Inc.
("YayYo" or the "Company") (OTC: YAYO) securities pursuant and/or
traceable to the Company's initial public offering conducted on
November 14, 2019 (the "IPO" or "Offering") in the United States
District Court for the Central District of California.
All investors who purchased shares of YayYo, Inc. and incurred
losses are urged to contact the firm immediately at
classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may
obtain additional information concerning the action or join the
case on our website, www.whafh.com.
If you have incurred losses in the shares of YayYo, Inc., you may,
no later than November 9, 2020, request that the Court appoint you
lead plaintiff of the proposed class.
The filed complaint alleges that throughout the Class Period,
Defendants made materially false and/or misleading statements, as
well as failed to disclose material adverse facts about the
Company's business, operations, and prospects. Specifically,
Defendants failed to disclose to investors that:
* defendant El-Batrawi continued to exercise supervision,
authority, and control over YayYo, and was intimately involved, on
a day-to-day basis, with the business, operations, and finances of
the Company, including assisting the Underwriter Defendants in
marketing YayYo's IPO;
* defendant El-Batrawi never sold the 12,525,000 "Private
Shares" and continued to own a controlling interest in YayYo
despite the NASDAQ's insistence that he retain less than a 10%
equity ownership interest in connection with the listing
agreement;
* defendants promised certain creditors of YayYo that in
exchange to their agreeing to purchase shares in the IPO in order
to permit the Underwriter
* defendants to close the IPO YayYo would repurchase those
shares after the IPO;
* defendants intended to repurchase shares purchased by
creditors of YayYo in the IPO using IPO proceeds:
* YayYo owed its former President, CEO, and Director a half of
million dollars at the time of the IPO;
* YayYo owed SRAX, Inc. (formerly Social Reality, Inc.) $426,286
in unpaid social media costs, most of which was more than a year
overdue as payment had been delayed while YayYo attempted to
complete its IPO; and
* that, as a result of the foregoing, Defendants' positive
statements about the Company's business, operations, and prospects
were materially misleading and/or lacked a reasonable basis.
In November 2019, YayYo completed its initial public offering
("IPO"), in which it sold approximately 2.7 million shares of
common stock at $4 per share.
Then, on February 10, 2020, the Company announced that its Board of
Directors had decided to delist YayYo's common stock from the
NASDAQ.
Since the IPO, the Company's shares have traded as low as $0.25, or
94% below the IPO price.
Wolf Haldenstein has extensive experience in the prosecution of
securities class actions and derivative litigation in state and
federal trial and appellate courts across the country. The firm has
attorneys in various practice areas; and offices in New York,
Chicago and San Diego. The reputation and expertise of this firm in
shareholder and other class litigation has been repeatedly
recognized by the courts, which have appointed it to major
positions in complex securities multi-district and consolidated
litigation.
If you wish to discuss this action or have any questions regarding
your rights and interests in this case, please immediately contact
Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at
classmember@whafh.com, or visit our website at www.whafh.com.
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules. [GN]
Asbestos Litigation
ASBESTOS UPDATE: AEP Transfers Liabilities for Conesville Plant
---------------------------------------------------------------
American Electric Power Company, Inc. (AEP) disclosed in its Form
10-Q filing with the U.S. Securities and Exchange Commission for
the quarterly period ended September 30, 2020, that the Company and
a non-affiliated joint-owner has executed an Environmental
Liability and Property Transfer and Asset Purchase Agreement with a
non-affiliated third-party related to the merchant Conesville Plant
site wherein the purchaser took ownership of the assets and assumed
responsibility for environmental liabilities, including ash pond
closure, asbestos abatement and decommissioning and demolition of
the Conesville Plant site.
The Company states, "In June 2020, AEP and a non-affiliated
joint-owner executed an Environmental Liability and Property
Transfer and Asset Purchase Agreement with a non-affiliated
third-party related to the merchant Conesville Plant site. The
purchaser took ownership of the assets and assumed responsibility
for environmental liabilities, including ash pond closure, asbestos
abatement and decommissioning and demolition of the Conesville
Plant site. In consideration of the transfer of the acquired
assets to the purchaser and the purchaser's assumption of
liabilities, AEP will pay approximately US$98 million, derecognized
US$106 million in ARO and recorded an immaterial gain on the
transaction which is recorded in Other Operation on the statements
of income. AEP paid approximately US$26 million in June 2020 and
will make additional payments totaling US$28 million in quarterly
installments from October 2020 to April 2021 and payments totaling
US$44 million in quarterly installments from July 2021 to July
2022."
A full-text copy of the Form 10-Q is available at
https://is.gd/kDZEoq
ASBESTOS UPDATE: Carlisle Cos. Still Faces Claims at Sept. 30
-------------------------------------------------------------
Carlisle Companies Incorporated said in its Form 10-Q filing with
the U.S. Securities and Exchange Commission for the quarterly
period ended September 30, 2020, that at this time, the amount of
reasonably possible asbestos claims, if any, is not material to the
Company's financial position, results of operations, or operating
cash flows.
The Company states, "Over the years, the Company has been named as
a defendant, along with numerous other defendants, in lawsuits in
various courts in which plaintiffs have alleged injury due to
exposure to asbestos-containing brakes, which Carlisle manufactured
in limited amounts between the late-1940s and the mid-1980s. In
addition to compensatory awards, these lawsuits may also seek
punitive damages. Generally, the Company has obtained dismissals
or settlements of its asbestos-related lawsuits with no material
effect on its financial condition, results of operations, or cash
flows. The Company maintains insurance coverage that applies to
the Company's defense costs and payments of settlements or
judgments in connection with asbestos-related lawsuits. At this
time, the amount of reasonably possible asbestos claims, if any, is
not material to the Company's financial position, results of
operations, or operating cash flows, although these matters could
result in the Company being subject to monetary damages, costs or
expenses, and charges against earnings in particular periods."
A full-text copy of the Form 10-Q is available at
https://is.gd/XFwNwT
ASBESTOS UPDATE: Dow Had $1.02BB Noncurrent Liabilities at Sept. 30
-------------------------------------------------------------------
Dow Inc. recorded Other Noncurrent Liabilities of US$1.02 billion
related to asbestos matters as of September 30, 2020, according to
the Company's Form 10-Q filing with the U.S. Securities and
Exchange Commission for the quarterly period ended September 30,
2020.
A full-text copy of the Form 10-Q is available at
https://is.gd/a9WKBt
ASBESTOS UPDATE: Lennox Int'l. Has $2.4MM Litigation Expense in Q3
------------------------------------------------------------------
Lennox International Inc. has $2.4 million expense, net of probable
insurance recoveries, for known and future asbestos-related
litigation for the three months ended September 30, 2020, according
to the Company's Form 10-Q filing with the U.S. Securities and
Exchange Commission for the quarterly period ended September 30,
2020.
The Company states, "We are involved in a number of claims and
lawsuits incident to the operation of our businesses. Insurance
coverages are maintained and estimated costs are recorded for such
claims and lawsuits, including costs to settle claims and lawsuits,
based on experience involving similar matters and specific facts
known.
"Some of these claims and lawsuits allege personal injury or health
problems resulting from exposure to asbestos that was integrated
into certain of our products. We have never manufactured asbestos
and have not incorporated asbestos-containing components into our
products for several decades. A substantial majority of these
asbestos-related claims have been covered by insurance or other
forms of indemnity or have been dismissed without payment. The
remainder of our closed cases have been resolved for amounts that
are not material, individually or in the aggregate. Our defense
costs for asbestos-related claims are generally covered by
insurance. However, our insurance coverage for settlements and
judgments for asbestos-related claims varies depending on several
factors and are subject to policy limits. We may have greater
financial exposure for future settlements and judgments.
"It is management's opinion that none of these claims or lawsuits
or any threatened litigation will have a material adverse effect on
our financial condition, results of operations or cash flows.
Claims and lawsuits, however, involve uncertainties and it is
possible that their eventual outcome could adversely affect our
results of operations for a particular period."
A full-text copy of the Form 10-Q is available at
https://is.gd/NTgqYi
ASBESTOS UPDATE: Pentair Units Had 610 Pending Claims at Sept. 30
-----------------------------------------------------------------
Pentair plc's subsidiaries remain defendants in approximately 610
claims related to asbestos matters as of September 30, 2020,
according to the Company's Form 10-Q filing with the U.S.
Securities and Exchange Commission for the quarterly period ended
September 30, 2020.
The Company states, "Our current and former subsidiaries and
numerous other unaffiliated companies are named as defendants in
personal injury lawsuits based on alleged exposure to
asbestos-containing materials. These cases typically involve
product liability claims based primarily on allegations of
manufacture, sale or distribution of industrial products that
either contained asbestos or were attached to or used with
asbestos-containing components manufactured by third-parties. Each
case typically names between several dozen to more than a hundred
corporate defendants. Our historical strategy has been to mount a
vigorous defense aimed at having unsubstantiated suits dismissed,
and, where appropriate, settling suits before trial. Although a
large percentage of litigated suits have been dismissed, we cannot
predict the extent to which we will be successful in resolving
lawsuits in the future.
"As of September 30, 2020, there were approximately 610 claims
outstanding against our subsidiaries. This amount is not adjusted
for claims that are not actively being prosecuted, identified
incorrect defendants, or duplicated other actions, which would
ultimately reflect our current estimate of the number of viable
claims made against us, our affiliates, or entities for which we
assumed responsibility in connection with acquisitions or
divestitures. In addition, the amount does not include certain
claims pending against third parties for which we have been
provided an indemnification."
A full-text copy of the Form 10-Q is available at
https://is.gd/FA4dKd
ASBESTOS UPDATE: PPG Industries Had 600 Open Claims at Sept. 30
---------------------------------------------------------------
PPG Industries, Inc. said in its Form 10-Q filing with the U.S.
Securities and Exchange Commission for the quarterly period ended
September 30, 2020, that it is aware of approximately 600 open and
active asbestos-related claims pending against the Company and
certain of its subsidiaries as of September 30, 2020.
The Company states, "These claims consist of non-PC Relationship
Claims against PPG and claims against a PPG subsidiary the Company
acquired on April 1, 2013. The Company is defending these open and
active claims vigorously.
"PPG has established reserves totaling approximately US$190 million
for asbestos-related claims that would not be channeled to the
Trust which, based on presently available information, we believe
will be sufficient to encompass all of PPG's current and estimable
potential future asbestos liabilities. These reserves, which are
included within Other liabilities on the accompanying condensed
consolidated balance sheets, represent PPG's best estimate of its
liability for these claims.
"These reserves include a US$162 million reserve established in
2009 in connection with an amendment to the PC plan of
reorganization for non-PC Relationship Claims other than claims
arising from premises-related exposures. PPG does not have
sufficient current claim information or settlement history on which
to base a better estimate of this liability in light of the fact
that the Bankruptcy Court's injunction staying most asbestos claims
against the Company was in effect from April 2000 through May
2016.
"These reserves also include PPG's best estimate, following an
analysis performed in 2019 of its claims history and discussions
with consultants and its counsel, of the value of the Company's
potential liability for premises-related non-PC Relationship Claims
against it and claims against PPG's subsidiary acquired on April 1,
2013 that are presently pending, and that are projected to be
asserted through December 31, 2028.
"PPG monitors the activity associated with its asbestos claims and
evaluates, on a periodic basis, its estimated liability for such
claims, its insurance assets then available, and all underlying
assumptions to determine whether any adjustment to the reserves for
these claims is required.
"The amount reserved for asbestos-related claims by its nature is
subject to many uncertainties that may change over time, including
(i) the ultimate number of claims filed; (ii) the amounts required
to resolve both currently known and future unknown claims; (iii)
the amount of insurance, if any, available to cover such claims;
(iv) the unpredictable aspects of the litigation process, including
a changing trial docket and the jurisdictions in which trials are
scheduled; (v) the outcome of any trials, including potential
judgments or jury verdicts; (vi) the lack of specific information
in many cases concerning exposure for which PPG is allegedly
responsible, and the claimants' alleged diseases resulting from
such exposure; and (vii) potential changes in applicable federal
and/or state tort liability law. All of these factors may have a
material effect upon future asbestos-related liability estimates.
As a potential offset to any future asbestos financial exposure,
under the PC plan of reorganization PPG retained, for its own
account, the right to pursue insurance coverage from certain of its
historical insurers that did not participate in the PC plan of
reorganization. While the ultimate outcome of PPG's asbestos
litigation cannot be predicted with certainty, PPG believes that
any financial exposure resulting from its asbestos-related claims
will not have a material adverse effect on PPG's consolidated
financial position, liquidity or results of operations."
A full-text copy of the Form 10-Q is available at
https://is.gd/hFynhG
ASBESTOS UPDATE: Travelers Had $1.41BB Net Reserves at Sept. 30
---------------------------------------------------------------
The Travelers Companies, Inc. has net asbestos reserves of US$1.41
billion at September 30, 2020, compared to $1.35 billion at
September 30, 2019, according to the Company's Form 10-Q filing
with the U.S. Securities and Exchange Commission for the quarterly
period ended September 30, 2020.
Travelers Companies states, "The Company believes that the property
and casualty insurance industry has suffered from court decisions
and other trends that have expanded insurance coverage for asbestos
claims far beyond the original intent of insurers and
policyholders. The Company has received and continues to receive a
significant number of asbestos claims. Factors underlying these
claim filings include continued intensive advertising by lawyers
seeking asbestos claimants and the focus by plaintiffs on
defendants who were not traditionally primary targets of asbestos
litigation. The focus on these defendants is primarily the result
of the number of traditional asbestos defendants who have sought
bankruptcy protection in previous years. The bankruptcy of many
traditional defendants has also caused increased settlement demands
against those policyholders who are not in bankruptcy but remain in
the tort system. Currently, in many jurisdictions, those who
allege very serious injury and who can present credible medical
evidence of their injuries are receiving priority trial settings in
the courts, while those who have not shown any credible disease
manifestation are having their hearing dates delayed or placed on
an inactive docket. Prioritizing claims involving credible
evidence of injuries, along with the focus on defendants who were
not traditionally primary targets of asbestos litigation,
contributes to the claims and claim adjustment expense payment
patterns experienced by the Company. The Company's
asbestos-related claims and claim adjustment expense experience
also has been impacted by the unavailability of other insurance
sources potentially available to policyholders, whether through
exhaustion of policy limits or through the insolvency of other
participating insurers.
"The Company continues to be involved in disputes, including
litigation, with a number of policyholders, some of whom are in
bankruptcy, over coverage for asbestos-related claims. Many
coverage disputes with policyholders are only resolved through
settlement agreements. Because many policyholders make exaggerated
demands, it is difficult to predict the outcome of settlement
negotiations. Settlements involving bankrupt policyholders may
include extensive releases which are favorable to the Company, but
which could result in settlements for larger amounts than
originally anticipated. Although the Company has seen a reduction
in the overall risk associated with these disputes, it remains
difficult to predict the ultimate cost of these claims. As in the
past, the Company will continue to pursue settlement
opportunities.
"In addition to claims against policyholders, proceedings have been
launched directly against insurers, including the Company, by
individuals challenging insurers' conduct with respect to the
handling of past asbestos claims and by individuals seeking damages
arising from alleged asbestos-related bodily injuries. It is
possible that other direct actions against insurers, including the
Company, could be filed in the future. It is difficult to predict
the outcome of these proceedings, including whether the plaintiffs
would be able to sustain these actions against insurers based on
novel legal theories of liability. The Company believes it has
meritorious defenses to any such claims and has received favorable
rulings in certain jurisdictions.
"Because each policyholder presents different liability and
coverage issues, the Company generally reviews the exposure
presented by each policyholder at least annually. Among the
factors the Company may consider in the course of this review are:
available insurance coverage, including the role of any umbrella or
excess insurance the Company has issued to the policyholder; limits
and deductibles; an analysis of the policyholder's potential
liability; the jurisdictions involved; past and anticipated future
claim activity and loss development on pending claims; past
settlement values of similar claims; allocated claim adjustment
expense; the potential role of other insurance; the role, if any,
of non-asbestos claims or potential non-asbestos claims in any
resolution process; and applicable coverage defenses or
determinations, if any, including the determination as to whether
or not an asbestos claim is a products/completed operation claim
subject to an aggregate limit and the available coverage, if any,
for that claim.
"In the third quarter of 2020, the Company completed its annual
in-depth asbestos claim review, including a review of active
policyholders and litigation cases for potential product and
"non-product" liability, and noted the continuation of the
following trends:
* a high level of litigation activity in certain jurisdictions
involving individuals alleging serious asbestos-related illness,
primarily involving mesothelioma claims;
* while overall payment patterns have been generally stable,
there has been an increase in severity for certain policyholders
due to the high level of litigation activity; and
* a moderate level of asbestos-related bankruptcy activity.
"In the home office and field office category, which accounts for
the vast majority of policyholders with active asbestos-related
claims, the number of policyholders with open asbestos claims
declined slightly while gross asbestos-related payments increased
slightly when compared to 2019. Payments on behalf of
policyholders in this category continue to be influenced by a high
level of litigation activity in a limited number of jurisdictions
where individuals alleging serious asbestos-related injury,
primarily mesothelioma, continue to target defendants who were not
traditionally primary targets of asbestos litigation.
"The Company's quarterly asbestos reserve reviews include an
analysis of exposure and claim payment patterns by policyholder
category, as well as recent settlements, policyholder bankruptcies,
judicial rulings and legislative actions. The Company also
analyzes developing payment patterns among policyholders in the
home office and field office category and the assumed reinsurance
and other category as well as projected reinsurance billings and
recoveries. In addition, the Company reviews its historical gross
and net loss and expense paid experience, year-by-year, to assess
any emerging trends, fluctuations, or characteristics suggested by
the aggregate paid activity. Conventional actuarial methods are
not utilized to establish asbestos reserves, and the Company's
evaluations have not resulted in a reliable method to determine a
meaningful average asbestos defense or indemnity payment.
"The completion of these reviews and analyses in the third quarters
of 2020 and 2019 resulted in US$295 million and US$220 million
increases, respectively, in the Company's net asbestos reserves.
In both 2020 and 2019, the reserve increases were driven by
increases in the Company's estimate of projected settlement and
defense costs related to a broad number of policyholders in the
home office and field office category. The increase in the
estimate of projected settlement and defense costs primarily
resulted from payment trends that continue to be higher than
previously anticipated due to the continued high level of
mesothelioma claim filings and the impact of the current litigation
environment surrounding those claims. Over the past decade, the
property and casualty insurance industry, including the Company,
has experienced net unfavorable prior year reserve development with
regard to asbestos reserves, but the Company believes that over
that period there has been a reduction in the volatility associated
with the Company's overall asbestos exposure as the overall
asbestos environment has evolved from one dominated by exposure to
significant litigation risks, particularly coverage disputes
relating to policyholders in bankruptcy who were asserting that
their claims were not subject to the aggregate limits contained in
their policies, to an environment primarily driven by a frequency
of litigation related to individuals with mesothelioma. The
Company's overall view of the current underlying asbestos
environment is essentially unchanged from recent periods, and there
remains a high degree of uncertainty with respect to future
exposure to asbestos claims.
"Net asbestos paid loss and loss expenses in the first nine months
of 2020 and 2019 were US$167 million and US$150 million,
respectively. Net asbestos reserves were US$1.41 billion and
US$1.35 billion at September 30, 2020 and September 30, 2019,
respectively."
A full-text copy of the Form 10-Q is available at
https://is.gd/aE9TWy
ASBESTOS UPDATE: Union Carbide Faces 9,641 Claims at Sept. 30
-------------------------------------------------------------
Dow Inc. disclosed in its Form 10-Q filing with the U.S. Securities
and Exchange Commission for the quarterly period ended September
30, 2020, that wholly owned subsidiary Union Carbide Corporation
has 9,641 unresolved asbestos-related claims at September 30,
2020.
The Company states, "Union Carbide is and has been involved in a
large number of asbestos-related suits filed primarily in state
courts during the past four decades. These suits principally
allege personal injury resulting from exposure to
asbestos-containing products and frequently seek both actual and
punitive damages. The alleged claims primarily relate to products
that Union Carbide sold in the past, alleged exposure to
asbestos-containing products located on Union Carbide's premises,
and Union Carbide's responsibility for asbestos suits filed against
a former Union Carbide subsidiary, Amchem Products, Inc.
("Amchem"). In many cases, plaintiffs are unable to demonstrate
that they have suffered any compensable loss as a result of such
exposure, or that injuries incurred in fact resulted from exposure
to Union Carbide's products.
"Plaintiffs' lawyers often sue numerous defendants in individual
lawsuits or on behalf of numerous claimants. As a result, the
damages alleged are not expressly identified as to Union Carbide,
Amchem or any other particular defendant, even when specific
damages are alleged with respect to a specific disease or injury.
In fact, there are no personal injury cases in which only Union
Carbide and/or Amchem are the sole named defendants. For these
reasons and based upon Union Carbide's litigation and settlement
experience, Union Carbide does not consider the damages alleged
against Union Carbide and Amchem to be a meaningful factor in its
determination of any potential asbestos-related liability."
A full-text copy of the Form 10-Q is available at
https://is.gd/a9WKBt
*********
S U B S C R I P T I O N I N F O R M A T I O N
Class Action Reporter is a daily newsletter, co-published by
Bankruptcy Creditors' Service, Inc., Fairless Hills, Pennsylvania,
USA, and Beard Group, Inc., Washington, D.C., USA. Rousel Elaine T.
Fernandez, Joy A. Agravante, Psyche A. Castillon, Julie Anne L.
Toledo, Christopher G. Patalinghug, and Peter A. Chapman, Editors.
Copyright 2020. All rights reserved. ISSN 1525-2272.
This material is copyrighted and any commercial use, resale or
publication in any form (including e-mail forwarding, electronic
re-mailing and photocopying) is strictly prohibited without prior
written permission of the publishers.
Information contained herein is obtained from sources believed to
be reliable, but is not guaranteed.
The CAR subscription rate is $775 for six months delivered via
e-mail. Additional e-mail subscriptions for members of the same
firm for the term of the initial subscription or balance thereof
are $25 each. For subscription information, contact
Peter A. Chapman at 215-945-7000.
*** End of Transmission ***